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        A molecular torsion balance was synthesized to study the halogen bond in nonpolar and 
polar solvents. The folding energies were found to be between -0.2 and -0.3 kcal/mol in 
deuterochloroform. The strength of the halogen bond decreased in the following order: Cl ~ Br > 
I, which is contrary to the computationally predicted order, I > Br > Cl. This reversed trend may 
be due to the gauche effect and/or simultaneous steric effects specific to our model system.  
Three different functionalities, an alcohol, a carbamate, and an amide, were used as the 
halogen bond acceptors. The amide gave among the highest folding ratios, indicative of the 
strength of the halogen bond with bromide or chloride. Solvent studies were performed on the 
brominated torsion balance as well as a hydroxy analog to compare the hydrogen and halogen 
bonding interactions. Based on the solvent data, it takes more water to obstruct a halogen bond 
compared to a hydrogen bond. The folding energies were also compared to several solvent 
parameters.   
A molecular torsion balance was also successfully synthesized to study the solvent 
exposed salt bridge interaction in water and in several buffer solutions. We found that the folding 
energies varied between -0.3 to -0.5 kcal/mol for the ammonium-carboxylate and guanidinium-
carboxylate interaction when exposed to solvent; unequivocally, salt bridges that are exposed to 
solvent are stabilizing.  Temperature is negligible whereas ionic strength has a weak but 
experimentally significant effect on the strength of the salt bridge interaction. The only 
measurable change in the folding ratios came from adjusting the pD of the buffer solutions.  
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1.0  TRÖGER’S BASE AND THE MOLECULAR TORSION BALANCE   
Tröger‘s base [2,8-dimethyl-6H,12H-5,11-methanodibenzo[b,f][1,5]diazocine] (Figure 1) 
was first described in 1887,
1
 though the structure was not elucidated until 1935.
2
  The 
dibenzodiazocine derivative is a concave, V-shaped molecule with angle of 89-104° between the 
two aryl rings
3,4
 and owes its chirality to the two configurationally stable amines.  Its relative 
rigidity, unique cleft-shape, and potential to direct functionalities towards the cleft through 
substitution at C-2 and C-8 make Tröger‘s base analogs ideal frameworks for biomimetic 
systems.  The dibenzodiazocine scaffold has been used in cyclophanes as receptors
3,4
  for 
benzenoid substrates and in diacids as hydrogen bonding hosts.
5-8
  
 
 
 
Figure 1. Tröger's base. 
 
The molecular torsion balance was first introduced in 1994
9
 as a tool to measure non-
covalent interactions (Figure 2).  Rotation of the asymmetric aryl ring atop a Tröger‘s base 
analog is gently restricted with an estimated barrier to rotation of approximately 14 kcal/mol, 
low enough to surmount at room temperature but high enough to monitor the populations of the 
two conformations by 
1
H NMR.  The dibenzodiazocine hinge is flexible enough to optimize 
distance requirements for non-covalent interactions.  The top ring has two possible orientations; 
 2 
any deviation from a 1:1 ratio between the two states is indicative of an intramolecular force.  
The torsion balance has been used to evaluate the benzene dimer edge-to-face, aryl- and alkyl-
CH-π interactions, and the hydrophobic effect. 
 
 
Figure 2. The first generation torsion balance (folded on left and unfolded on right). 
1.1 MEASURING THE EDGE-TO-FACE INTERACTION USING THE FIRST 
GENERATION MOLECULAR TORSION BALANCE 
Aromatic rings have been found to adopt an edge-to-face (EF, Figure 3) configuration in 
the solid state for benzene
10
 and in protein crystal structures.
11-13
  The arrangement brings the 
partially positive protons of the edge ring in close proximity to the partially negative center of 
the face ring.  The approach is perpendicular with centroid separations of 3.4-6.5 Å.  Monte 
Carlo simulations
14
 and ab initio calculations
15
 determined separately that the tilted-T edge-to-
face interaction (TT, Figure 3) with a centroid distance of 5.0-5.5 Å was favored for benzene. 
 
 
 
Figure 3. Structures of a benzene dimer. 
  
 3 
The first set of torsion balances synthesized were used to measure the stability of the 
tilted-T edge-to-face interaction and the effects of substitution (Figure 4, Table 1).
9
  The electron 
withdrawing substituents of 1d and 1e perturb the folding ratio by increasing electron deficiency 
of the edge ring, though the iodoester 1f shows the same stabilization of folding.  Surprisingly, 
the tert-butyl 2c shows greater folding than its aryl counterparts, indicating that the tert-butyl-
aryl interaction is as significant as the edge-to-face interaction.  
 
 
 
Figure 4. Torsion balances for the tilted-T edge-to-face interaction. 
 
Table 1. Experimental folding energies for esters 1a-i and 2a-c in CDCl3 at 25 °C. 
Ester Y R -ΔG°a,b 
1a H  0.24 
1b p-CH3  0.37 
1c p-OCH3  0.24 
1d p-CN  0.65 
1e p-NO2  0.65 
1f p-I  0.65 
1g m-CH3  0.00 
1h m-CN  0.24 
1i 3,5-dimethyl  -0.37 
2a  CH3 0.00 
2b  cyclohexyl 0.37 
2c  tert-butyl 0.82 
a) ±10% error. b) kcal/mol. 
A series of phenyl, methyl, and isopropyl esters were then analyzed by 
1
H NMR to 
determine the relationship between the electrostatic potential of the aromatic face ring and the 
strength of edge-to-face and CH-π interactions (Table 2, Figure 5).16  The isopropyl ester is 
 4 
preferentially folded, and the free energy of folding is about -0.5 kcal/mol at room temperature, 
whereas the phenyl ester, despite its relative electron deficiency in the edge ring, exhibited a less 
favorable free energy of folding of -0.3 kcal/mol.
16
  The substituents have little to no effect on 
folding, which belies the significance of electrostatic potential and is consistent with London 
dispersion forces as the major driving force in edge-to-face interactions.  
 
 
 
Figure 5. Methyl, isopropyl, and phenyl esters. 
 
Table 2. Folding energies for methyl (3), isopropyl (4), and phenyl esters (5) in CDCl3 at 25 
°C. 
X -ΔG°a,b (3) -ΔG°a,b (4) -ΔG°a,b (5) 
NO2 -0.11 0.21 0.51 
CN -0.06 0.30 0.64 
I 0.06 0.23 0.46 
Br -0.02 0.26 0.54 
OCH3 0.04 0.27 0.44 
OH 0.03 0.23 0.47 
NH2 0.06 0.18 0.34 
a) ±10% error. b) kcal/mol. 
 5 
 
1.2 MEASURING THE ATTRACTION BETWEEN ORGANIC FLUORINE AND AN 
AMIDE GROUP 
In medicinal chemistry, fluorine, which has been exchanged for hydrogen due to steric 
similarity, enhances metabolic stability, pharmacokinetic and toxicological properties, and 
binding efficacy and selectivity.
17,18
  Yet fluorine differs considerably from hydrogen in terms of 
electronegativity, and reasons for improved efficacy have not been fully addressed.  Diederich et 
al. noticed a characteristic geometry of an organic fluorine orthogonal to a carbonyl in a 
fluorinated inhibitor-thrombin complex and in other examples from the Cambridge Structural 
Database (CSD) and RCSB Protein Data Bank.
19
 
 
Figure 6. Torsion balances to measure the C-F
…
amide interaction. 
 
The Diederich group has applied the torsion balance
20
 to measure the C-F
…
amide 
interaction in combination with the double mutant cycle approach,
21
 using trifluorophenyl 6 
(Figure 6).  The C-F
…
amide coupling energy was -0.25 kcal/mol in CDCl3, -0.20 kcal/mol in 
C6D6, and negligible in CD3OD.
20
  However, several uncertainties regarding these data called for 
a subsequent study in which an indole was appended to the Tröger‘s base scaffold (7, Figure 6).  
The interaction was strongest in nonpolar solvents: -0.19 kcal/mol in C6D6 versus -0.07 kcal/mol 
in CDCl3 and -0.10 in CD3OD.  To reduce perturbations upon acetylation of indole, napthyl 8 
 6 
was designed, obtaining values of -0.29 kcal/mol in C6D6 and -0.14 kcal/mol in CDCl3.
22
  These 
data support the attractive orthogonal dipolar Csp3F
…
amide and Csp2F
…
amide interactions.  
1.3 MEASURING HYDROPHOBIC AND CH-Π EFFECTS IN WATER WITH THE 
SECOND GENERATION TORSION BALANCE 
In the first generation torsion balances, an aryl or alkyl ester was opposite a methyl 
group; these two groups differ in dipole moment and with solvation, which can affect the 
conformer ratio.  To improve the symmetry of the molecule and address the above issue, an ester 
was set against another ester.  A major purpose of the second generation torsion balances was to 
measure noncovalent interactions in water, and therefore, hydrophilic groups were added to 
improve solubility.  Because these groups are located on the axis of rotation and will not 
experience changes in environment due to rotation, they cannot contribute to the energy change 
observed during folding (Figure 7, 11).
23
 
 
Figure 7. Torsion balances to measure hydrophobic effects. 
 
The hydrophobic contribution to folding in water was defined as the difference between 
the folding energies of the torsion balance in water and in nonpolar solvents, the value of which 
 7 
grew with increasing alkyl group size.  The hydrophobic contribution for an isopropyl ester was  
-0.22 kcal/mol and for an adamantyl ester -0.35 kcal/mol (Table 3),
23
 demonstrating the 
influence of water on the conformation of small molecules. 
Table 3. Folding energies for esters 11a-f at 25 °C.  
Ester R -ΔGfold [CDCl3]
a,b
 -ΔGfold [D2O]
a,b
 
11a (CH3)2HC- 0.50 0.72 
11b (CH3)3C- 0.65 0.92 
11c cyclohexyl 0.36 0.67 
11d 1-adamantyl 0.36 0.68 
11e 2-adamantyl 0.55 0.90 
11f H3C- 0.00 0.00 
a) ±10% error. b) kcal/mol. 
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2.0  THE HALOGEN BOND 
The halogen bond is a noncovalent interaction between a halogen such as iodine, bromine 
or chlorine but not fluorine, and a Lewis base, which can include but is not limited to oxygen, 
nitrogen and sulfur.  The interaction has a strong directional preference with an angle, , (Figure 
8) typically between 160° and 180°.  In a CSD survey of 40,000 structures containing C-X 
bonds
24
 and an analysis of PBD crystal structures,
25
 nucleophiles of oxygen or nitrogen 
approached preferentially at an θ of approximately 160-165°, regardless of the substitution 
pattern of the carbon (primary, secondary, tertiary or sp
2
 hybridized), whereas gas phase studies
26
 
and other CSD surveys
27,28
 suggest linearity in θ.  The angle corresponds to angular orientation 
of the ζ* antibonding orbital of the C—X bond. Charge transfer between the HOMO of the 
Lewis base and the LUMO of the halogen dictate this angle.
27,28
   
 
Figure 8. Schematic of a halogen bond interaction. 
 
The stabilizing potential energy of the halogen bond has been estimated from 1 kcal/mol 
to slightly greater than that of the average hydrogen bond.
29
  On the lower end of the spectrum, 
the strength of N
…
Cl interactions of gas phase cyanuric chlorides are estimated to be -1.2 
kcal/mol by ab initio calculations,
30
 and the energy gain for a chloro-cyanoacetylene dimer is      
 9 
-2.4 kcal/mol (half that of a hydrogen bond) based on IMPT calculations.
28
  The interaction 
energy is -5.8 kcal/mol for CF3I
…
NH3 according to MP2 quantum chemical calculations
31
 and     
-7.4 kcal/mol for 2,2,6,6-tetramethylpiperidine and 1-iodoperfluorohexane as measured by an 
adiabatic accelerating calorimeter.
32
  The halogen bond interaction can be as strong as -18.9 
kcal/mol, which is calculated for the interaction between ammonia and BrF using density 
functional theory and atoms in molecular theory.
33
  
The halogen bond is attributed to electrostatics, dispersion, and charge transfer
24,28
 as 
well as the anisotropy of halogen electron density.
34,35
  This polar flattening
28
 refers to the 
emergence of an electropositive crown
25
 or sigma hole
36
 along the C-X axis that increases with 
the polarizability of the halogen.  This implies that halogen bonding would be strongest with 
iodine but would not occur with fluorine.  According to CSD surveys
28
 and computational 
studies,
25,37
 the tendency to form halogen bonds among the halogens is as follows: I > Br > Cl >> 
F.  Surveys have also suggested propensity for halogen bonding occurs in terms of 
electronegativity; sp
1
 hybridized nucleophiles show the strongest preference to form the 
interaction compared to sp
3
, which shows the weakest, and oxygen forms the interactions at a 
higher percentage than nitrogen and even more so than sulfur.
28
  Computational studies have 
suggested Lewis bases in the following order for the strength of interaction: N > S > O.
33,38
 
Halogen bonding was proposed more than a century ago in the synthesis of NH3I2,
39
 but 
was not verified until Odd Hassel‘s crystallographic studies of molecular bromine and p-dioxane 
in 1954,
40
 which elucidated a Br···O distance of 2.71 Å (the sum of the van der Waals radii for 
singly bonded bromine and oxygen is 3.35 Å) and a C—Br···O angle of 180°.  Since then 
halogen bonding has been reviewed,
29,41,42
 used extensively in crystal engineering,
29
 and gained 
recognition in biological systems. 
 10 
Halogen bonding has only recently captured the attention of the biological community.  
The enzyme aldose reductase (AR) complexes to halogenated inhibitor, IDD594, and NADP
+
, 
forming a short Br···O contact of 3.0 Å between the bromine of the inhibitor and a threonine 
oxygen of the enzyme.
43
   Bromination decreases the IC50 value of the inhibitor by a factor of 2.3 
compared to that of chlorination.
44
  In 2003, two biomolecular single-crystal structures were 
isolated which exhibited halogen bonding.   Ho and coworkers found that of two analogous DNA 
sequences, d(CCAGTACTGG) and d(CCAGTACbr
5
UGG),
45
 differing mainly by a methyl 
group versus a bromine, only the brominated version forms a four-way Holliday junction.
46
  The 
junction draws the bromine into a halogen bond with an oxygen of a backbone phosphate 
group.
25
  To directly compare hydrogen and halogen bonding, four-stranded DNA constructs, 
capable of conformational isomerization at their Holliday junction, were synthesized in a 
crystallographic assay.  Of the structurally similar and isoenergetic isomers, which differed only 
by hydrogen or halogen bond stabilization, a preference was shown for the latter; the halogen 
bond was estimated to be 2 kcal/mol more stable than the hydrogen bond.
47
  However, this value 
was based on two assumptions: 1) there is no entropic difference between the two isomers and 2) 
the crystals formed reflect a preestablished equilibrium in solution. 
Parallels have been drawn between hydrogen and halogen bonding.  Simple complexes in 
the gas phase between Lewis bases and hydrogen or halogen bonding acceptors demonstrated 
similar angular geometries and binding strengths,
26
 indicating that the origins of the interactions 
derive from comparable sources.  Attempts to cooperatively incorporate both interactions were 
moderately successful in cocrystallization reactions,
48-50
 but replacement of hydrogen for 
halogen bonding in biomolecules has had limited success.
51,52
  The two interactions were in 
 11 
direct competition in few experiments, including the Holliday junction study,
47
 but halogen 
bonding has shown it can compete
53
 and even prevail over hydrogen bonding.
32,54,55
  
While there is an abundance of data for hydrogen bonding interactions in solution,
56
 there 
is little information measuring the strength of the halogen bond in solution.  To date, association 
constants for halogen-bonding interactions have been determined in only a few cases,
57-61
 and 
most information regarding the strength of the interaction is computational.  However, 
computational studies will fail to accurately represent halogen bonding unless based on 
experimental evidence.  Rational drug design depends upon a comprehensive knowledge of weak 
intermolecular interactions; the significant impact of halogen bonding brings to attention the 
need for a more thorough understanding of the effects of halogenation and halogen bonding in 
solution.  Our objective in this project is to provide quantitative experimental data concerning the 
halogen bond by using the molecular torsion balance.  
 12 
3.0  EVALUATION OF THE HALOGEN BOND 
Our first objective was to address the deficiency in quantitative measurements of the 
halogen bond in solution and to examine the effects of solvent polarity on the halogen bond.  The 
second generation torsion balance was modified to have two isosteric esters, one functionalized 
with a bromine and the other with an alkyl group (Figure 9).  The torsion balance adopts two 
conformational states, folded and unfolded, separated by a barrier of 14 kcal/mol and easily 
discernable by 
1
H NMR.  
 
 
Figure 9. Representative chemical structures for the folded and unfolded conformers.  
 
The top ring of the torsion balance has always featured a methyl group, either attached 
directly to the aryl ring in place of or as an ester.  The reason for this choice was twofold: 1) 
interactions with the lower half of the dibenzodiazocine cleft would be minimized, and 2) the 
methyl group with its unfolded and folded signals is relatively easy to examine by line shape 
analysis.  However, a balance of a haloalkyl ester versus a propyl ester would be more 
appropriate.  If the project had assumed its original course, the torsion balances would have been 
analyzed in water.  A methyl ester, as the smaller group, would preferentially fold out due to 
 13 
hydrophobic effects.  It would be difficult to discern halogen bonding stabilization from 
hydrophobic effects in the resulting folding energies.  The rotation of the pseudo-symmetric 
diester ring exchanges a methyl group for a bromine; any deviation from a 1:1 ratio between the 
two states is indicative of a halogen bond. 
3.1 SYNTHESIS OF THE HALOGEN BONDING TORSION BALANCES 
Three different sets of torsion balances were synthesized to measure the strength of the 
halogen bonding interaction, each featuring an asymmetric diester.  To provide this common 
fragment, diacid, 12, prepared from commercially available 2-bromo-m-xylene,
62
 was treated 
with nitric and sulfuric acid and subsequently alkylated
63
 to provide hemiester, 14 (Scheme 1).  
Esterification with dicyclohexylcarbodiimide (DCC) and 4-dimethylaminopyridine (DMAP) 
afforded the desired diesters, 15a-c.
64
  In torsion balances prepared from 15a-b, a Lewis basic 
moiety is positioned to interact with an alkyl halide side chain that incorporates a bromine or 
chlorine.  It would be illuminating to compare the halogen bond interaction with a hydrogen 
bonding interaction.  With this in mind, hydroxyethylester 15c was synthesized. 
We planned to use Suzuki coupling to synthesize the desired torsion balances, but the 
presence of an alkyl bromide and chloride could lead to competitive side reactions.  The 
oxidative addition of palladium(0) to alkyl halides is generally slower than that of aryl halides.
65
   
However, the rates between the alkyl and aryl halides can be competitive in certain situations; 
alkyl iodides have been shown to couple under mild conditions
66
 and specific electron rich 
phosphine ligands (P(i-Pr)3 and PCy3) can induce Pd catalyzed coupling of alkyl bromides.
67
  
Therefore, we expected that a Suzuki-type coupling reaction using substrates 15a-15c would 
 14 
yield predominantly the desired torsion balances but expected that the iodo ester would be better 
synthesized by a substitution reaction after the Suzuki coupling.  
Scheme 1. Modification of isophthalates. 
 
 
 
According to the method of Wärnmark, 4-bromoaniline and paraformaldehyde were 
converted to 2,8-dibromo-6H,12H-5,11-methanodibenzo[b,f][1,5]diazocine 16,
68
 which was then 
selectively transformed into different functional groups via the bromine-lithium exchange.
69
  As 
shown in Scheme 2, bromide 16 was converted to carboxylic acid 17, which underwent Curtius 
rearrangement of the isocyanate using diphenyl phosphoryl azide ((PhO)2P(O)N3) in tert-butanol 
to give carbamate 18.
70
  Subsequent treatment with dichlorobis[methylene-
bis(diphenylphosphine)]-dipalladium-dichloromethane adduct
71
 (Pd(II)) as the catalyst and 
bis(pinacolato)diboron (PinB2) gave 19.
72
   
Scheme 2. Synthesis of tert-butyl carbamate. 
 
 
 
 15 
Treatment of 16 with n-butyllithium and then DMF, reduction of the resulting aldehyde 
with sodium borohydride to provide alcohol 21, and subsequent borylation gave the boronate, 22 
(Scheme 3).  The last Tröger‘s base analog, dimethylamide 25, (Scheme 4) was obtained by 
starting with the aldehyde 20, which was treated with trimethylsilyl cyanide and zinc bromide to 
give 23.
73
  Reduction and hydrolysis
74
 provided the carboxylic acid, and subsequent amidation
75
 
provided 24.  Borylation of the aryl bromide furnished boronic ester, 25.  
Scheme 3. Synthesis of the primary alcohol. 
 
 
 
Scheme 4. Synthesis of the dimethylamide. 
 
 
 
 Formation of the torsion balances proved to be difficult under traditional Suzuki 
conditions.  The Suzuki coupling of the isophthalates and 19 with tetrakis(triphenylphosphine) 
palladium in xylenes at 90 °C for 16 hours returned starting material.  The solvent polarity was 
increased and the palladium catalyst was substituted.  Each of the boronic esters were treated 
with Blaser‘s catalyst76 and heated overnight in a 1:1 solution of dimethoxyethane and water in 
 16 
the presence of isophthlates 15a-c and sodium bicarbonate
77
 to give the desired torsion balances.  
The yields for each conversion are summarized in Table 4. 
Table 4. Synthesis of torsion balances 26-28. 
 
R X Yield (%) 
BocNH (26a) Br 44 
BocNH (26b) Cl 44 
BocNH (26c) OH 40 
HOCH2 (27a) Br 28 
HOCH2 (27b) Cl 63 
HOCH2 (27c) OH 45 
Me2NOCCH2 (28a) Br 42 
Me2NOCCH2 (28b) Cl 68 
Me2NOCCH2 (28c) OH 69 
 
We were interested in obtaining the folding energies of an iodide compared to bromide 
and chloride analogs. Therefore, an iodoester of the dimethylamide was synthesized from the 
corresponding bromide. Bromide 28a was refluxed with sodium iodide in acetone overnight to 
give the iodide 28d in quantitative yield (Scheme 5).  
Scheme 5. Iodination of dimethylamide. 
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Molecular modeling suggested that the carbamate functionality of torsion balances 26a-c 
preferentially lies in the same plane as the adjacent aromatic ring, which increases the distance 
between the Lewis base and the halogen and decreases the strength of the halogen bond.  To 
form a halogen bond would require rotation about the Caryl—N bond, which would need to be 
offset by the stabilization of the interaction.  The energetic penalty of this rotation could be 
reduced by increasing the substitution of the carbamates, thereby destabilizing the planar 
configuration.
78,79
  Therefore, the torsion balances 26a and 26b were methylated to give tertiary 
carbamates 29a and 29b (Scheme 6).  
Scheme 6. Methylation of carbamate. 
 
 
3.2 1H NMR ANALYSIS AND FOLDING ENERGIES OF THE TORSION 
BALANCES IN DEUTERATED CHLOROFORM 
The 
1
H NMR spectra of the torsion balances exhibited two sets of signals, one for each of 
the two slowly interconverting conformers available to these biaryl esters.  When the haloethyl 
ester is inside the cleft and in a position where it may potentially contact both dibenzodiazocine 
aromatic rings and their substituents, it will be referred to as the ‗folded‘ conformer.  The 
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conformers where the halogenated alkyl ester is outside the cleft, and is able to contact only one 
of the dibenzodiazocine rings, will be identified as ‗unfolded.‘ 
Esters 26-29 gave useful 
1
H NMR spectra, although they were somewhat complicated 
due to the diastereotopicity of the geminal methylene protons in the side chains and their partial 
overlap with the dibenzodiazocine bridging methylene groups.  The 
1
H NMR spectra for torsion 
balance 26a in CDCl3 at -5 °C provides a good example of the data obtained for all the esters.   
 
Figure 10. 
1
H NMR spectrum of 26a at -5 °C. 
 
Folding ratios were found to be concentration independent in the 1-10 mM range in 
CDCl3.  Isophthalate 15a exhibits a triplet at 4.39 ppm for the inner methylene of the propyl 
ester.  After Suzuki coupling, the two methylene protons are diastereotopic and exhibit unique 
signals in the unfolded and folded states; in the latter, two doublet of triplets partially overlap at 
4.03 ppm (c, Figure 10), while the shielded signals in the unfolded state appear at 3.61 and 3.41 
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ppm (c', Figure 10).  Parallel changes also occur for the bromoethyl ester.  The inner methylene 
of isophthalate 15a appears as a triplet at 4.68 ppm.  After coupling, this signal moves to 3.90 
and 3.74 ppm in the folded (b) and 4.41 ppm (b') in the unfolded state of the torsion balance.  
The distal methylene of 15a appears as a triplet at 3.67 ppm. This moves upfield to 3.36 and 3.26 
ppm in the unfolded (a') and 2.34 and 2.26 ppm in the folded state (a, not shown in Figure 10).  
Upon Suzuki coupling, the alkyl side chains of the isophthalate are in close proximity to the 
dibenzodiazocine.  The chemical shift difference of more than 1 ppm between the isophthalate 
15a and the folded signals (a, not shown in Figure 10) of the bromoethyl‘s distal methylene are a 
result of its proximity to both upper and lower rings of the dibenzodiazocine.  
 
 
Figure 11. 
1
H NMR spectra of 26a at -5 °C, 5 °C, 15 °C, and 25 °C. 
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1
H NMR spectra were acquired at temperatures ranging from -5 °C to 25 °C by ten 
degree increments.  All samples were 1 mM in CDCl3, a concentration at which no aggregation 
was observed.  Torsion balance 26a again represents the other esters in the 
1
H NMR spectra at 
varying temperatures (Figure 11), which change considerably in appearance over the 30 °C 
range.  The splitting patterns of the geminal methylene protons are difficult to discern at 15 °C, 
significant broadening of the peaks occur at room temperature, and the signals begin coalescing 
(e.g. c' clearly moves downfield and a' upfield from -5 to 25 °C). 
 
 
Figure 12. Simulations of bromoethyl (middle spectrum) and propyl (top spectrum) esters 
of 26a at -5 °C (bottom spectrum) using iNMR. 
 
The population of the folded to unfolded conformers were determined for temperatures -5 
to 15 °C using dynamic NMR line shape fitting assisted with the program iNMR.
80
  NMR 
spectra taken at room temperature or above were too difficult to analyze due to significant signal 
broadening and poor signal to noise ratio.  
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Spin system simulations become prohibitively slow when the total number of protons in 
the system exceed six.  Therefore, NMR simulations were conducted on three sets of protons: the 
inner methylene, and outer methyl of the propyl group, and the bromoethyl group.  In Figure 12, 
the simulations of the inner methylene (top) and a portion of the bromoethyl group (middle) are 
shown compared to the experimental spectrum (bottom).  The simulated spectrum was similar to 
the experimental spectrum and was sensitive to changes in the folding ratio.  Changes as little as 
1.5% to the overall folding percent lead to distinct discrepancies between observed and 
calculated spectra.  Therefore, the error in amount of folded conformer was estimated to be 
±1.5%.  Error analysis is discussed further in Section 6.3. 
The free energy of folding is defined by the following equations: 
Keq = 
][
][
1
1
unfolded
folded
k
k


   (Equation 1) 
ΔG° = -RT ln Keq    (Equation 2) 
in which R is the universal gas constant (1.9875 cal / K mol), T is the temperature in Kelvin, and 
Keq represents the equilibrium constant or the ratio of the concentrations of the folded state to the 
unfolded state.  Three sets of line shape analyses were performed to obtain three ratios of folded 
and unfolded states, which were averaged to provide experimental folding energies for torsion 
balances 26-29.  The results are shown in Table 5.   
We conclude that the folding energies of torsion balances are not affected (within the 
limits of the uncertainty of our experiments) by temperature in the range of temperatures 
between -5 °C and 15 °C.  These data imply small enthalpy changes in our limited range of 
temperatures.  In general, the folding energies for the torsion balances are modest: the values for 
26a, 26b, 27a, and 27b are all approximately -0.2 kcal/mol.  We attribute these folding energies 
to a halogen bonding interaction.  The results may be interpreted to suggest the carbamate and 
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the hydroxymethyl functionalities have similar halogen bond acceptor abilities.  However, the 
generally accepted order of strength for the hybridization of the halogen bond acceptor is 
sp>sp
2
>sp
3
,
28
 even though the carbamate oxygen is sp
2
 hybridized and the hydroxymethyl            
s        
Table 5. Folding energies for torsion balances 26-29 in CDCl3.  
 R X T (°C) % Folded
a,b 
-ΔG° c,d 
26a BocNH Br -5 57 0.15 
   5 58 0.18 
26b BocNH Cl -5 58 0.18 
   5 59 0.20 
   15 57 0.17 
26c BocNH OH -5 66 0.36 
   5 66 0.37 
   15 66 0.38 
27a HOCH2 Br -5 61 0.23 
   5 60 0.21 
   15 60 0.23 
27b HOCH2 Cl -5 59 0.19 
   5 58 0.18 
   15 59 0.20 
27c HOCH2 OH -5 71 0.47 
   5 70 0.48 
   15 69 0.46 
28a Me2NOCCH2 Br -5 60 0.20 
   5 61 0.25 
   15 63 0.30 
28b Me2NOCCH2 Cl -5 61 0.24 
   5 62 0.26 
   15 61 0.25 
28c Me2NOCCH2 OH -5 79 0.70 
   5 78 0.71 
   15 74 0.60 
28d Me2NOCCH2 I -5 56 0.14 
   5 56 0.13 
   15 57 0.16 
29a BocNMe Br -5 64 0.32 
   5 66 0.36 
   15 66 0.37 
29b BocNMe Cl -5 64 0.31 
   5 66 0.37 
   15 62 0.29 
a) The percentages folded were determined from line shape analyses of the 
1
H NMR spectra, acquired on a 500 
MHz NMR. b) ±1.5% error. c) ±15% error for the free energy. d) kcal/mol. 
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oxygen is sp
3
 hybridized.  This similarity of the two functional groups could be an accident due 
to unequal geometry requirements for the two groups.  
As noted earlier, the preferred geometry of the aryl-carbamate is one in which the group 
is planar with the adjacent aryl ring, though the halogen bond would require orthogonality 
between the carbamate and the benzene ring.  The barrier to rotation about the N—Ccarbonyl bond 
of a carbamate is reported to be 12.3 kcal/mol at -23 °C.
78,81
  Rotation about the N—Caryl bond is 
less hindered compared to that of the amide bond.  The barrier to rotation for the N—Caryl bond 
of N-methylaniline is calculated to be 6.3 kcal/mol at -135 °C.
82
  For N,N-dimethylaniline, the 
barrier is calculated to be 5.1 kcal/mol at -140 °C.
83
  The barrier for an N-phenylcarbamate 
derivative is likely to be lower than found in these aniline systems.  
Tertiary carbamates, 29a and 29b, were designed to increase the propensity for 
orthogonality and improve a halogen bonding interaction.  In general, anilides, which bear some 
resemblance to N-phenylcarbamates, adopt a trans configuration.  Based on ab intio molecular 
orbital (MO) calculations,
79
 the trans structure places the phenyl ring preferentially coplanar to 
the acetamido group.  This preference for the trans orientation reverses upon methylation of 
acetanilide, but in both the lowest energy cis and trans conformers, the phenyl group is 
perpendicular to the amide group.
79
  The perpendicularity is observed both in the solid state
84,85
 
and in solution.
84
   
The folding energies observed for the secondary and tertiary carbamates differed only by 
0.1 kcal/mol.  If the tertiary carbamate mimicked the amide conformational changes by adopting 
a cis conformation, halogen bond could no longer form and the folding energy of the tertiary 
carbamate would be significantly different from that of the secondary carbamates.  The 0.1 
kcal/mol difference suggests that methylation of the secondary carbamates destabilizes the 
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coplanar geometry without altering the trans configuration.  The tertiary phenylcarbamates, 29a 
and 29b, gave some of the highest folding ratios for all the torsion balances synthesized.  
A carbamate functionality was not originally intended for use in this halogen bond 
project, but in the synthetic route to access the dimethylamidomethyl torsion balances 28a-d, 
carbamates 26a-c were easily accessible.  As a result, lower folding ratios were almost to be 
expected.  The alcohols 27a-c had greater flexibility and did not have the geometric constraints 
in the same way as the carbamates, but the nature of the halogen bond acceptor, an sp
3
 
hybridized oxygen, is in theory poor compared to the sp
2
 hybridized oxygen of a 
dimethylamide.
28
  The less favorable folding energies of -0.2 kcal/mol calculated for 27a-b were 
reasonable. 
We expected more favorable folding for the dimethylamides 28a-d compared to the 
hydroxymethyl and Boc-protected aminomethyl torsion balances, 26a-c and 27a-c, because of 
the hybridization of the oxygen in the dimethylamide and molecular modeling.   To our delight, 
the strength of the halogen bond increased between bromine or chlorine and the carbonyl oxygen 
of the amide to approximately -0.3 kcal/mol.  Notably, among the dimethylamidomethyl analogs 
28a-d, iodide 28d has the least favorable folding energy of -0.15 kcal/mol.  Contrary to the 
prediction that the strength of the halogen bond will decrease in the order of I > Br > Cl > F,
28,29
 
the results indicate that the iodinated species has the weakest interaction with the carbonyl 
oxygen of the dimethylamide moiety among the halogens studied, and that there is no 
statistically verifiable difference in folding between bromine and chlorine.  Therefore, based on 
these data, the strength of the interaction follows the order, Cl ≈ Br > I.  
The folding energies observed for the halogen bonding torsion balances in chloroform are 
small compared to that of the hydrogen bonding molecules.  The folding energies for the 
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carbamate 26c, hydroxymethyl 27c, and dimethylamidomethyl 28c are approximately -0.4, -0.5 
and -0.7 kcal/mol respectively.  In each case, the folding of the hydroxylated analog is favored 
by a factor of two compared to that of the brominated or chlorinated form.  The geometric 
requirements for halogen and hydrogen bond formation are quite similar.  Therefore, these 
results reveal that the hydrogen bond is stronger than the halogen bond in chloroform.  
The results may be summarized as follows: the strength of interaction measured by our 
torsion balance follows the order, Cl ≈ Br > I, which does not follow the conventional order of I 
> Br > Cl > F for a halogen bond.  The tertiary Boc-protected aminomethyl and the 
dimethylamidomethyl torsion balances 29a-b and 28a-c formed stronger interactions in the 
folded state compared to the alcohols and secondary carbamates 27a-c and 26a-c.  And finally, 
the strength of the hydrogen bond is stronger than that of the halogen bond in chloroform.  
3.3 THE OBSERVED TREND FOR THE STRENGTH OF THE HALOGEN BOND 
The folding of the torsion balance increased in the following order: Cl ~ Br > I.  This 
observed trend is contrary to the calculated halogen bond, I > Br > Cl.  The halogen bond is 
attributed to electrostatics, dispersion, charge transfer,
24,28
 and most especially the anisotropy of 
halogen electron density.
34,35
  These properties however support the established trend, not the 
experimental observed results.  Therefore, another factor must be occurring to alter the 
propensity for halogen bond formation.  
This reversed trend may be due to the gauche effect and/or simultaneous steric effects 
specific to our model system.  Typically, the anti conformation for a 1,2-disubstituted ethane is 
preferred, but the substitution of certain electronegative atoms in the ethane will cause a 
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preference for the gauche configuration over the anti, the quintessential example of which is 1,2-
difluoroethane.  The arrangement is primarily attributed to bent bonds and a stabilizing ζCH → 
ζ*CF hyperconjugative effect in molecules such as 1-fluoropropane,
86
 though other factors may 
contribute or outweigh hyperconjugation.
87
  2-chloro-,
88
 2-bromo-
89,90
 and 2-iodoethanol
89
 show 
evidence for a gauche-gauche preference (concerning the dihedral angle of the C—C and C—O 
bonds), due to the gauche effect as well as internal hydrogen bonding.  
The energy difference between the anti and gauche conformations increases as the size of 
the halogen increases.  The preference for the gauche effect decreases in the 1,2-dihaloethanes in 
the following order: F > Cl > Br > I.
91
  Of the four halogens, iodine prefers the anti over the 
gauche by a considerable energetic difference.  The spatial requirements for halogen bond 
formation require the haloethylester to adopt an anti conformation; as the population of gauche 
haloethylesters increased, we would see a reduction in the folding ratio of the torsion balances.  
If the gauche effect is prevalent in the synthesized torsion balances and reduces the 
folding ratios of the torsion balances, compounds containing the 2-haloethoxycarbonyl 
functionality should also exhibit this conformational preference.  A search through the 
Cambridge Structural Database for the haloethylester (XCH2CH2O2C-) yielded a limited number 
of results.  The iodoethylester did not return any matching results, whereas seven unique crystal 
structures were acquired for the bromoethylester and three for the chloroethylesters.  The latter 
crystals were exclusively in the gauche conformation,
92-94
 and only one
95
 of the seven
92,94-98
 
bromides were isolated in the anti configuration.  Overwhelmingly, the gauche conformer was 
favored in the solid state. 
The relationship between the crystals and the compounds in solution is tentative.  Solvent 
polarity is known to affect conformational equilibria, and it has been reported that the energetic 
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difference between the trans and gauche configurations reduces with greater solvent polarity 
experimentally and computationally.
99-102
  
Chlorine is more likely than bromine and iodine to adopt a gauche conformation and yet 
the chlorinated torsion balance has one of the highest folding ratios, comparable to that of the 
brominated torsion balance.  The smaller folding energies of the iodide 28d may be due to the 
gauche effect and/or simultaneous steric effects specific to our model system.  Iodine has a van 
der Waals radius of 1.97 Å.
103
  Charton suggests that the van der Waals radius for a methyl group 
ranges from 1.72 Å to 2.23 Å;
104
 Bondi proposes 2.0 Å.
103
  According to these data, a methyl 
group is the same size as iodine.  However, the reduction in folding ratios for iodide 28d 
compared to the bromide and chloride 28a and 28b suggest that the proposed van der Waals radii 
for a methyl group are not accurate and that an iodine is in fact larger than the methyl group.  
Measurement of a van der Waals radius is context dependent, and 2.0 Å is an overestimation for 
the radius of a methyl group.  The iodine may prefer the gauche conformation to alleviate steric 
strain, which is paid in part by stabilization from the halogen bond.  
3.4 FOLDING ENERGIES IN NONPOLAR AND POLAR SOLVENTS 
The dimethylamidomethyl torsion balances 28a and 28c (Figure 13) were examined in 
additional deuterated solvents, methanol, acetone, dimethylformamide, and a 1:1 methanol: 
water solution, to ascertain the role of solvent in folding and to compare these folding ratios to 
common empirical solvent parameters.  
Though designed for intramolecular interactions between two functionalities, the torsion 
balances interact with solvent.  Solvent interactions stabilize the unfolded state of the torsion 
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balance, thereby diminishing the folding energy.  The results indicate that the solvent competes 
effectively as an alternative hydrogen or halogen bond acceptor (Table 6).  The highest folding 
ratios and most favorable energies for hydroxyethylester 28c were found in chloroform, which is 
a weak hydrogen bond donor, whereas 28c shows little to no preference for the folded state in 
deuterated methanol and dimethylformamide, one of which will form strong hydrogen bonds to 
the carbonyl group and the other capable of hydrogen bonding with the hydroxyl group.  Both 
solvents inhibit hydrogen bond formation.  
 
Figure 13. Torsion balances used in solvent studies.  
 
Table 6. Solvent effects on folding data for torsion balances 28a and 28c. 
 
T (°C) 
CDCl3
 
CD3OD
 
Acetone-d6
 
DMF-d7
 
1:1 CD3OD:D2O
 
 % Folded
a,b
 
28a (Br) -5 60 59 54 49 53 
 5 61 62 54 52 51 
 15 63 59 55 56  
28c (OH) -5 79 50 54 50 45 
 5 76 50 59 49 44 
 15 74 50 61 48 42 
 T (°C) -ΔG° c,d 
28a (Br) -5 0.22 0.20 0.09 -0.02 0.06 
 5 0.25 0.27 0.09 0.04 0.01 
 15 0.30 0.20 0.11 0.13  
28c (OH) -5 0.71 0.00 0.09 0.00 -0.11 
 5 0.70 -0.02 0.20 -0.02 -0.14 
 15 0.60 -0.02 0.24 -0.04 -0.18 
a) The percentages folded were determined from line shape analyses of the 
1
H NMR spectra, acquired on a 500 
MHz NMR. b) ±1.5% error in folding ratios. c) ±15% error for the free energies. d) kcal/mol. 
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The folding ratios of bromoethylester 28a are lower than that of hydroxyethylester 28c in 
chloroform.  In deuterated methanol, the percent folded of 28a is higher than that of 28c.  
Chloroform may be a competitor for the intramolecular halogen bonding interaction in 28a.  Its 
abilities at hydrogen bond donation on the other hand are considered weak, and the solvent is not 
as able at competing with the intramolecular interaction in 28c.  Methanol stabilizes the unfolded 
state of 28a through strong hydrogen bonding such that there are equal populations of the two 
conformers, but is a poor competitor for halogen bonding.  
It is interesting to note that in the equimolar solution of water and methanol, 28c favors 
the unfolded conformer by 0.1-0.2 kcal/mol.  This propensity to place the alcohol outside the 
cleft indicates the strength of the hydrogen bonding stabilization in the (albeit diluted) presence 
of water.  The desolvation of the amide and alcohol is so costly as to make folding unfavorable.  
Meanwhile, the folding energies of 28a in chloroform are similar to that in methanol, although 
chloroform is considered weakly polar.  The halogen bonding interaction only slightly favors the 
folded state over the unfolded state in dimethylformamide, and only the introduction of water 
obliterates the folding event in the presence of the halogen bond.  
Several conclusions can be drawn from the data in Table 6.  Methanol is capable of 
blocking the hydrogen bonding interaction and inhibiting the folding event in balance 28c but 
cannot impede the halogen bonding interaction as effectively in torsion balance 28a.  Equimolar 
amounts of water and methanol favor the unfolded state for 28c, but equally favor the folded and 
unfolded states for 28a.  Based on the solvent data, it takes a significant amount of water to 
obstruct the halogen bond.   
To evaluate solvent effects on folding energies, the data were compared to common 
solvent parameters (Table 7).  Dielectric constants (ε), Taft and Kamlet‘s π* scale105 and 
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Reichardt‘s normalized parameters, ,106 are measures of solvent polarity, while Taft and 
Kamlet‘s β scale105 measures the ability of solvent to donate an electron pair in a solute-to-
solvent hydrogen bond.  
Table 7. Folding data at 15 °C compared to solvent parameters. 
Solvent 
% Folded
a 
log Keq
 
εb 
c 
βd π*d 
28a 28c 28a 28c 
CDCl3 63 74 0.23 0.45 4.81 0.259 0 0.58 
CD3OD 59 49 0.16 -0.02 32.7 0.762 0.62 0.60 
acetone-d6 59 61 0.16 0.19 20.7 0.355 0.48 0.71 
DMF-d7 56 48 0.10 -0.03 36.7 0.386 0.69 0.88 
a)  ±1.5% error in folding ratios. b) dielectric constant. c) Reichardt’s normalized values.106 d) Taft and Kamlet’s 
basicity, β, and polarity, π*, scales.105 
 
For 28a, log Keq was derived from the folding ratios and graphed against empirical 
solvent scales.  The resulting graphs are presented in Figure 14.  A strong correlation between 
log Keq and each of the solvent parameters was found (R
2
 ≥ 96%), but only when linear 
regression excluded methanol.  As shown in Figure 14 methanol is a clear outlier in all cases, 
indicating its ability to compete with the folding of the balances as a strong hydrogen bond 
donor.  The data suggest that halogen bonding is strongly affected by polarity and basicity of 
solvents, but loses predictability of its strength in the presence of strong hydrogen bond donors 
like methanol.    
These results differ from those obtained recently from Taylor and coworkers.
61
  The log 
of association constants for a iodoperfluorooctane-triethylamine complex varied very slightly 
relative to solvent polarity except in t-butanol, i-propanol and chloroform, which significantly 
weakened binding by competing through hydrogen bonding.  In our dataset, we consider 
chloroform to be a weak competitor and it corresponded well with the trendlines.  This difference 
may be attributable to the systems studied: titration and complexation of triethylamine with 
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iodides are more sensitive to bulk solvent properties compared to the intramolecular interactions 
of torsion balances. 
 
      
       
Figure 14. Experimental folding data of 28a at 15 °C (log Keq) against solvent parameters. 
 
There are two points to consider regarding these folding data compared to solvent 
parameters: 1) the highest temperature at which folding ratios were obtained was 15 °C and not 
room temperature, the temperature at which many of these parameters were calculated and 
measured, and 2) the torsion balances were analyzed in deuterated solvents, but the solvent 
 32 
parameters are measured specifically for the protonated versions.  Although attempts were made 
to obtain folding ratios at 25 °C, low signal-to-noise ratios made line shape analysis of the 
1
H 
NMR
 
spectra challenging.  However, folding ratios did not change greatly from -5 to 15 °C (see 
Table 5), so one can assume that the equilibrium constants of 15 and 25 °C would be similar at 
room temperature as well.  The second point is difficult to address, as parameters are typically 
not measured in deuterated solvents.  Only the  value for CDCl3 is provided as 0.256 versus 
0.259 for CHCl3.
106
  And if the 1% difference between the two chloroforms is of any indication, 
the variation between protonated and deuterated solvents is negligible. 
3.5 CONCLUSIONS 
Halogen bonding has been recognized for decades and has been used extensively in the 
assembly of supramolecular structures. The strength of the halogen bonding interaction in 
solution is a relatively unknown quantity.  Association constants for halogen-bonding 
interactions have been determined in only a few cases,
57-61
 and most information regarding its 
strength was determined computationally.  However, computational studies will fail to accurately 
represent halogen bonding unless based on experimental evidence.  Rational drug design 
depends upon a comprehensive knowledge of weak intermolecular interactions; the significant 
impact of halogen bonding brings to attention the need for a more thorough understanding of the 
effects of halogenation and halogen bonding in solution.  For these reasons, we sought to 
measure the halogen bond by using the molecular torsion balance. 
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We found that the strength of the halogen bond as measured by ΔG decreased in the 
following order: Cl ~ Br > I.  This observed trend is contrary to the computationally predicted 
order, I > Br > Cl.  The halogen bonding interaction requires an anti conformation in the 
haloethylester group to minimize the distance between the acceptor and donor.  This reversed 
trend may be due to the gauche effect and/or simultaneous steric effects specific to our model 
system.  The substitution of certain electronegative atoms in a 1,2-disubstituted ethane will cause 
a preference for the gauche configuration over the anti.  This gauche effect decreases with the 
size of the halogen, however; iodide 28d, which featured the lowest folding ratios, should be 
least prone of the halogens to adopt a gauche configuration.  The lower folding preference could 
also be a result of steric hindrance, in which the iodoethylester is too large to be in an anti 
conformation.  As a result, propensity for folding decreases.  
We found that the stabilizing potential energy of the halogen bond was -0.2-0.3 kcal/mol 
in chloroform.  These values are considerably lower than those reported for gas phase studies and 
computational studies.  The interaction between bromobenzene and formaldehyde reduces in 
strength from -1.15 kcal/mol in vacuum to -0.64 kcal/mol in water, according to ab initio 
calculations with solvation corrections.
37
  In addition, the folding energies of torsion balances are 
not affected by temperature in the range of temperatures between -5 °C and 15 °C. 
The hydroxymethyl and carbamate functionalities gave similar folding energies of 0.2 
kcal/mol, though this does not necessarily contradict the generally accepted order of strength of 
sp>sp
2
>sp
3
;
28
 instead, this could be an accident due to unequal geometric requirements for the 
two groups.  The secondary carbamates may prefer coplanarity between the carbamate and the 
adjacent aryl ring, increasing the distance between the halogen bond donor and acceptor and 
thereby reducing the folding energies.  Methylation of the secondary carbamate reduces this 
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preference for coplanarity.  The tertiary carbamates gave modest folding ratios of approximately 
-0.3 kcal/mol, more than observed for the secondary carbamates.  
The dimethylamides 28a-d had folding energies similar to the tertiary carbamates.  The 
strength of the halogen bond between bromine or chlorine and the carbonyl oxygen of the amide 
was approximately -0.3 kcal/mol.  Our desired dimethylamides served as a model system, 
providing not only the bromide and chloride 28a-b but the iodide as well, 28d.  Notably, iodide 
28d had the least favorable folding energy of -0.15 kcal/mol, indicating that among the halogens 
studied, the iodinated species has the weakest interaction with the dimethylamide moiety.  
Our solvent studies provide invaluable data for comparing the strengths of hydrogen and 
halogen bonding.  The halogen bond interaction is weaker in chloroform than hydrogen bonding.  
Methanol is capable of blocking the hydrogen bonding interaction and inhibiting the folding 
event in balance 28c but in 28a, methanol cannot impede the halogen bonding interaction as 
effectively.  Equimolar amounts of water and methanol favor the unfolded state for 28c, but 
equally favor the folded and unfolded states for 28a.  Based on the solvent data, it takes a 
significant amount of water to obstruct the halogen bond.   
The folding energies of the torsion balances were also compared to the solvent 
parameters, dielectric constant, Taft and Kamlet‘s π* and β scales, and Reichardt‘s normalized 
parameters.  A strong correlation between log Keq and these solvent parameters were found only 
when linear regression excluded methanol.  Methanol is a clear outlier in all cases, indicating its 
ability to compete with the folding of the balances as a strong hydrogen bond donor.  The data 
suggest that halogen bonding is strongly affected by polarity and basicity of solvents, but loses 
predictability of its strength in the presence of strong hydrogen bond donors like methanol.   
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4.0  THE STRENGTH OF SALT BRIDGES AND THEIR CONTRIBUTION TO 
PROTEIN STABILIZATION 
The tertiary structure of proteins relies on non-covalent interactions for stabilization,
107
 
among which are London dispersion forces and electrostatic interactions.  Electrostatic 
interactions can be attractive or repulsive and occur over a wide range of distances.  The salt 
bridge interaction is an attraction between two oppositely charge amino acids separated by 3-5 
Å;
108,109
 as one or more hydrogen bonds frequently accompany such close functional group 
arrangements, salt bridges are typically considered a special type of hydrogen bond.
110
  
Ion pairs occur between negatively and positively charged amino acid side chains; 
negative side chains occur in aspartate and glutamate residues and the common amino acids with 
positively charged side chains are lysine, arginine, and histidine.  According to a survey 
conducted among 38 proteins with 229 total ion pairs, 38% of ion pairs occurred with arginine, 
29% with histidine and 20% with lysine.
108
  The potential for monodentate or bidentate 
interactions and thus a greater flexibility in arginine‘s111 and histidine‘s binding modes may 
account for the more frequent participation of these amino acids in salt bridges.  In two separate 
surveys, arginine was preferred as the cationic amino acid in buried salt bridges whereas lysine 
was favored for surface salt bridges, though no preference was noted for the anionic residues, 
aspartic and glutamic acids.
108,109
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Studies on the contribution of salt bridges to protein stability have provided contradictory 
results – probably because the strength of salt bridges is highly context dependent.  The protein, 
the geometry of the interaction, solvent conditions, nearby chemical groups, and other aspects of 
the environment of the salt bridge all play important roles in its strength.
109,112
  Evidence from 
continuum electrostatic calculations of 21 different salt bridges suggest that the replacement of 
salt bridge residues with hydrophobic isoteres would be favorable,
113
 which has also been shown 
experimentally.
114-116
  The desolvation penalty for the salt bridge residues diminishes with 
increases in solvent exposure
113
 and also temperature.
117
  On the other hand, it has been 
suggested that the desolvation costs were overestimated in the continuum electrostatic 
calculations,
118,119
 and continuum electrostatic calculations by Kumar and Nussinov for 222 salt 
bridges considered nearly all (86%) the interactions stabilizing by -3.7(±3.9) kcal/mol; they also 
determined that buried salt bridges were more stabilizing than exposed ones.
109
 
The general consensus is that salt bridges buried in the interior of a protein are 
stabilizing; the energetic penalty for the desolvation of charged residues in the unfolded state to 
form the folded state is offset by the strength of the interaction in an environment with a low 
dielectric constant.
119
  Chymotrypsin exists in two conformations, the enzymatically active and 
inactive forms.  The equilibrium between these states was found to be affected by the existence 
of a buried salt bridge between the amino terminus of Ile16 and the carboxylate of Asp194.
120
  
Deprotonation of this salt bridge at a pH greater than 8 contributes to a loss of 2.9 kcal/mol in 
stabilization energy, a value calculated from equilibrium constants.
121
  A site-directed mutation 
of Arg10 to methionine of the DNA-binding domain of 434 repressor led to a 2 kcal/mol 
decrease in stability.
122
  Site-directed mutagenesis of two buried salt bridges of barnase, 
Arg69/Asp93 and Arg83/Asp75, proved to be destabilizing; substitution of the aspartates with 
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lysines led to 4.11 and 4.80 kcal/mol losses in protein stability and coupling energies of the salt 
bridges determined by double mutant cycle were -3.34 and -3.53 kcal/mol respectively.
111
  
The contribution of salt bridges located at the surface of proteins to the stability of 
proteins has proven to be a contentious issue.  Results suggest that salt bridge contributions to 
the stability of the protein decrease as exposure to solvent increases, and that this is due to 
solvent screening and the entropic cost of amino acid immobilization.
119,123,124
  Site-directed 
mutagenesis of the glutamic and aspartic acids to the corresponding amides of each of the six 
surface salt bridges on or near the surface of human lysozyme was conducted to determine the 
salt bridge contribution to stability.  The results suggest that salt bridge contributions to 
stabilization energies would be insignificant when fully exposed to solvent and would be as large 
as -2.2 kcal/mol when fully buried.
125
  
Crystal structures of the B1 domain of protein G reveal consistent formation of three 
surface salt bridges involving lysines.  That these salt bridges do not appear in solution is shown 
by the fact that in 50 mM phosphate buffer, the lysine protons exchange more readily with the 
solvent than the carboxylate.
126
  The coupling energy of the engineered surface salt bridge 
between Glu28 and Lys32 of barnase was only -0.2 kcal/mol, measured by double mutant 
cycle.
127
  The incorporation of salt bridges to the surface of the CGN4 leucine zipper increased 
its stability by only -0.08 kcal/mol,
128
 while engineered surface salt bridges of T4 lysozyme only 
added between -0.1 to -0.25 kcal/mol to its stability.
129
  Solvent exposure seems to have a 
deleterious effect on the strength of the salt bridge. 
Solvent screening and the entropic cost of amino acid immobilization are two possible 
reasons for decreased strength of the salt bridge with greater solvent exposure.
119,123,124
  The 
analysis of two salt bridges of a rubredoxin variant (PFRD-XC4) support the concept of entropic 
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penalties for amino acid immobilization.  Hyperthermophilic organisms maintain stability at 
significantly higher temperatures than their mesophilic counterparts with optimum growth 
temperatures usually between 80 and 100 °C.  The resilience of hyperthermophiles is typically 
ascribed to an increased number of salt bridges and salt bridge networks in their 
hyperthermophilic proteins.  The rubredoxin variant PFRD-XC4 has two important surface salt 
bridges that potentially contribute to the hyperthermostability, one between the side chains of 
Lys6 and Glu49 and another between the amino-terminus and Glu14.  The Lys6-Glu49 salt 
bridge was found to have a negligible bonding energy whereas a main chain to side chain salt 
bridge between the amino-terminus and Glu14 was measured to be -1.5 kcal/mol.
130
  The greater 
strength of the latter salt bridge may be due to preorganization of the N-terminus, which is 
immobilized as part of the main chain; fixing the position of only one residue reduces the 
entropic penalty and increases the interaction energy.  
The strength of salt bridging is not always weak or negligible when exposed to solvent. In 
one study, all the surface arginines of ubiquitin were modified to ureas; little difference in 
stability between the mutant and the wild type was observed.
131
  These results however only 
account for the electrostatic portion of the salt bridge; the ureas are capable of hydrogen bonding.  
In another study evaluating the strength of two conserved surface salt bridges in the 
hyperthermophilic protein Ssh10b, the salt bridges between Glu36 and Lys68 and between 
Glu54 and Arg57 were measured as -1.4 kcal/mol and -0.60 kcal/mol respectively.  Both salt 
bridges are near the surface of the protein, but the solvent accessible surface areas (ASA) for the 
residues indicated only partial exposure: Glu54: 5%, Arg57: 28%, Glu36: 40%, Lys68: 58%.   
The Glu36/Lys68 salt bridge was significantly more exposed to solvent and yet its strength is 
twice that of its more buried counterpart.
132
  Due to the close proximity of the two residues in the 
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primary sequence, a Glu54/Arg57 salt bridge may potentially form in the unfolded state, for 
which the double mutant cycle cannot account.  These data may be an example of a faulty double 
mutant cycle or a contradiction to the norm that solvent exposed salt bridges are weak.  
There are further examples in which surface salt bridges lead to increased stability of the 
protein.  Random-mutagenesis of β-glucosidase A gave thermostable mutant, Glu96Lys, which 
formed a new salt bridge between Lys96 and Asp28. This mutation doubled the half-life for 
unfolding relative to that of the wild-type β-glucosidase A at 48 °C.133  A double mutant cycle to 
analyze a partially solvent exposed ion pair between Asp23 and the N-terminus of ribosomal 
protein L9 gave varying coupling energies from -0.7 to -1.7 kcal/mol.
134
  The coupling energy of 
the salt bridge between Lys11 and Glu34 of ubiquitin was found to be -0.86  kcal/mol, using a 
double mutant cycle.
135
  A surface salt bridge formed between Asp70 and His31 of T4 lysozyme 
had an estimated strength of 3-5 kcal/mol, based on site-directed mutagenesis and thermal 
unfolding transitions.
136
  A triad of residues, Asp8, Asp12, and Arg110, on the surface of barnase 
form two salt bridges.  Fersht used double and triple mutant cycles to determine coupling 
energies of -0.98 kcal/mol between Asp8 and Arg110 and -1.25 kcal/mol between Asp12 and 
Arg110.  These interactions were cooperative; absent one salt bridge, the energy of the other was 
reduced by 0.77 kcal/mol.
137
 
As shown above, the relationship between the strength of a salt bridge interaction and its 
degree of solvation is controversial.  Under physiological conditions, ionic strength also affects 
salt bridge stability, but the correlation between the two is murky.  Salt bridges are primarily 
electrostatic in nature; therefore, as ionic strength of solution increases, the strength of the 
interaction should become smaller.
113
  Experimental results have largely attested to this 
prediction.  In one case, the coupling energy between aspartic acid and arginine decreased from   
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-0.98 to -0.35 kcal/mol when the ionic strength increased from 0.0 M NaCl to 0.5 M NaCl.
137
  In 
human lysozyme, mutation studies showed that salt bridges with greater than 50% exposure to 
solvent did not contribute to the stability of the protein in 0.2 M KCl.  The mutations did not 
eliminate the hydrogen bonding component of the salt bridge.
125
  
On the other hand, the strength of the salt bridge between Asp23 and the N-terminus of 
protein L9 was largely unaffected by the ionic strength increase from 100 mM NaCl to 750 mM 
NaCl.
134
  A salt bridge of GCN4 leucine zipper monomer, which has been shown to be 
indispensable for folding of the coiled-coil formation,
138
 and salt bridges in alanine-based model 
peptides with lysine or histidine interspersed with aspartic or glutamic acid at regular 
intervals
139,140
 were only partially screened at salt concentrations up to 2.0 M.  Finally, an 
analysis of the pKa of a histidine in haemoglobin (His HC3(146)β) verified pKa did not alter 
considerably (8.0-8.1) regardless of ionic strength and demonstrated the independence of the 
strength of surface salt bridges from external salt concentrations in solution.
141
  Salt bridges may 
be immune to changes in ionic strength if the interaction acts more like a hydrogen bond than a 
Coulombic or electrostatic interaction.
134,142
  Even clearly electrostatic interactions can show 
insensitivity to ionic strength.
139,143
  
In a survey conducted on 28 proteins, maximum accessible contact surface areas (ϕ-
areas) were calculated for the 134 salt bridges to determine degree of solvent exposure. 24% 
were considered buried (ϕ-areas of 0-15% of the maximum), 37% were partially buried (ϕ-areas 
of 15%-50%) and the remaining 39% were deemed exposed or surface salt bridges.
108
  A similar 
survey of 36 proteins determined that 30% of the total 222 salt bridges were buried (ϕ ≤ 20%).109  
It is, for the most part, accepted that buried salt bridges stabilize the protein, but a significant 
number of salt bridges are not buried, and occur on the surface or are partially solvent exposed.  
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Unfortunately, research has not reached a consistent conclusion on whether or not these solvent 
exposed interactions are stabilizing.  If solvent exposed salt bridges are destabilizing to the 
protein, why would nature preserve this interaction?  One possible explanation, that salt bridges 
reduce the number of stable conformations adopted by the protein and lend specificity to 
folding,
111,113,144
 does not justify the frequency with which salt bridges are used. 
It is apparent from the data obtained in the past decades that the contribution of salt 
bridges to the stabilization of proteins is highly context dependent, but many questions are still 
unanswered.  What is the contribution of solvent exposed salt bridges to the stability of proteins?  
What is the strength of the interaction?  How do the factors of ionic strength and temperature 
affect the strength of the interaction?  Our research delves into these questions outside the 
context and complexity of proteins, using the molecular torsion balance. 
4.1 EVALUATION OF METHODS TO MEASURE THE SALT BRIDGE 
One must break a salt bridge to measure its strength, and there are two common methods 
to do so: by mutation effects or by pKa studies.  In the first method, the salt bridge is broken 
upon protonation of the acidic residue or deprotonation of the basic amino acid, and changes in 
pKa are measured to obtain a relative stability contribution.  Although this method does not 
require structural modification of the residues and is considered non-invasive, residual 
electrostatic interactions between the neutralized and charged amino acids can still occur.
145
  
The second method requires modification of one or both charged residues to uncharged 
surrogates, usually aliphatic amino acids.  Site-directed mutagenesis of a salt-bridge participant 
and measurement of the resulting destabilization is a popular method to determine the strength of 
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a salt bridge,
122,125,129,133,136 ,142
 although the correlation between the strength of the salt bridge 
and its contribution to the stability of a protein is difficult to establish.
113
  The relationship is at 
best tenuous due to new interactions or solvation differences between the folded and unfolded 
states.
111
  For example, the coupling energy derived from a double mutant cycle of the Asp166-
Arg119 salt bridge in T4 lysozyme is a mere 0.10 kcal/mol, while the lysozyme loses 0.51 
kcal/mol in stability when either of the residues are modified.  The strength of the salt bridge of 
Arg6-Glu53 in protein GB1 is predicted by double mutant cycle to be 0.60 kcal/mol, but the 
stability of the protein is unaffected by the loss of the salt bridge.
135
  Arg31, Glu36 and Arg40 
form a buried salt bridge triad in Arc repressor.  The coupling energies of Arg31/Glu36 and 
Glu36/Arg40 are -1.7 and -4.7 kcal/mol respectively, yet the interactions are not considered 
major contributors to the overall stability of the protein.
114
  Changes to the stability of the protein 
do not directly correlate to the strength of the salt bridge, because the relationship is tempered by 
local context.
145
  
The double mutant cycle approach solves these problems in part by attempting to isolate 
one specific noncovalent interaction by cancelling out background interactions.  It requires the 
syntheses of one double and two single mutants, and the system must fulfill several assumptions: 
1) no significant structural rearrangements occur in the mutants relative to the wild-type, 2) no 
interactions occur between the substituted residues in the area of interest, and 3) no changes to 
the unfolded state transpire.
134,135
  To confirm that the assumptions have been met, more than one 
double mutant cycle should be carried out and these should yield similar coupling energies.
145
  
Most research groups however only perform one double mutant cycle, while others have 
obtained dissimilar results from multiple mutant cycles.
134
  Only one group has conducted a 
multiple double mutant cycles to obtain the similar strengths for the two salt bridges studied.
132
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All data regarding the salt bridge have been derived from peptides or proteins.  The 
intricacy of these systems complicates and obscures the accurate measurement of a single 
interaction.  Although the double mutant cycle can alleviate some of these issues, several 
assumptions must be met for the data to be valid.  By subjecting the torsion balances to different 
conditions, we can obtain accurate, quantitative data for the coupling energy of the salt bridge. 
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5.0  EVALUATION OF THE SALT BRIDGE USING THE MOLECULAR TORSION 
BALANCE 
Our objective was to measure this salt bridge interaction in a small molecular framework.  
We sought to obtain quantitative information regarding the strength of the interaction when 
exposed to water, without employing a double mutant cycle.  To achieve this goal, amino and 
guanidino groups were appended to the lower arm of the dibenzodiazocine framework of our 
second generation torsion balance (Figure 15).  For the two esters that make up the two 
competing sides of this torsion balance, an alkyl ester (methyl or isopentyl) was balanced against 
a carboxyethyl ester.  At neutral pH in water, a salt bridge may form between the carboxylate 
and the amine or guanidine, and we planned to use this tool to measure the effects of a salt bridge 
on folding.  
 
 
Figure 15. Representative chemical structures for the folded and unfolded conformers.  
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5.1 SYNTHESIS OF SALT BRIDGE TORSION BALANCES 
By observing perturbation in the orientation of the isophthalate moiety, we could use the 
torsion balance to get a direct comparison of a carboxyethyl and an alkyl group, R (e.g. methyl or 
isopentyl), as they interact with the interior of the dibenzodiazocine and the amino or guanidino 
group.   The retrosynthetic strategy for the torsion balances is shown in Scheme 7.  
Scheme 7. Retrosynthetic analysis.  
 
 
 
The guanidine 30 can be accessed from corresponding amine 31.  Protecting groups will 
be necessary to form the biphenyl bond of the torsion balance through Suzuki coupling between 
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pinacolatoboronate 34 and bromide 33.  The pinacolatoboronate 34 can be derived from the 
Tröger's base analog 35, and the asymmetrical isophthalate was to be synthesized from 2-
bromoisophthalic acid 12.  
The pinacolatoboronate 34 was relatively simple to access from the hydroxyalcohol 21.  
It is reported that the Mitsunobu reaction works efficiently with acidic nucleophiles with pKa 
values lower than 11.
146,147
  Though the pKa of di-tert-butyl iminodicarboxylate (Boc2NH) 
should be between 8 and 11, the major product obtained using the usual Mitsunobu conditions 
formed the new C—N bond between the substrate and the di-tert-butyl azodicarboxylate.  The 
addition of triethylamine facilitated the formation of the desired product 35, which was obtained 
in 65% yield.
148
  Borylation provided 34 in 93% yield.   
Scheme 8. Mitsunobu reaction. 
 
 
As part of the project on the analysis of hydrophobic effects that was previously carried 
out in our laboratory, a solubilizing group was appended to the isophthalate moiety of the torsion 
balance in order to improve solubility of the balance in water.
23
  We found that the glutaramide 
functionality was not necessary to achieve the 1 mM concentration of our desired molecules in 
water.  Although the glutaramide and consequently the nitro group (R
2
, Scheme 7) were not 
essential, we retained the nitro group in order to have an opportunity to evaluate any effects that 
changes in this remote position might have on folding.  
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The carboxyethyl group was initially positioned against a methyl group (R, Scheme 7) 
due to the accessibility of starting materials and the ease of line shape analysis.  However, to 
evaluate steric effects in folding, we also sought to introduce a lipophilic isostere of the 
carboxyethyl group.  Therefore, isopentyl esters (isoamyl, abbreviated as i-Am) were also 
synthesized. 
In all, four carboxyethyl isophthalates were generated: 37, 40, 42, and 44.  These 
included two methyl esters (one bearing the 5-nitro group) and the two isopentyl esters (one with 
the 5-nitro group).  The syntheses of the isophthalates are illustrated in Schemes 9-12. Diacid 12 
was esterified and selectively hydrolyzed to give intermediate 36.
149
  Steglich esterification gave 
the product 37 in 82% yield (Scheme 9).  Nitration followed by dicyclohexylcarbodiimide 
(DCC) coupling provided 40 (Scheme 10).  Monoesterification of the diacid 12 furnished 
hemiester 41, which underwent DCC coupling to give 42 (Scheme 11).  
Scheme 9. Synthesis of isophthalate 37. 
 
 
 
Scheme 10. Synthesis of isophthalate 40. 
 
 
Scheme 11. Synthesis of isophthalate 42. 
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For the last needed isophthalate, diacid 13 was esterified with isoamyl bromide to give 
the monoester 43 (Scheme 12).  Although the Steglich esterification of the hemiesters provided 
37, 40, and 42 in moderate to high yields, these conditions consistently led to poor yields and 
decomposition for the synthesis of 44.  Therefore, an alternate route via an acid chloride
150
 was 
followed to provide the last ester 44 with moderate yield.   
Scheme 12. Synthesis of isophthalate 44. 
 
 
 
The Suzuki couplings between the four isophthalates and pinacolatoboronate 34 gave the 
torsion balances in moderate to good yields (Scheme 13), and treatment with trifluoroacetic acid 
(TFA) deprotected the Boc groups.
151
  The polarity of the products at this point was high enough 
that purification through normal phase column chromatography would have been difficult.  
Fortuantely, the crude products of the TFA deprotection did not require purification to move 
onto the next step.  Treatment of 46a-d with palladium on carbon and hydrogen gas at 40 PSI
152
 
deprotected the benzyl carboxylates and reduced the nitro groups to give products, 47a-d.  The 
torsion balances were purified using reverse phase HPLC by applying a linear gradient of water 
containing 0.1% TFA and acetonitrile containing 0.1% TFA over the course of 20-30 minutes at 
a flow rate of 15 mL/min. 
Attempts to directly convert the torsion balances 47a-d to their corresponding guanidines 
failed.  The best route required treatment of 46a-d with pyrazole-1-carboxamidine in the 
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presence of Hünig‘s base in DMF,153 followed by debenzylation and reduction to give the 
desired guanidines 48a-d (Scheme 14).  The guanidines were less polar compared to their amine 
analogs and were readily purified by reverse phase HPLC. 
Scheme 13. Synthesis of amines 47. 
 
 
 
Scheme 14. Synthesis of guanidines 48. 
 
 
 One last torsion balance was synthesized in order to determine the role of the isopentyl 
group in the preference for folding (Scheme 15).  The diester 49 was obtained through DCC 
coupling of the hemiester, which was used in a subsequent Suzuki coupling to provide the Boc-
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protected torsion balance.  Deprotection of the amine gave the desired product 51 in quantitative 
yield.  
Scheme 15. Synthesis of the control. 
 
 
5.2 1H NMR SPECTRA OF SALT BRIDGING TORSION BALANCES 
To determine folding ratios, the torsion balances 47a-d and 48a-d were analyzed by 
1
H 
NMR at concentrations of 0.5-1.0 mM in D2O.  Changing the concentration used for NMR 
analysis over a range from 0.1 mM to 2.0 mM did not alter the spectra and the folding ratios 
determined, signifying a lack of aggregation in water.  
1
H NMR spectra were taken at varying 
temperatures from 5 to 25 °C with ten degree increments on the 700 MHz NMR.  Water 
suppression experiments were tested to improve the resolution of the spectra, but the attenuation 
of signals within 2 ppm of the water peak made this method impractical for quantitative data 
acquisition.  Torsion balances 47a-d, containing the ammonium side chain, were very soluble in 
water, while the corresponding guanidines 48a-d were decidedly less water soluble.  Torsion 
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balances 47a-d and 48a-b were sufficiently soluble in D2O to obtain 1 mM solutions, but 
guanidines 48c-d required more D2O to be solvated completely; the latter two torsion balances 
were run at concentrations of 0.5 mM.  
 
Figure 16. 
1
H NMR spectrum of 47a at 15 °C in D2O. 
 
The 
1
H NMR spectra for compounds 47a and 47c serve as suitable models for discussion 
of the spectra of all the salt bridging torsion balances.  The 
1
H NMR spectrum of 47a at 5 °C in 
D2O is shown  in Figure 16.  Assignments of the signals for the two conformers were facilitated 
by examination of EXSY cross peaks acquired at 5 °C (with a mixing time of 0.5 seconds). 
The largest chemical shift difference of the isophthalate before and after the Suzuki 
coupling occurs at the methylene (b, b') distal from ester.  The methylene resonates at 1.11 ppm 
in the folded state (b) and at 2.15 ppm in the unfolded state (b'), while these protons appear as a 
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triplet in the model compound bromide 37 at 2.83 ppm; this is a 1.04 ppm difference between the 
conformers and a 1.73 ppm difference between the folded conformer and the isophthalate before 
Suzuki coupling.  This significant shielding effect induced upon folding is indicative of the close 
proximity of this group with the lower ring of the dibenzodiazocine in the folded state.  
 
Figure 17. The 
1
H NMR spectrum for 47c at 5 °C in D2O. 
 
Similar results were observed for other protons, although the difference was not as large.  
The methyl ester of bromide 37 appears at 3.93 ppm.  In 47a, these protons resonate at 3.47 and 
2.76 ppm in the folded (c) and unfolded conformers (c') respectively.  
The 
1
H NMR spectrum for 47c is similar to 47a, but the isoamyl ester group complicates 
the region from 1.0 to 0.2 ppm (Figure 17).  Again, the largest chemical upfield shift induced as 
a result of Suzuki coupling is that of the distal methylene in the folded state (b) which appears at 
1.08 ppm, compared to 2.82 ppm in the starting isophthalate, 42, a difference of 1.74 ppm.  The 
inner methylene (e'/e) of the isoamyl group experiences comparable changes; the 1.63 ppm 
signal in 42 moves upfield by 1.3 ppm to 0.33 ppm in the unfolded state (e').  
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Figure 18. 
1
H NMR spectra at 5 (purple), 15 (green), and 25 °C (orange) for 47c in D2O. 
 
The 
1
H NMR spectra do not considerably change over a 20 °C range (Figure 18).  The 
signal attributed to b moves slowly downfield from 1.1 to 1.2 ppm as the temperature increases, 
while the signal for e' separates from the triplet at 0.3 ppm (g').  The splitting patterns lose 
definition and broaden as the temperature rises (e.g. b), though the signals are still sharper than 
the halogen bond torsion balances described in Section 3.2.  
The population of the folded to unfolded conformers were determined for temperatures 5 
to 25 °C using dynamic NMR line shape fitting assisted with the program iNMR.
80
  NMR 
spectra taken at 35 °C or above were too difficult to analyze due to significant signal broadening 
and poor signal to noise ratio.  
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Figure 19. Simulations of the NMR signals of the carboxyethyl (middle spectrum) and 
methyl (top spectrum) esters of 47a at 5 °C (bottom spectrum). 
 
Two sets of NMR simulations were conducted for 47a, the methyl ester and the 
carboxyethyl ester.  In Figure 19, the simulations of the methyl (top) and carboxyethyl groups 
(middle) are shown compared to the experimental spectrum (bottom).  Differences between the 
simulated and experimental spectra for the methyl ester were sensitive to changes of as little as 
1.5% to the folding population.  Therefore, the error in amount of folded conformer is posited to 
be ±1.5%.  Error analysis is discussed further in Section 6.3.  The splitting patterns and 
consequent folding ratios for the carboxyethyl ester portion of these molecules were difficult to 
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reliably replicate for the torsion balances (and not feasible for the isopentyl esters 47c, 47d, 48c, 
and 48d due to signal overlap).  For balances 47a, 47b, 48a, and 48b, the folding ratios reported 
in Table 8 are derived from the line shape analysis of only the methyl ester signals (c/c', Figure 
19).  For the isopentyl torsion balances, the terminal methyls of the isopentyls (g/g') were used 
for the evaluation of folding with an accuracy equal to that of the methyl esters (±1.5%).  
5.3 THE STRENGTH OF THE SALT BRIDGE INTERACTION  
1
H NMR spectra of torsion balances 47a-d and 48a-b at 1 mM and 48c-d at 0.5 mM 
concentrations in D2O and in 50 mM buffer solutions of varying pD.  Because few buffer 
mixtures can cover the entire pH or in this case pD range without exhibiting interfering 
1
H NMR 
signals, several different buffers solutions were made.  The buffers used at pD 3.1 and 5.5 were 
prepared from potassium deuterium phthalate, which displayed two signals in the aromatic 
region but did not interfere with our analysis.  A phosphate buffer was used at pD 7.2, a borate 
buffer at pD 10.0, and two buffers were used at pD 12, carbonate and phosphate buffers.  
However, the torsion balances decomposed at pD 12 in both these buffers.  Therefore, the pD 12 
data are not included in Table 8 below.  
The free energy of folding is defined by the following equations: 
Keq = 
][
][
1
1
unfolded
folded
k
k


   (Equation 1) 
ΔG° = -RT ln Keq    (Equation 2) 
in which R is the universal gas constant (1.9875 cal / K mol), T is the temperature in Kelvin, and 
Keq represents the equilibrium constant or the ratio of the concentrations of the folded state to the 
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unfolded state.  Line shape analysis was performed to obtain ratios of folded and unfolded states, 
which were used to calculate the experimental folding energies for torsion balances 47a-d and 
48a-d.  The results are shown in Table 8.   
The preference for folding was strongest for 47 between pD of 5.5 and 10.0.  This is 
supportive of a salt bridge interaction between the protonated amine and the deprotonated 
carboxylate for 47.  The range of folding energies varied within this pD range between -0.39 
kcal/mol for 47a at 5 °C and -0.66 kcal/mol for 47c at 5 and 15 °C.  Therefore, the strength of 
the ammonium-carboxylate interaction is considerable at -0.7 kcal/mol when exposed to solvent.  
We observed diminished folding at pD 3.1, which correlates to the protonation of the carboxylate 
and the ―breaking‖ of the salt bridge interaction.  The folding energies are still as stabilizing as      
-0.1 – -0.2 kcal/mol for torsion balances 47a-d at the pD 3.1.  This is indicative of the strength of 
residual electrostatic interactions that can still occur between a charged and a neutral group.
145
  
The folding energies of torsion balances 48a-d vary between -0.39 to -0.59 kcal/mol in 
the pD range of 5.5 to 10.0, similar to the stabilization obtained for 47a-d.  Ester 48a-d forms a 
salt bridge in the folded state between a guanidinium and a carboxylate, while 47a-d forms one 
between ammonium and carboxylate.  In proteins, ion pairs form more frequently with arginine 
as the positively charged residue than with lysine.  This has been attributed to the ability of the 
guanidinium ion to bind in a variety of modes.
111
  We found that a salt bridge between a 
carboxylate and a guanidinium group or an ammonium had similar strengths in the context of 
these torsion balances.  
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Table 8. Folding ratios and energies at varying pD.  
  
T 
D2O pD 3.1 pD 5.5 pD 7.2 pD 10.0 
  %F
a,b
 -ΔG°c,d %Fa,b -ΔG°c,d %Fa,b -ΔG°c,d %Fa,b -ΔG°c,d %Fa,b -ΔG°c,d 
47a 5 57 0.16 56 0.13 67 0.39 69 0.43 68 0.43 
 
15 57 0.16 57 0.16 69 0.44 69 0.47 69 0.46 
 
25 57 0.16 56 0.15 70 0.49 71 0.54 70 0.50 
47b 5 62 0.28 57 0.16 72 0.52 68 0.41 70 0.47 
 
15 61 0.24 57 0.17 69 0.45 69 0.45 71 0.52 
 
25 60 0.23 58 0.19 69 0.47 71 0.54 71 0.54 
47c 5 63 0.28 58 0.19 77 0.66 75 0.60 74 0.57 
 
15 61 0.25 57 0.16 76 0.66 73 0.55 73 0.57 
 
25 59 0.21 56 0.15 73 0.59 73 0.59 72 0.54 
47d 5 61 0.25 58 0.18 70 0.48 73 0.56 72 0.52 
 
15 61 0.26 58 0.17 71 0.52 73 0.56 73 0.56 
 
25 61 0.26 58 0.18 73 0.57 75 0.63 73 0.59 
48a 5 60 0.22 59 0.20 67 0.39 68 0.42 70 0.46 
 
15 60 0.24 59 0.20 67 0.40 69 0.45 71 0.52 
 
25 61 0.26 59 0.22 67 0.41 70 0.50 71 0.52 
48b 5 59 0.21 59 0.19 66 0.37 68 0.40 70 0.48 
 
15 61 0.25 59 0.20 66 0.39 68 0.44 70 0.48 
 
25 60 0.25 59 0.22 68 0.44 70 0.50 70 0.51 
48c 5 61 0.24 55 0.11 67 0.39 67 0.40 68 0.41 
 
15 58 0.19 54 0.10 67 0.40 67 0.41 70 0.48 
 
25 58 0.18 53 0.07 66 0.39 72 0.57 73 0.59 
48d 5 58 0.17 57 0.15 67 0.39 68 0.41 71 0.49 
 
15 61 0.26 55 0.11 69 0.46 70 0.47 74 0.59 
  25 60 0.24 53 0.06 69 0.47 70 0.49 71 0.53 
a) ‗%F‘ represents percent folded, which were determined from line shape analyses of the 1H NMR spectra acquired 
on a 700 MHz NMR. b)  ±1.5% error in folding ratios. c) ±15% error for the free energy. d) kcal/mol.  
 
We used molecular modeling to evaluate the possible conformations of torsion balances 
47b and 48b.  The MMFF94s forcefield
154,155
 was applied in systematic conformational searches 
to locate the lowest energy conformations, shown below in Figures 20 and 21 respectively.  The 
distances measured between the ammonium and the two oxygens of the carboxylate group of 
47b were 2.37 and 2.38 Å, indicative of a strong ionic pairing.  The lowest energy conformer in 
Figure 21 for 48b features a bidentate interaction with distances of 2.33 and 2.32 Å between the 
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two oxygens of the carboxylate and two nitrogens of the guanidinium.  This indicates that the 
torsion balance is geometrically capable of forming a bidentate salt bridge.  
The forcefield MMFF94s is parameterized for gas phase small organic molecules.  As 
indicated by the modeling, the bidentate interaction is certainly possible, but we were curious as 
to how the mode of binding may be affected by solvation.  To evaluate the effects of solvation on 
the guanidinium 48b, energy minimization was applied to the lowest energy conformer shown in 
Figure 21, using the MMFF94s forcefield in conjunction with the generalized Born implicit 
solvent model and including several water molecules around the guanidinium and carboxylate 
functionalities (Figure 22).  Water molecules are shown in light blue.  The carboxylate group no 
longer forms a bidentate interaction with the guanidinium, instead approaching in a nearly 
perpendicular fashion from one side.  
 
 
Figure 20. Lowest energy conformer for 47b.  
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Figure 21. Lowest energy conformer for 48b. 
 
While the distance between oxygen and nitrogen for 47b were calculated to be as low as 
2.3 Å, the distances measured for the conformer in Figure 22 were close to or slightly greater 
than the sum of the van der Waals radii of oxygen and nitrogen; the distances between the β-
nitrogen and the two oxygens were 3.08 and 3.67 Å, and the distances between the δ-nitrogen 
and the carboxylate oxygens were 3.41 and 4.47 Å.  Both the β- and δ-nitrogens of the 
guanidinium are relatively close to the carboxylate, but as a result of aqueous solvation, the salt 
bridge features longer distances between the carboxylate and the guanidinium ions.  
The substituent at the meta position (R
2
, Scheme 7), whether proton or amine, makes no 
experimentally significant difference to the folding ratios of the torsion balances. This is 
consistent with the observations made in our studies of hydrophobic interactions,
156
 in which 
substitution of a nitro, amine or glutaramide group did not affect folding energies, though 
interestingly, changes to the rates of rotation were seen.   
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Figure 22. The lowest energy conformer of solvated 48b (front and side views) 
 
Temperature has little effect on the folding energies of these torsion balances.  The 
strength of the ion pair interaction remains constant over the 20 °C temperature range.  Although 
the range is too small, other research groups have reached the same conclusion.  The strength of 
salt bridges in hyperthermophilic protein Ssh10b were unchanged when the temperature was 
raised by 55 °C; Glu36/Lys68 was measured to be -1.4 kcal/mol and Glu54/Arg57 decreased 
slightly from -0.57 to -0.52 kcal/mol at 25 and 80 °C.
132
  Molecular dynamics also demonstrated 
the resilience of salt bridges at 25 and 100 °C.
157
  Our data confirm that temperature does not 
adversely affect the strength of a salt bridge.   
Most of the isopentyl esters are more prone to folding compared to their methyl analogs 
by approximately -0.1 kcal/mol.  The difference between the folded and unfolded states for the 
chemical shift of the methine proton (f/f', Figure 18) is minimal, suggesting that the isopentyl 
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group is not proximate to the dibenzodiazocine rings even when the isopentyl group is inside the 
cleft.  Although, for the right size group, the hydrophobic effect will cause an alkyl group to 
remain inside,
156
 steric effects discourage the isopentyl group from being inside the cleft.   
To determine the degree to which the isopentyl group, which is similar in size to the 
carboxyethyl chain, affects folding, torsion balance 51 was synthesized.  For convenience, we 
will refer to the convex side of the dibenzodiazocine as the endo position.  In torsion balance 51, 
the folded conformer in the following discussion is defined as the one in which the isopentyl 
group is endo to the cleft.  The folding energies for 51 are shown in Table 9.  The preference for 
the isopentyl group to stay outside the cleft of the dibenzodiazocine rings is about -0.06 
kcal/mol.  This small energetic difference explains the approximately 0.1 kcal/mol disparity 
between the methyl and isopentyl esters in Table 8 (47, 48: a and b versus c and d).  Although 
the isopentyl and carboxyethyl groups are isosteric, the energetic difference is due to the 
unfavorable fit of the isopentyl group in the endo position.  
Table 9. Folding data for control 51. 
    pD 3.1 pD 7.2 pD 10.0 
  T %F
a,b
 -ΔG°c,d %Fa,b  -ΔG°c,d %Fa,b  -ΔG°c,d 
51 5 48 -0.04 47 -0.06 46 -0.08 
 
15 48 -0.04 47 -0.06 49 -0.03 
  25 49 -0.03 49 -0.03 49 -0.02 
a) ‗%F‘ represents percent folded, which were determined from line shape analyses of the 1H NMR spectra acquired 
on a 700 MHz NMR. b)  ±1.5% error in folding ratios. c) ±15% error for the free energy. d) kcal/mol.  
 
5.4 THE EFFECTS OF IONIC STRENGTH ON SALT BRIDGE INTERACTIONS 
The effect of ionic strength on the salt bridge interaction is under debate in the biophysics 
community.  Salt bridges are electrostatic in nature.  Theoretically, as the ionic strength of the 
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solution increases, the strength of the interaction should diminish.
113
  Experimental results 
however have led to contradictory conclusions.  In human lysozyme, salt bridges with more than 
50% exposure to solvent did not contribute to the stability of the protein in 0.2 M KCl,
125
 and a 
loss of half or 0.57 kcal/mol in coupling energy between aspartic acid and arginine was measured 
in 0.5 M NaCl.
137
  Meanwhile, in alanine-based model peptides with lysine or histidine 
interspersed with aspartic or glutamic acids at regular intervals
139,140
 salt bridges were only 
partially screened at salt concentrations up to 2.0 M, and the strength of salt bridges in 
haemoglobin (His HC3(146)β) were found to be independent from external salt concentrations in 
solution.
141
 
Torsion balances 47a-b were examined in phosphate buffers of two concentrations, 0.200 
and 0.050 M.  The phosphate buffers at pD 7.2 were composed of disodium hydrogen phosphate 
and sodium dihydrogen phosphate.  The ionic strength, I, of a solution, which is the 
concentration of all the ions present in solution, is defined by the following equation:  
        (Equation 3) 
in which ci is the molar concentration of ion i, and zi is the charge number of ion i.  According to 
equation 3, a 0.200 M phosphate buffer has an ionic strength of approximately 0.4 M, which a 
phosphate buffer of 0.050 M has an ionic strength of approximately 0.1 M.  
 The experimentally observed 
1
H NMR spectra of torsion balances 47a and 47b were 
simulated using line shape analysis to determine the folding ratios and energies in the two 
phosphate buffers (Table 10).  There is a small but experimentally significant difference in the 
folding energies between the two balances in 0.200 and 0.050 M buffers with a four-fold 
difference in ionic strengths.   
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Table 10. Ionic strength effect on folding energies.  
  T 
0.200 M phosphate 0.050 M phosphate 0.050 M + KCl 
%F
a,b
 -ΔG°c,d %Fa,b -ΔG°c,d %Fa,b -ΔG°c,d 
47a 5 70 0.48 74 0.58 72 0.53 
 
15 73 0.58 76 0.65 74 0.59 
 
25 72 0.56 75 0.64 71 0.54 
47b 5 74 0.56 74 0.57 71 0.49 
 
15 75 0.62 78 0.71 74 0.59 
  25 75 0.64 78 0.75 74 0.63 
a) Percent folded was determined from line shape analyses of the 
1
H NMR spectra acquired on a 700 MHz NMR. b)  
±1.5% error in folding ratios. c) ±7% error for the free energy in this folding range (see Section 6.3). d) kcal/mol.  
 
The 0.050 M phosphate buffer has an ionic strength of 0.1 M.  The addition of potassium 
chloride to a concentration of 0.3 M in a 0.050 M phosphate buffer increases the ionic strength of 
the solution from 0.1 to 0.4 M.  The torsion balances were studied in this adjusted solution to 
obtain their folding ratios (―0.050 M + KCl, Table 10).  It is apparent from the data that ionic 
strength has a modest effect on the strength of the salt bridge interaction; the addition of 0.3 M 
potassium chloride to the 0.050 M phosphate buffers has an experimentally significant effect on 
the folding ratios.  
Salt bridges are ion pairs, separated by short distances.  The strength of the salt bridge is 
attributed partly to the hydrogen bond that forms between the two charged residues and partly to 
the Coulombic interaction.  When salt bridges are immune to changes in ionic strength, this 
behavior has been justified by considering the salt bridge as more like a hydrogen bond than an 
electrostatic interaction.
134,142
  However, even clearly electrostatic interactions can still behave in 
this manner.
139,143
  There are multiple cases in which it appears that salt effects do not diminish 
salt bridges, but the results obtained from the torsion balances above suggest that the effects must 
be carefully considered on a case by case basis.  
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5.5 CONCLUSIONS 
It is, for the most part, accepted that buried salt bridges stabilize the protein, but a 
significant number of these interactions occur on the surface or are partially solvent exposed.  
The biophysics community has not reached a consistent conclusion on whether or not these 
solvent exposed interactions are stabilizing.  However, one limitation to the research conducted 
involves the use of proteins or peptides to determine the stabilization of the interaction.  
Quantification of the strength of one single interaction within this complex environment reduces 
the accuracy in the measurements and creates ambiguity in the interpretation of any observed 
effect.  Our research sought to measure the energy of a salt bridge and its effect on folding by 
using a small molecule; the torsion balance is well-controlled, sensitive to weak interactions of 
less than 0.1 kcal/mol, and effectively reduces the number of interfering variables relative to a 
protein. 
Surface or exposed salt bridges typically have maximum accessible contact surface areas 
(ASA) of 50% or greater, which compares the degree of solvation of residues in tertiary 
structures to that in the primary, unfolded state.  An approximate ASA for the carboxyethyl 
group of 47a was calculated to be 54%, indicating that the carboxyethyl group is to be 
considered exposed.  
We found conclusively that the salt bridge was a stabilizing interaction when exposed to 
solvent.  The stabilizing force varies between -0.3 to -0.5 kcal/mol for both the ammonium- and 
guanidinium-carboxylate interactions.  This range is lower for the ammonium-carboxylate 
interaction compared here than reported results for solvent exposed ion pairs of proteins; an 
interaction between Asp23 and the N-terminus of ribosomal protein L9 gave coupling energies 
from -0.7 to -1.7 kcal/mol,
134
 while the salt bridge between Glu36 and Lys68 was -1.4 kcal/mol 
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in hyperthermophilic protein Ssh10b.
132
  Measured salt bridge interactions between guanidinium 
and carboxylate groups were found to be considerably stronger in some proteins: the coupling 
energy of the salt bridge between Lys11 and Glu34 of ubiquitin was found to be -0.86  kcal/mol, 
using a double mutant cycle,
135
 and in a cooperative network of two salt bridges between three 
residues, Asp8, Asp12, and Arg110, on the surface of barnase, the two salt bridges had coupling 
energies of -0.98 kcal/mol and -1.25 kcal/mol.
137
  These latter values actually fall into our 
measured range when one salt bridge was removed from the network; strengths become -0.21 
and -0.48 kcal/mol respectively.  In future studies, it would be interesting to examine the effects 
of preorganization on salt bridge stability by restricting the number of positions and orientations 
that the ionic groups may occupy. 
We found that the guanidinium and ammonium torsion balances gave similar folding 
energies, though this does not imply that the guanidinium-carboxylate interaction optimally is 
only as strong as the ammonium-carboxylate torsion balance. Molecular modeling using force 
field, MMFF94s, and a generalized Born solvation model suggest that water plays an integral 
role in increasing the distance between the guanidinium and carboxylate ions to form a pseudo-
bidentate interaction.  
Temperature seems negligible with regards to the strength of the salt bridge interaction. 
The temperature was varied within a 20 °C range, which is admittedly limited, and little 
difference was seen in the folding energies. Ionic strength was varied from 0.050 M to 0.200 M 
and this four-fold difference had a modest but experimentally significant effect on the strength of 
the salt bridge interaction in our torsion balances. A measurable change in the folding ratios also 
came from adjusting the pD of the buffer solutions. At pD 3.1 (and at 12 for the ammonium 47), 
the folding ratios dropped from approximately 68% to no more than 59%, indicative of the 
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protonated state of the carboxylate and the breaking of the salt bridge interaction. The fact that 
the torsion balance still favors the folded state implies an interaction of some strength, 
approximately -0.2 kcal/mol, between the charged ammonium and the neutral carboxylic acid.  
We found conclusively that a salt bridge is still a stabilizing force whether or not it is 
exposed to solvent. Solvent exposure has been shown to weaken the interaction, reducing the 
strength of the guanidinium-carboxylate to that measured for the ammonium-carboxylate 
interaction. The strength of the interaction was shown to be approximately -0.3 to -0.5 kcal/mol, 
independent of temperature and weakly dependent on ionic strength, and sensitive to pD 
changes.  
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6.0  EXPERIMENTAL 
Melting points were determined using a Thomas Hoover capillary melting point 
apparatus and are uncorrected. Proton and carbon nuclear magnetic resonance spectra (
1
H and 
13
C NMR) were obtained using Bruker Avance 500 (halogen bonding torsion balances) and 700 
MHz (salt bridge torsion balances) spectrometers.  Chemical shifts are in parts per million (δ) 
using the residual solvent peak as the reference value.  The values used for proton and carbon 
spectra, respectively, are 7.24 and 77.23 ppm for CDCl3, 3.34 and 49.17 ppm for MeOD, and  
and 2.49 and 39.50 ppm for d6-DMSO.  Abbreviations used in proton data are: s = singlet; d = 
doublet; t = triplet; q = quartet; dd = doublet of doublets; dt = doublet of triplets; m = multiplet.  
Also 
1
H NMR chemical shifts are listed for all the possible conformations of a given molecule.  
For example, compound 45a has protons with two possible environments due to different 
rotational isomers.  Consequently these protons are exemplified as follows: 3.59/2.77.  The 
1
H 
NMR data of compounds 26a-c, 27a-c, 28a-d, 29a-b, 45a-d, 47a-d, and 48a-d include the 
temperature at which the spectrum was taken.  The 
13
C NMR spectra were taken at room 
temperature unless otherwise indicated.   
Thin layer chromatography (TLC) was performed on E. Merck 60F 254 (0.25 mm) 
analytical glass plates.  The normal phase column chromatography was performed on SiliaFlash 
P60 silica gel (40-63 µm).  Dry solvents were obtained by distilling the solvents from the 
appropriate drying agent under nitrogen atmosphere shortly before use.  Dichloromethane 
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(CH2Cl2) was distilled from CaH2, and diethyl ether and THF were distilled from sodium metal 
and benzophenone.  Dry DMSO was purchased from Aldrich and used as supplied. References to 
―removal of volatile components under reduced pressure‖ refer to rotary evaporation of the 
sample at 25-65°C at a pressure of 18-25 mm Hg and then overnight under high vacuum (0.1 
mm Hg) at room temperature.  All percentage yields are for material of >95% purity as indicated 
by 
1
H NMR spectra, unless stated otherwise.  
RP-HPLC purification was performed using a Hitachi HPLC system on a Jupiter 300 
reverse phase column (C18, 300 Å, 250 × 21.2 mm, 10 µm) with a linear gradient of solvent 
polarity over the course of 20-30 minutes at a flow rate of 15 mL/min and detection at UV 220 
nm. Solvents used for the HPLC elution were (A) H2O containing 0.1% TFA and (B) acetonitrile 
containing 0.1% TFA. The solvent gradient is noted for each compound purified using RP-
HPLC.  
6.1 SYNTHESIS.  
2-Bromoisophthalic acid (12): To a stirred solution of 100.3 g (0.63 mol) of 
potassium permanganate and 2.0 g (0.05 mol) of sodium hydroxide in 300 mL of 
water was added 25.0 g (0.135 mol) of 2-bromo-m-xylene. The reaction was refluxed for 24 
hours, then cooled to room temperature and 40.0 g (0.38 mol) of NaHSO3 were slowly added to 
the reaction. The mixture was filtered through a plug of Celite, which was then sonicated in 100 
mL of water and filtered again. The combined filtrate was boiled to reduce the volume by 100 
mL and then acidified with HCl (200 mL, 1 M). The solution was cooled slowly to room 
temperature over several hours and set aside for two days during which time solid precipitated. 
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Filtration afforded 18.57 g (56%) of the title compound as white crystals: 
1
H NMR (CD3OD, 300 
MHz) δ 7.73 (d, 2H, J = 7.6 Hz), 7.48 (t, 1H, J = 7.8 Hz), 5.32 (s, 2H).158 
 
2-Bromo-5-nitroisophthalic acid (13): To a stirred solution of 0.56 mL of 
fuming nitric acid HNO3 and 3.37 mL of fuming sulfuric acid at 0 °C was 
added 0.50 g (2.04 mmol) of 12 portionwise over 10 minutes. The reaction was slowly warmed 
and stirred overnight. The solution was added dropwise to 20 mL of H2O at 0 °C, which was 
warmed to room temperature and extracted with EtOAc (4 x 20 mL). The organic extracts were 
washed with brine (20 mL), dried over MgSO4, and filtered, and voltatile components of the 
filtrate were removed under reduced pressure to afford 0.5826 g (98%) of 2-bromo-5-
nitroisophthalic acid as a white solid: IR (liquid) υ 3540-2500 (broad), 3084, 1717, 1349; 1H 
NMR (MeOD-d4, 300 MHz) δ 8.55 (s, 2H); 13C NMR (MeOD-d4, 300 MHz) δ 167.55, 166.52, 
148.09, 139.22, 138.91, 127.29, 127.00, 126.22, 69.50, 23.09, 10.99; HRMS calculated for 
C8H4BrNO6 288.922198, found 288.921733.  
 
2-Bromo-5-nitroisophthalic acid 1-propyl ester (14): To a stirred 
solution of 0.10 g (0.35 mmol) of 2-bromo-5-nitroisophthalic acid (13) in 
3.4 mL of dimethyl sulfoxide was added 0.11 g (0.83 mmol) of potassium carbonate and then 
0.03 mL (0.35 mmol) of 1-iodopropane. The mixture was stirred for six hours at 60 °C 
temperature, after which the reaction mixture was treated with 20 mL of 1 M HCl and extracted 
with EtOAc (3 x 20 mL). The organic extracts were washed with brine (20 mL), dried over 
MgSO4, filtered and the volatile components of the filtrate were removed under reduced 
pressure. The residue was purified by column chromatography (hexanes: EtOAc, 1:1) to afford 
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0.84 g (73%) of the 2-bromo-5-nitroisophthalic acid monopropyl ester: IR (thin film) υ 3700-
2400 (broad), 3089, 2971, 1711, 1347, 1292, 1242, 1148; 
1H NMR (MeOD, 700 MHz) δ 8.59 (d, 
1H, J = 2.8 Hz), 8.52 (d, 1H, J = 2.8 Hz), 4.39 (t, 2H, J = 6.3 Hz), 1.85 (t, 2H, J = 7 Hz), 1.08 (t, 
3H, J = 7.7 Hz); 
13C NMR (MeOD, 700 MHz) δ 166.02, 164.99, 146.56, 137.68, 137.38, 125.76, 
125.47, 124.69, 67.08, 21.55, 9.46; HRMS calculated for C11H10BrNO6 330.969148, found 
330.969002.  
 
General Esterification Procedure: To a stirred solution of the alcohol in dry CH2Cl2 at 0°C 
was added 1,3-dicyclohexylcarbodiimide (DCC) and 4-dimethylaminopyridine (DMAP) in 
CH2Cl2. After ten minutes, the carboxylic acid 13 was added in four portions over eight minutes. 
The reaction mixture was warmed to room temperature and then stirred for four hours. The 
precipitated urea was removed by filtration and washed with CH2Cl2. Volatile components of the 
filtrate were removed under reduced pressure, and the residue was purified by column 
chromatography (hexanes, EtOAc, 20:1).  
 
2-Bromo-5-nitroisophthalic acid 1-(2'-bromoethyl) ester 3-propyl 
ester (15a): By the general esterification procedure, 0.12 mL (1.75 
mmol) of 2-bromoethanol, 0.24 g (1.17 mmol) of DCC and 0.02 g (0.15 mmol) of DMAP in 3.0 
mL of dry CH2Cl2, treated with 0.19 g (0.58 mmol) of 13, provided 0.19 g (74%) of the title 
compound as an oil: IR (thin film) υ 3083, 2968, 1739, 1535, 1232,; 1H NMR (CDCl3, 300 MHz) 
δ 8.52 (dd, 2H, J = 15.6 and 2.7 Hz), 4.68 (t, 2H, J = 6.0 Hz), 4.33 (t, 2H, J = 6.9 Hz), 3.64 (t, 
2H, J = 6 Hz), 1.77 (sextet, 2H, J = 6.9 Hz), 0.989; 
13
C NMR (CDCl3, 300 MHz) δ 164.58, 
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164.08, 146.39, 137.49, 136.14, 126.85, 126.78, 126.76, 68.64, 65.84, 28.11, 22.01, 10.64; 
HRMS calculated for formula C13H13BrNO6 436.910960, found 436.910006.  
 
2-Bromo-5-nitroisophthalic acid 1-(2'-chloroethyl) ester 3-propyl 
ester (15b): By the general  esterification procedure, 0.06 mL (0.90 
mmol) of 2-chloroethanol, 0.12 g (0.90 mmol) of DCC and 0.01 g (0.08 mmol) of DMAP in 1.5  
mL of dry CH2Cl2, treated with 0.10 (0.30 mmol) of 13, provided 0.08 g (68%) of the title 
compound as an oil: IR (thin film) υ 3085, 2966, 2926, 1738, 1536, 1232, 1184; 1H NMR 
(CDCl3, 300 MHz) δ 8.513 (dd, 2H, J = 2.7 and 12.0 Hz), 4.625 (t, 2H, J = 5.4 Hz), 4.332 (t, 2H, 
J = 6.6 Hz), 3.813 (t, 2H, J = 5.7 Hz), 1.789 (sextet, 2H, J = 7.2 Hz), 0.989 (t, 3H, 3.6 Hz); 
13
C 
NMR (CDCl3, 300 MHz) δ 164.71, 164.21, 146.39, 137.49, 136.17, 126.84, 126.74, 68.64, 66.1, 
41.27, 22, 10.63; HRMS calculated for C13H13BrClNO6 392.961476, found 392.961003.  
 
2-Bromo-5-nitroisophthalic acid 1-(2'-hydroxyethyl) ester 3-
propyl ester (15c): By the general  esterification procedure, 0.10 
mL (1.81 mmol) of ethylene glycol, 0.37 g (1.81 mmol) of DCC and 0.02 g (0.15 mmol) of 
DMAP in 3.0 mL of dry CH2Cl2, treated with 0.20 g (0.60 mmol) of 13, provided 0.11 g (49%) 
of the title compound as an oil: IR (thin film) υ 3431 (broad), 3085, 2967, 1738, 1536, 1351, 
1238; 
1
H NMR (CDCl3, 300 MHz) δ 8.517 (dd, 2H, J = 2.7 and 8.4 Hz), 4.518 (t, 2H, J = 4.8 
Hz), 4.347 (t, 2H, J = 6.6 Hz) 3.970 (t, 2H, J = 4.8 Hz), 1.803 (sextet, 2H, J = 6.9 Hz), 1.018 (t, 
3H, J = 7.5 Hz); 
13
C NMR (CDCl3, 300 MHz) δ 164.69, 164.57, 146.23, 137.16, 136.61, 126.53, 
126.45, 126.37, 68.49, 68.02, 60.67, 21.83, 10.45; HRMS calculated for C13H14BrNO7 
374.995363, found 374.994979.  
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2-Bromo-8-carboxy-6H,12H-5,11-methanodibenzo[b,f][1,5] 
diazocine (17): To a stirred solution of 1.50 g (4.0 mmol) of 2,8- 
dibromo-6H,12H-5,11-methanodibenzo[b,f][1,5]diazocine (16) in 44 mL of dry THF:ether (8:3) 
at –78°C was added n-butyllithium (2.7 mL, 1.6 M in THF, 4.3 mmol) over two minutes. The 
solution was stirred for five minutes at –78°C and then carbon dioxide was bubbled through the 
reaction. The pink heterogeneous mixture was slowly warmed to room temperature over an hour, 
after which the volatile components were removed under reduced pressure. The residue was 
dissolved completely in methanol (10 mL) and then diluted with 50 mL of 1M HCl. The solution 
was extracted with EtOAc (5 x 50 mL), which in turn was washed with brine (100 mL). The 
organic extracts were dried over MgSO4, filtered, and volatile components of the filtrate were 
removed under reduced pressure. The residue was purified by column chromatography (hexanes: 
EtOAc, 2:1) to afford 0.84 g (61%) of the carboxylic acid as a pale yellow foam: 
1
H NMR 
(MeOH-d4, 300 MHz) δ 7.90-7.95 (m, 1H), 7.78-7.79 (m, 1H), 7.34-7.51 (m, 4H), 4.81-5.05 (m, 
4H), 4.43-4.55 (m, 2H). 
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2-Bromo-8-(tert-butoxycarbonylamino)-6H,12H-5,11-
methanodibenzo[b,f][1,5]diazocine (18): To a stirred solution of 
1.24 g (3.6 mmol) of the carboxylic acid (17)  and 0.75 mL (5.4 mmol) of triethylamine in 36 
mL of t-butanol was added 1.2 mL (5.4 mmol) of diphenyl phosphoryl azide dropwise. The 
solution was refluxed for 24 hours, cooled to room temperature, and then diluted with 50 mL of 
EtOAc. The resulting mixture was washed successively with 25 mL of the following: 5% citric 
acid, water, saturated NaHCO3, and brine. The organic extract was dried over MgSO4, filtered, 
and volatile components of the filtrate were removed under reduced pressure. The residue was 
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purified by column chromatography (hexanes: EtOAc, 4:1) to afford 0.87 g (58%) of the 
carbamate as a white foam: IR (thin film) υ 3307, 1718, 1529, 1496, 1477, 1160; 1H NMR 
(CDCl3, 300 MHz) δ 6.96-7.22 (m, 6H), 6.33 (s, 1H), 4.61 (dd, 2H, J = 7.5 and 16.5 Hz), 4.25 (d, 
2H, J = 4.8 Hz), 4.07 (dd, 2H, J = 7.2 and 16.8 Hz), 1.45 (s, 9H); 
13
C NMR (CDCl3, 300 MHz) δ 
153.1, 147.2, 142.9, 134.8, 130.7, 130.1, 129.9, 128.3, 126.9, 125.5, 118.7, 117.0, 116.8, 80.8, 
67.1, 59.0, 58.5, 28.5; HRMS calculated for C20H22
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BrN3O2 415.0895, found 415.0894. 
 
2-(4,4,5,5-Tetramethyl-[1,3,2]dioxaborolan-2-yl)-8-(tert-
butoxycarbonylamino)-6H,12H-5,11-methanodibenzo[b,f]  
[1,5]diazocine (19): The carbamate (18) (0.25 g, 0.6 mmol), bis(pinacolato)diboron (0.31 g, 1.2 
mmol), dichlorobis[methylene-bis(diphenylphosphine)]-dipalladium-dichloromethane adduct 
(9.0 mg, 0.009 mmol), and potassium acetate (0.08 g, 0.8 mmol) were combined in a flask, 
which was placed under vacuum for five to ten minutes and then filled with N2. Addition of 3.6 
mL of anhydrous DMSO to this mixture provided an orange solution which was degassed twice 
by freeze pump thaw cycle and then heated at 80°C for 12 hours. The reaction was cooled to 
room temperature, diluted with 50 mL of CH2Cl2, and the resultant mixture was washed with 
water (3 x 50 mL). The combined aqueous layers were extracted with CH2Cl2 (2 x 50 mL). The 
organic extracts were dried over MgSO4, filtered and the volatile components of the filtrate were 
removed under reduced pressure. The residue was purified by column chromatography (hexanes: 
EtOAc, 3:1) to afford 0.22 g (77%) of the title compound as a white foam: IR (thin film) υ 3327, 
2977, 1723, 1609, 1361, 1160; 
1
H NMR (CDCl3, 300 MHz) δ 7.57 (d, 1H, J = 13.5 Hz), 7.36 (s, 
1H), 7.09 (d, 2H, J = 13.5 Hz), 7.01 (s, 1H), 6.95 (t, 1H, J = 4.0 Hz), 6.30 (s, 1H), 4.67 (s, 1H), 
4.62 (s, 1H), 4.29 (s, 2H), 4.14 (t, 2H, J = 27.5 Hz), 1.45 (s, 9H), 1.27 (s, 12H); 
13
C NMR 
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(CDCl3, 300 MHz) δ 153.04, 151.17, 143.07, 134.53, 133.94, 130.62, 128.54, 127.17, 126.93, 
125.52, 124.50, 118.55, 116.97, 83.88, 67.17, 66.06, 59.07, 58.75, 28.50, 24.99, 15.48; HRMS 
calculated for C26H34
11
BN3O4 463.2642, found 463.2658.  
 
2-Bromo-8-formyl-6H,12H-5,11-methanodibenzo[b,f]  [1,5]diazocine 
(20): To a stirred solution of 1.50 g (3.9 mmol) of 2,8- dibromo-6H,12H-
5,11-methanodibenzo[b,f][1,5]diazocine (16) in 43 mL of dry THF:ether (8:3) at –78°C was 
added n-butyllithium (2.7 mL, 1.6 M in THF, 4.3 mmol) over two minutes. The solution was 
stirred for five minutes at –78°C, and dimethylformamide (mL, mmol) was added to the reaction. 
The heterogeneous mixture was slowly warmed to room temperature over an hour, after which 
20 mL of H2O was added to quench the reaction. The solution was extracted with EtOAc (3 x 30 
mL), which in turn was washed with brine (100 mL). The organic extracts were dried over 
MgSO4, filtered, and volatile components of the filtrate were removed under reduced pressure. 
The residue was purified by column chromatography (hexanes: EtOAc, 5:1) to afford 0.94 g 
(72%) of the aldehyde as a pale yellow foam: 
1
H NMR (CDCl3, 300 MHz) δ 9.82 (s, 1H), 7.67 
(d, 1H, J = 6.0 Hz), 7.45 (s, 1H), 7.22-7.28 (m, 2H), 7.02 (t, 2H, J = 8.4 Hz), 4.70 (dd, 2H, J = 
6.9 and 16.5 Hz), 4.28 (s, 2H), 4.19 (dd, 2H, J = 4.8 and 17.1 Hz).
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2-Bromo-8-hydroxymethyl-6H,12H-5,11-methanodibenzo 
[b,f][1,5]diazocine (21): To a stirred solution of 0.50 g (1.52 mmol) of 
the aldehyde (20) in 8.9 mL of methanol at 0 °C was added 0.07 g (1.84 mmol) of sodium 
borohydride. The heterogeneous solution was slowly warmed to room temperature over 10 
minutes, stirred for an additional hour, and then diluted with 25 mL of H2O. The resulting 
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solution was extracted with EtOAc (4 x 25 mL). The organic extracts were dried over MgSO4, 
filtered, and volatile components of the filtrate were removed under reduced pressure. The 
residue was purified by column chromatography (hexanes: EtOAc, 1:1) to afford 0.45 g (89%) of 
the Tröger‘s base analog as a white foam: IR (thin film) υ 3317 (broad), 2902, 2851, 1494, 1476, 
1206, 833; 
1
H NMR (CDCl3, 300 MHz) δ 6.906 – 7.240 (m, 6H), 4.642 (dd, 2H, J = 9.3 and 16.8 
Hz), 4.542 (d, 2H, J = 4.5 Hz), 4.255 (s, 2H), 4.105 (d, 2H, J = 17.1 Hz); 
13
C NMR (CDCl3, 300 
MHz) δ 147.33, 147.22, 137.01, 130.67, 130.12, 129.91, 127.78, 126.95, 126.72, 125.91, 125.35, 
116.82, 66.94, 65.13, 58.90, 58.56; HRMS calculated for C16H16BrN2O 331.0446, found 
331.0435.  
 
2-Hydroxymethyl-8-(4,4,5,5-tetramethyl-[1,3,2] dioxaborolan-
2-yl)-6H,12H-5,11-methanodibenzo[b,f][1,5] diazocine (22): 
The alcohol (21) (0.54 g, 1.6 mmol), bis(pinacolato)diboron (0.50 
g, 2.0 mmol), dichlorobis[methylene-bis(diphenylphosphine)]-dipalladium-dichloromethane 
adduct (25 mg, 0.02 mmol), and potassium acetate (0.23 g, 2.3 mmol) were combined in a flask, 
which was placed under vacuum for five to ten minutes and then filled with N2. Addition of 9.9 
mL of anhydrous DMSO to this mixture provided an orange solution which was degassed twice 
by freeze pump thaw cycle and then heated at 80°C for 16 hours. The reaction was cooled to 
room temperature, diluted with 50 mL of CH2Cl2, and the resultant mixture was washed with 
water (3 x 50 mL). The combined aqueous layers were extracted with CH2Cl2 (2 x 50 mL). The 
organic extracts were dried over MgSO4, filtered and the volatile components of the filtrate were 
removed under reduced pressure. The residue was purified by column chromatography (pentane: 
Et2O, 1:1) to afford 0.59 g (95%) of the title compound as a white foam: IR (thin film) υ 3392 
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(broad), 2977, 1609, 1360, 1145; 
1
H NMR (CDCl3, 300 MHz) δ 7.57 (d, 1H, J = 7.8 Hz), 7.35 (s, 
1H), 7.00-7.09 (m, 3H), 6.80 (s, 1H), 4.58 (dd, 2H, J = 5.7 and 16.8 Hz), 4.46 (s, 2H), 4.20 (s, 
2H), 4.10 (d, 2H, J = 16.8 Hz), 1.26 (s, 12H); 
13
C NMR (CDCl3, 300 MHz) δ 151.01, 147.23, 
136.94, 134.09, 133.90, 127.84, 127.14, 126.52, 125.78, 125.20, 124.45, 83.86, 66.86, 64.93, 
58.81, 58.68, 24.93; HRMS calculated for C22H27
11
BN2O3 378.211473, found 378.21158. 
 
2-Bromo-8-(cyano(hydroxy)methyl)-6H,12H-5,11-
methanodibenzo [b,f][1,5]diazocine (23): To a stirred solution of 
0.54 g (1.63 mmol) of the aldehyde (20) in 16.3 mL of dry CH2Cl2 was added 0.4 mL of 
trimethylsilyl cyanide (3.25 mmol) and then 0.18 g (0.81 mmol) of zinc bromide. The reaction 
was stirred for 45 minutes, after which the volatile components were removed under reduced 
pressure. To a solution of the residue in 12 mL of acetonitrile was then added 3 mL of 3M 
aqueous HCl. The solution was then diluted with 10 mL of H2O and was extracted with CH2Cl2 
(3 x 25 mL). The organic extracts were dried over MgSO4, filtered, and volatile components of 
the filtrate were removed under reduced pressure. The crude was taken directly to the next step 
residue to afford 0.36 g (82%) of the cyanohydrin as a white foam: IR (thin film) υ 3110, 2951, 
2905, 1493, 1477, 1208, 837; 
1
H NMR (CDCl3, 300 MHz) δ 7.25-7.31 (m, 2H), 7.12 (dd, 1H, J = 
3.6 and 8.4 Hz), 7.01 (dd, 3H, J = 8.7 and 16.2 Hz), 5.38 (d, 1H, J = 2.4 Hz), 4.61 (dd, 2H, J = 
5.7 and 16.8 Hz), 4.20 (s, 2H), 4.09 (d, 2H, J = 17.1 Hz); 
13
C NMR (CDCl3, 300 MHz) δ 149.21, 
146.69, 131.44, 130.94, 129.92, 129.68, 128.61, 126.95, 126.27, 125.77, 125.65, 118.93, 117.15, 
66.69, 63.42, 58.63, 58.50; HRMS calculated for C17H15BrN3O 356.0398, found 356.0402.  
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2-Bromo-8-(2-(dimethylamino)-2-oxoethyl)-6H,12H-5,11-
methanodibenzo[b,f]  [1,5]diazocine (24): Step 1 – Oxidation: To 
a solution of the cyanohydrin (0.68 g, 1.90 mmol) in 10.9 mL of hydroiodic acid was added red 
phosphorus (0.71 g, 22.78 mmol). The solution was heated to 80 °C for 6 hours and then cooled 
to room temperature, after which the phosphorus was removed by filtration. The filtrate was 
treated with 1 M NaHSO3 (20 mL) and was extracted with EtOAc (3 x 30 mL). The organic 
extracts were washed with brine (40 mL), dried over MgSO4, and the volatile components were 
removed under reduced pressure. The crude was taken directly to the next step. Step 2 – 
Amidation: To a stirred solution of dimethyl amine hydrochloride (0.11 g, 1.30 mmol) in 2.2 mL 
dry CH2Cl2 at 0°C was added 0.18 g (0.87 mmol) DCC and 0.01 g (0.11 mmol) of DMAP and 
then 0.12 mL (0.87 mmol) of triethylamine. After ten minutes, the crude carboxylic acid was 
added in four portions over eight minutes. The reaction mixture was warmed to room 
temperature and then stirred for five hours. The precipitated urea was removed by filtration and 
washed with CH2Cl2. Volatile components of the filtrate were removed under reduced pressure, 
and the residue was purified by column chromatography (EtOAc) to afford 0.15 g (58%) of the 
amide: IR (thin film) υ 2923, 2852, 1641, 1475, 1207; 1H NMR (CDCl3, 700 MHz) δ 7.24 (s, 
1H), 7.02-7.05 (m, 3H), 6.98 (d, 1H, J = 8.4 Hz), 6.80 (s, 1H), 4.62 (t, 2H, J = 16.1 Hz), 4.24 (dq, 
2H, J = 1.4 and 11.2 Hz), 4.09 (dd, 2H, J = 17.5 and 20.3 Hz), 3.55 (d, 2H, J = 2.1 Hz), 2.97 (s, 
3H), 3.92 (s, 3H); 
13
C NMR (CDCl3, 700 MHz) δ 171.00, 147.21, 146.34, 130.89, 130.41, 
130.08, 129.72, 128.22, 127.67, 127.17, 126.84, 125.19, 116.51, 66.72, 58.61, 58.28, 40.13, 
37.76, 35.65; HRMS calculated for C19H20BrNaN3O 408.0687, found 408.0702;  
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2-(2-(Dimethylamino)-2-oxoethyl)-8-(4,4,5,5-tetramethyl-
[1,3,2]dioxaborolan-2-yl)-6H,12H-5,11-methanodibenzo[b,f]  
[1,5]diazocine (25): The amide (0.06 g, 0.15 mmol), 
bis(pinacolato)diboron (0.05 g, 0.19 mmol), dichlorobis[methylene-bis(diphenylphosphine)]-
dipalladium-dichloromethane adduct (2 mg, 0.0002 mmol), and potassium acetate (0.02 g, 0.21 
mmol) were combined in a flask, which was placed under vacuum for five to ten minutes and 
then filled with N2. Addition of 0.9 mL of anhydrous DMSO to this mixture provided an orange 
solution which was degassed twice by freeze pump thaw cycle and then heated at 80°C for 16 
hours. The reaction was cooled to room temperature, diluted with 10 mL of CH2Cl2, and the 
resultant mixture was washed with water (3 x 10 mL). The combined aqueous layers were 
extracted with CH2Cl2 (2 x 10 mL). The organic extracts were washed with brine (20 mL), dried 
over MgSO4, filtered and the volatile components of the filtrate were removed under reduced 
pressure. The residue was purified by column chromatography (pentane: Et2O, 1:4) to afford 
0.05 g (75%) of title product as a white foam: IR (thin film) υ 2975, 2928, 1643, 1360, 1145; 1H 
NMR (CDCl3, 700 MHz) δ 7.57 (d, 1H, J = 7.7 Hz), 7.36 (s, 1H), 7.00-7.10 (m, 3H), 6.77 (s, 
1H), 4.65 (d, 2H, J = 16.8 Hz), 4.27 (s, 2H), 4.14 (dd, 2H, J = 3.5 and 16.8 Hz), 3.53 (s, 2H), 
2.94 (s, 3H), 2.90 (s, 3H), 1.27 (s, 12H); 
13
C NMR (CDCl3, 700 MHz) δ 171.07, 151.17, 146.53, 
133.91, 133.67, 130.58, 127.98, 127.97, 127.21, 127.05, 125.21, 124.43, 83.72, 66.80, 58.65, 
58.51, 40.26, 37.79, 35.63, 24.82; HRMS calculated for C25H32B
23
NaN3O3 456.2434, found 
456.2426. 
 
General Suzuki Coupling Procedure: The isophthalate (15a, 15b, or 15c), dibenzodiazocine 
pinacolatoboronate (19, 22, or 25), and chloro(di-2-norbornylphosphino)(2‘-dimethylamino-1,1‘-
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biphenyl-2-yl)palladium (II) were combined in a pressure reaction tube, which was placed under 
vacuum for five to ten minutes and then filled with N2. The solids were dissolved in 1,2-
dimethoxyethane (DME), and the solution was degassed twice by freeze pump thaw cycle. First 
water and then solid sodium bicarbonate were added to the pressure tube, and the contents were 
degassed two more times. The reaction was heated to 80°C for approximately 16 hours, cooled to 
room temperature, diluted with less than 1 mL of water. The subsequent mixture was extracted 
with CH2Cl2 or EtOAc (3 x 10-15 mL), the organic extracts were dried over MgSO4, filtered and 
volatile components of the filtrate were removed under reduced pressure. The residue was 
purified by column chromatography and then by HPLC. 
 
(2''-Bromoethyl) propyl 4'-nitro-2-phenyl-8-(tert-butoxy-
carbonylamino)-6H,12H-5,11-methanodibenzo[b,f]  
[1,5]diazocine-3',6'-dicarboxylate (26a): By the general 
Suzuki coupling procedure, 0.10 g (0.23 mmol) of isophthalate 
15a, 0.12 g (0.25 mmol) of the pinacolatoboronate 19, and 13.0 mg (0.023 mmol) of the 
palladium catalyst in 1.13 mL of DME were treated with 1.13 mL of water and 0.12 g (1.37 
mmol) of sodium bicarbonate and purified by column chromatography (pentane: diethyl ether: 
CH2Cl2, 1:1:0.002) to provide 0.069 g (44%) of the title compound: IR (thin film) υ 3367, 2969, 
1723, 1531, 1159; 
1
H NMR (CDCl3, 500 MHz, 25 °C) δ 8.63 (d, 2H, J = 11.5 Hz), 6.95-7.14 (m, 
5H), 6.75 (s, 1H), 6.38 (s, 1H), 4.67 (d, 1H, J = 17.0 Hz), 4.63 (d, 1H, J = 17.0 Hz), 4.29 (s, 2H), 
4.16 (d, 1H, J = 16.5 Hz), 4.11 (d, 1H, J = 17.5 Hz), 4.37/3.82 {s/d, (0.7/0.6+0.6) H, J = 68.0 
Hz}, 4.03/3.53 {s/d, (1.2/0.4+0.4) H, J = 82 Hz}, 3.26/2.40 {d/d, (0.4+0.4/0.5+0.5) H, J = 39.5 
and 16.5 Hz}, 1.46 (s, 12H), signal obscured at ~1.45/0.72 (s/s, {signal obscured/0.9) H} 
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0.78/0.27 (s/s, (1.5/1.1) H}; 
13
C NMR (CDCl3, 500 MHz) δ 166.22, 166.13, 153.06, 152.86, 
148.71, 148.65, 146.62, 146.46, 143.03, 134.68, 133.11, 133.00, 128.21, 127.78, 127.50, 126.74, 
126.57, 125.70, 125.55, 124.85, 123.13, 118.87, 117.14, 116.58, 80.77, 67.93, 67.37, 65.25, 
59.32, 58.87, 34.41, 30.51, 29.88, 28.49, 27.59, 21.82, 10.47; HRMS calculated for 
C33H35BrN4O8 694.163826, found 694.162873. 
 
(2''-Chloroethyl) propyl 4'-nitro-2-phenyl-8-(tert-butoxy-
carbonylamino)-6H,12H-5,11-methanodibenzo[b,f]  
[1,5]diazocine-3',6'-dicarboxylate (26b): By the general Suzuki 
coupling procedure, 0.11 g (0.27 mmol) of isophthalate 15b, 0.14 
g (0.30 mmol) of the pinacolatoboronate 19, and 15.0 mg (0.027 mmol) of the palladium catalyst 
in 1.4 mL of DME were treated with 1.4 mL of water and 0.14 g (1.64 mmol) of sodium 
bicarbonate and purified by column chromatography (pentane: diethyl ether: CH2Cl2, 1:1:0.002) 
to provide 0.081 g (44%) of the title compound: IR (thin film) υ3367, 2970, 1723, 1531, 1158; 
1
H NMR (CDCl3, 500 MHz, 25 °C) δ 8.62 (d, 2H, J = 28.0 Hz), 6.95-7.13 (m, 5H), 6.75 (d, 1H, J 
= 1.5 Hz), 6.38 (s, 1H), 4.67 (d, 1H, J = 17.0 Hz), 4.63 (d, 1H, J = 16.5 Hz), 4.32/3.73 {s/d, (0.8/ 
0.6+0.6) H, J = 76.5 Hz}, 4.29 (s, 2H), 4.15 (d, 1H, J = 17.0 Hz), 4.03/3.51 {s/d, (1.3/0.4+0.4) H, 
J = Hz}, 4.10 (d, 1H, J = 16.0 Hz), 3.40/2.54 {s/d, (0.9/0.5+0.5) H, J = 19.5 Hz},1.45 (s, 12H), 
signal obscured at ~1.45 ppm/0.72 {signal obscured/s, (signal obscured/0.9)H}, 0.78/0.26 {s/s, 
(1.8/1.1) H}; 
13
C NMR (CDCl3, 500 MHz) δ 153.04, 152.97, 148.77, 148.59, 146.62, 146.47, 
143.04, 135.97, 134.66, 133.13, 128.26, 127.46, 126.73, 126.56, 125.70, 125.54, 124.82, 118.37, 
117.09, 80.76, 67.94, 67.38, 65.36, 59.38, 58.90, 40.54, 34.41, 30.51, 28.48, 21.82, 21.37, 10.48; 
HRMS calculated for C33H35N4O8Cl 650.214342, found 650.212944. 
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(2''-Hydroxyethyl) propyl 4'-nitro-2-phenyl-8-(tert-butoxy-
carbonylamino)-6H,12H-5,11-methanodibenzo[b,f]  
[1,5]diazocine-3',6'-dicarboxylate (26c): By the general 
Suzuki coupling procedure, 0.025 g (0.07 mmol) of isophthalate 
15c, 0.03 g (0.07 mmol) of the pinacolatoboronate 19, and 4.0 mg (0.01 mmol) of the palladium 
catalyst in 0.3 mL of DME were treated with 0.3 mL of H2O and 0.03 g (0.41 mmol) of sodium 
bicarbonate and purified by column chromatography (diethyl ether) to provide 0.017 g (40%) of 
the title compound: IR (thin film) υ 3360 (broad), 2926, 2754, 1721, 1531, 1159; 1H NMR 
(CDCl3, 500 MHz, 25 °C) δ 8.63 (s, 2H), 6.96-7.16 (m, 5H), 6.76 (s, 1H), 6.30 (s, 1H), 4.67 (t, 
2H, J = 17.5 Hz), 4.32 (s, 2H), 4.19 (d, 1H, J = 15.5 Hz), 4.12 (s, 1H), 4.06/3.57 {d/d, 
(0.9+0.9/0.4+0.4) H, J = 25.0 and 60.0 Hz}, signal obscured/3.64 {signal obscured/d, 
(unknown/0.7+0.7) H, J = 85.0 Hz}, 3.55/2.58 {s/s, (0.4/1.0) H}, 1.46 (s, 12H), signal 
obscured/0.73 {signal obscured/s, (signal obscured/0.7) H}, 0.79/0.28 {s/s, (1.9/0.8) H}; 
13
C 
NMR (CDCl3, 500 MHz) δ 166.83, 166.19, 153.60, 148.67, 146.67, 146.23, 143.65, 143.38, 
135.46, 135.10, 134.48, 134.21, 133.43, 128.50, 127.42, 126.80, 126.56, 125.53, 124.78, 119.71, 
118.39, 81.08, 67.91, 67.35, 66.89, 60.72, 59.56, 59.37, 59.00, 29.89, 28.49, 21.83, 21.18, 10.49; 
HRMS calculated for C33H37N4O9 633.2561, found 633.2609. 
 
 
 (2''-Bromoethyl) propyl 4'-nitro-2-phenyl-8-(tert-butoxy-
carbonyl-(methyl)amino)-6H,12H-5,11-methanodibenzo[b,f][1,5]diazocine-3',6'-
dicarboxylate (29a): To a solution of 0.04 g (0.05 mol) of 26a in 0.7 mL of dry THF at 0 °C 
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was added 6.0 mg (0.16 mmol) of 60% sodium hydride in mineral oil, which was stirred for 5 
minutes. Methyl iodide (0.03 mL, 0.53 mmol) was added dropwise to the reaction mixture, 
which was warmed to room temperature and then stirred for an additional 30 minutes. The 
reaction was added to 10 mL of ice water and extracted with EtOAc (4 x 10 mL). The organic 
extracts were dried over MgSO4, filtered and volatile components of the filtrate were removed 
under reduced pressure. The crude residue was purified by column chromatography (pentane: 
Et2O, 2:1) to afford 0.02 g (58%) of the title compound: IR (thin film) υ 2969, 1723, 1698, 1532, 
1496, 1351, 1309, 1243, 1151; 
1
H NMR (CDCl3, 700 MHz, 25 °C) δ 8.64 (d, 2H, J = 9.8 Hz), 
7.14 (d, 1H, J = 7.7 Hz), 7.06 (s, 2H), 7.01 (d, 1H, J = 7.7 Hz), 6.82 (s, 1H), 6.78 (s, 1H), 4.67 
(dd, 2H, J = 16.1 and 30.8 Hz), 4.38/3.84 {s/d, (0.7/0.6+0.5)H, J = 63.0 Hz}, 4.29 (s, 2H), 4.10-
4.20 (m, 2H), 4.02/3.62 {s/d, (1.1/0.3+0.3)H, J = 77.7 Hz}, 3.26/2.43 {d/d, (0.3+0.3/0.4+0.5)H, J 
= 63.7 and 21.0 Hz}, 3.16 (s, 3H), 1.42 (s, 12H), signal obscured at ~1.45/~0.78 {signals 
obscured, (signal obscured/~0.5)H}, 0.78/0.22 {s/s, (2.0/1.0)H}; 
13
C NMR (CDCl3, 700 MHz) δ 
166.69, 166.19, 165.77, 154.87, 148.92, 148.59, 146.61, 145.01, 139.99, 135.81, 134.82, 134.45, 
133.24, 133.02, 128.04, 127.68, 127.57, 126.70, 125.29, 124.98, 123.58, 123.36, 80.59, 67.94, 
67.17, 65.37, 59.04, 58.72, 37.62, 28.54, 28.03, 21.82, 21.22, 10.50, 10.29; HRMS calculated for 
C34H37BrNaN4O8 731.1692, found 731.1648. 
 
(2''-Chloroethyl) propyl 4'-nitro-2-phenyl-8-(tert-butoxy-
carbonyl(methyl)amino)-6H,12H-5,11-methanodibenzo[b,f]  
[1,5]diazocine-3',6'-dicarboxylate (29b): To a solution of 0.03 g 
(0.04 mol) of 26b in 0.6 mL of dry THF at 0 °C was added 5.0 mg 
(0.14 mmol) of 60% sodium hydride in mineral oil, which was stirred for 5 minutes. Methyl 
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iodide (0.03 mL, 0.5 mmol) was added dropwise to the reaction mixture, which was warmed to 
room temperature and then stirred for an additional 30 minutes. The reaction was added to 10 
mL of ice water and extracted with EtOAc (4 x 10 mL). The organic extracts were dried over 
MgSO4, filtered and volatile components of the filtrate were removed under reduced pressure. 
The crude residue was purified by column chromatography (pentane: Et2O: CH2Cl2, 1:1:0.1) to 
afford 0.01 g (34%) of the title compound: IR (thin film) υ 2969, 1724, 1698, 1496, 1351, 1312, 
1238, 1151; 
1
H NMR (CDCl3, 700 MHz, 25 °C) δ 8.63 (s, 2H), 7.14 (d, 1H, J = 8.4 Hz), 7.02-
0.10 (m, 2H), 7.00 (d, 1H, J = 7.7 Hz), 6.81 (s, 1H), 6.77 (s, 1H), 4.67 (dd, 2H, J = 16.8 and 30.8 
Hz), 4.29 (s, 2H), ~4.29/3.80 {signal obscured/d, (~1.0/0.5+0.5)H, J = 68.6 Hz}, 4.08-4.19 (m, 
2H), 4.02/3.62 {s/d, (1.1/0.3+0.3)H, J = 72.8 Hz}, 3.44/2.57 {d/s, (0.3+0.3/1.0)H, J = 59.5 Hz}, 
3.15 (s, 3H), 1.41 (s, 12H), signal obscured at ~1.45/~0.78 {signals obscured, (signal 
obscured/~0.8)H}, 0.78/0.22 {s/s, (2.0/1.0)H}; 
13
C NMR (CDCl3, 700 MHz) δ 166.67, 166.25, 
165.87, 154.86, 148.90, 148.57, 146.60, 145.03, 139.98, 135.79, 135.27, 134.88, 134.46, 133.25, 
133.01, 128.03, 127.70, 127.52, 126.68, 125.29, 124.93, 123.56, 123.37, 80.57, 67.93, 67.17, 
65.55, 59.07, 58.73, 41.24, 40.80, 37.61, 30.49, 29.88, 28.52, 21.81, 21.22, 10.49; HRMS 
calculated for C34H37ClNaN4O8  687.2198, found 687.2176. 
 
(2''-Bromoethyl) propyl 4'-nitro-2-phenyl-8-hydroxymethyl-6H, 
12H-5,11-methanodibenzo[b,f][1,5]diazocine-3',6'-dicarboxylate 
(27a): By the general Suzuki coupling procedure, 0.03 g (0.08 mmol) 
of isophthalate 15a, 0.05 g (0.12 mmol) of the pinacolatoboronate 22, and 4.0 mg (0.008 mmol) 
of the palladium catalyst in 0.4 mL of DME were treated with 0.4 mL of water and 0.48 g (0.48 
mmol) of sodium bicarbonate and purified by column chromatography (hexanes: EtOAc, 1:2) to 
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provide 0.013 g (28%) of the title compound: IR (thin film) υ 3372, 2924, 1719, 1531, 1494, 
1349, 1309, 1243; 
1
H NMR (CDCl3, 500 MHz, 25 °C) δ 8.63 (s, 2H), 7.13 (dd, 3H, J = 8.0 and 
23.0 Hz), 7.01 (dd, 1H, J = 14.0 and 14.0 Hz), 6.94 (s, 1H), 6.77 (s, 1H), 4.72 (d, 1H, J = 17.0 
Hz), 4.66 (d, 1H, J = 16.0 Hz), 4.56 (d, 2H, J = 5.0 Hz), 4.39/3.84 {s/d, (0.7/0.6+0.6) H, J = 58.0 
Hz}, 4.32 (s, 2H), 4.19 (d, 1H, J = 17.0 Hz), 4.15 (d, 1H, J = 18.0 Hz), 4.03/3.56 {s/d, 
(0.9/0.5+0.5) H, J = 75.0 Hz}, 3.28/2.34 {d/s, (0.4+0.4/1.0) H, J = 55.0 Hz}, 1.48/0.72 {s/s, 
(0.7/0.6) H }, 0.79/0.24 {s/s, (1.5/0.8) H }; 
13
C NMR (CDCl3, 600 MHz) δ 166.24, 148.72, 
147.46, 146.62, 146.40, 136.87, 135.35, 134.79, 133.17, 130.67, 129.92, 127.83, 127.58, 127.18, 
126.95, 126.62, 126.10, 125.73, 125.39, 124.97, 67.99, 67.24, 67.04, 65.14, 59.20, 58.59, 29.91, 
28.08, 27.50, 22.91, 21.84, 21.16, 14.34, 10.49; HRMS calculated for C29H28BrN3O7 
609.111.062, found 609.110945. 
 
 (2''-Chloroethyl) propyl 4'-nitro-2-phenyl-8-hydroxymethyl-6H, 
12H-5,11-methanodibenzo[b,f][1,5]diazocine-3',6'-dicarboxylate 
(27b): By the general Suzuki coupling procedure, 0.03 g (0.08 mmol) of 
isophthalate 15b, 0.05 g (0.12 mmol) of the pinacolatoboronate 22, and 
4.0 mg (0.008 mmol) of the palladium catalyst in 0.4 mL of DME were treated with 0.4 mL of 
water and 0.04 g (0.48 mmol) of sodium bicarbonate and purified by column chromatography 
(hexanes: EtOAc, 1:2) to provide 0.03 g (63%) of the title compound: IR (thin film) υ 3403, 
3086, 2924, 1719, 916; 
1
H NMR (CDCl3, 500 MHz, 25 °C) δ 8.63 (s, 2H), 7.13 (dd, 3H, J = 8.5 
and 21.0 Hz), 7.01 (dd, 1H, J = 2.0 and 8.5 Hz), 6.94 (s, 1H), 6.76 (s, 1H), 4.72 (d, 1H, J = 16.5 
Hz), 4.68 (d, 1H, J = 17.5 Hz), 4.55 (d, 2H, J = 5.5 Hz), 4.35/3.75 {s/d, (0.8/0.7+0.7) H, J = 70.0 
Hz}, 4.32 (s, 2H), 4.19 (d, 1H, J = 17.0 Hz), 4.15 (d, 1H, J = 17.0 Hz), 4.03/3.57 {s/d, 
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(1.1/0.4+0.4) H, J = 65.0 Hz}, 3.46/2.49 {d/s, (0.5+0.5/1.1) H, J = 45.0 Hz}, 1.47/0.73 {s/s, 
(1.0/0.7) H}, 0.79/0.24 {s/s, (1.8/1.0) H}; 
13
C NMR (CDCl3, 600 MHz) δ 166.32, 166.17, 
148.68, 147.45, 146.62, 146.42, 136.87, 135.87, 135.30, 134.87, 133.17, 127.80, 127.54, 126.85, 
126.67, 126.50, 126.02, 125.72, 125.37, 124.92, 67.98, 67.27, 65.57, 65.10, 59.24, 58.96, 41.24, 
40.45, 29.90, 22.90, 21.83, 21.15, 14.34, 10.50; HRMS calculated for C29H28ClN3O7 
565.161578, found 565.160998. 
 
 (2''-Hydroxyethyl) propyl 4'-nitro-2-phenyl-8-hydroxymethyl-6H, 
12H-5,11-methanodibenzo[b,f][1,5]diazocine-3',6'-dicarboxylate 
(27c): By the general Suzuki coupling procedure, 0.01 g (0.03 mmol) 
of isophthalate 15c, 0.02 g (0.05 mmol) of the pinacolatoboronate 22, 
and 2.0 mg (0.003 mmol) of the palladium catalyst in 0.2 mL of DME were treated with 0.2 mL 
of H2O and 0.02 g (0.19 mmol) of sodium bicarbonate and purified by column chromatography 
(ethyl acetate) to provide 0.01 g (45%) of the title compound: IR (thin film) υ 3390 (broad), 
2925, 1721, 1530, 1349, 1307, 1243; 
1
H NMR (CDCl3, 500 MHz, 25 °C) δ 8.63 (s, 1H), 8.61 (s, 
1H), 6.97-7.17 (m, 5H), 6.75 (s, 1H), 4.70 (dd, 2H, J = 17.0 and 26.5 Hz), 4.54 (d, 2H, J = 4.5 
Hz), 4.30-4.34 (m, 2H), 4.17 (dd, 2H, J = 16.0 and 28.5 Hz), signal obscured ~ 4.2/3.61 {signal 
obscured/d, (0.6/0.8+0.8) H, J = 75.0 Hz}, 4.03/3.58 {s/d, (1.3/0.3+0.3) H, J = 50.0 Hz}, 
3.56/2.53 {s/s, (0.4/1.4) H}, 1.46/0.74 {s/s, (1.1/0.8) H}, 0.79/0.24 {s/s, (2.3/0.9) H}; 
13
C NMR 
(CDCl3, 700 MHz) δ 166.82, 166.18, 148.66, 147.60, 147.55, 146.68, 146.11, 136.54, 135.32, 
135.10, 133.38, 127.99, 127.42, 127.34, 126.80, 126.61, 126.50, 125.43, 125.24, 124.73, 67.98, 
67.41, 66.52, 65.14, 59.51, 59.42, 59.27, 29.92, 21.85, 10.51; HRMS calculated for C29H29N3O8 
547.195465, found 547.194958. 
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(2''-Bromoethyl) propyl 4'-nitro-2-phenyl-8-(2-(dimethylamino)-
2-oxoethyl)-6H,12H-5,11-methanodibenzo[b,f][1,5]diazocine-
3',6'-dicarboxylate (28a): By the general Suzuki coupling 
procedure, 0.04 g (0.09 mmol) of isophthalate 15a, 0.04 g (0.10 mmol) of the pinacolatoboronate 
25, and 5.0 mg (0.009 mmol) of the palladium catalyst in 0.5 mL of DME were treated with 0.5 
mL of water and 0.05 g (0.55 mmol) of sodium bicarbonate and purified by column 
chromatography (EtOAc) to provide 0.026 g (42%) of the title compound: IR (thin film) υ 2925, 
1723, 1643, 1308, 1143; 
1
H NMR (CDCl3, 500 MHz, 25 °C) δ 8.64 (s, 2H), 7.14 (d, 1H, J = 8.0 
Hz), 6.99-7.08 (m, 3H), 6.83 (s, 1H), 6.77 (d, 1H, J = 2.0 Hz), 4.70 (d, 1H, J = 16.5 Hz), 4.65 (s, 
1H), 4.30 (s, 2H), 4.38/3.87 {s/d, (0.9/0.6+0.6) H, J = 25.0 Hz}, 4.17 (d, 2H, J = 14.0 Hz), 
4.03/3.65+signal obscured {s/d, (1.24/0.6+signal obscured) H}, 3.56 (s, 2H), 3.27/2.36 {d/s, 
(0.5+0.5/1.2) H, J = 40.0 Hz}, 3.02 (broad s, 3H), 2.92 (s, 3H), 1.46/0.75 {s/s, (0.9/0.8) H}, 
0.81/0.22 {s/s, (1.0/0.8) H}; 
13
C NMR (CDCl3, 500 MHz) δ 171.05, 166.24, 146.67, 146.62, 
133.23, 132.22, 128.76, 128.73, 127.74, 127.55, 127.27, 126.73, 126.60, 125.48, 125.44, 125.00, 
68.01, 67.09, 65.41, 59.09, 58.80, 37.95, 35.85, 29.92, 28.04, 21.87, 14.35, 10.52; HRMS 
calculated for C32H33Br
23
NaN4O7 687.1430, found 687.1466. 
 
 
(2''-Chloroethyl) propyl 4'-nitro-2-phenyl-8-(2-(dimethylamino)-2-
oxoethyl)-6H,12H-5,11-methanodibenzo[b,f][1,5]diazocine-3',6'-
dicarboxylate (28b): By the general Suzuki coupling procedure, 0.03 g (0.06 mmol) of 
isophthalate 15b, 0.03 g (0.07 mmol) of the pinacolatoboronate 25, and 4.0 mg (0.006 mmol) of 
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the palladium catalyst in 0.3 mL of DME were treated with 0.3 mL of water and 0.03 g (0.38 
mmol) of sodium bicarbonate and purified by column chromatography (EtOAc) to provide 0.03 
g (68%) of the title compound: IR (thin film) υ 2927, 1723, 1643, 1494, 1350, 1312, 1238; 1H 
NMR (CDCl3, 500 MHz, 25 °C) δ 8.64 (s, 2H), 7.14 (d, 1H, J = 8.5 Hz), 6.99-7.08 (m, 3H), 6.83 
(s, 1H), 6.77 (s, 1H), 4.70 (d, 1H, J = 16.5 Hz), 4.66 (d, 1H, J = 16.5 Hz), 4.33/3.79 {s/d, 
(0.6/0.5+0.5) H, J = 30.0 Hz}, 4.30 (s, 2H), 4.17 (d, 2H, J = 16.0 Hz), 4.03/3.65+signal obscured 
{s/d, (1.2/0.5+signal obscured) H}, 3.56 (s, 2H), 3.46/2.50 {d/s, (0.4+0.4/1.1) H, J = 45.0 Hz}, 
3.01 (broad s, 3H), 2.92 (s, 3H), 1.46/0.75 {s/s, (1.2/0.9) H}, 0.80/0.22 {s/s, (1.3/0.8) H}; 
13
C 
NMR (CDCl3, 600 MHz) δ 171.04, 166.24, 148.68, 146.63, 135.27, 134.92, 133.22, 131.17, 
128.68, 128.19, 127.77, 127.60, 127.48, 127.36, 127.16, 126.69, 126.57, 126.31, 125.40, 124.94, 
124.15, 67.94, 67.22, 66.97, 65.57, 59.10, 58.78, 41.23, 40.83, 40.31, 39.98, 37.92, 35.82, 29.90, 
21.83, 21.21, 10.49; HRMS calculated for C32H33Cl
23
NaN4O7 632.1935, found 643.1975. 
 
 (2''-Hydroxyethyl) propyl 4'-nitro-2-phenyl-8-(2-(dimethyl-
amino)-2-oxoethyl)-6H,12H-5,11-methanodibenzo[b,f]  
[1,5]diazocine-3',6'-dicarboxylate (28c): By the general Suzuki 
coupling procedure, 0.02 g (0.03 mmol) of the pinacolatoboronate 25, 0.02 g (0.05 mmol) of 
isophthalate 15c, and 2.0 mg (0.003 mmol) of the palladium catalyst in 0.2 mL of DME were 
treated with 0.2 mL of H2O and 0.02 g (0.21 mmol) of sodium bicarbonate and purified by 
column chromatography (EtOAc: MeOH, 40:1) to provide 0.01 g (69%) of the title compound: 
IR (thin film) υ 3400 (broad), 2927, 1722, 1632, 1530, 1494, 1349, 1307; 1H NMR (CDCl3, 500 
MHz, 25 °C) δ 8.62 (s, 2H), 7.14 (d, 1H, J = 7.5 Hz), 7.08 (d, 1H, J = 8.5 Hz), 6.97-7.04 (m, 2H), 
6.79 (s, 1H), 6.75 (s, 1H), 4.68 (t, 2H, J = 18.0 Hz), 4.32 (s, 2H), 4.22 (t, 1H, J = 17.0 Hz), 4.16 
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(d, 1H, J = 16.5 Hz), signal obscured ~4.2/3.65 {signal obscured/doublet of multiplets, (signal 
obscured/1.1+1.1) H, J = 48.0 Hz}, 3.99-4.06/signal obscured ~3.6 and 3.7 {m/d, (1.7/signal 
obscured) H},2.86/2.48 {s/d, (0.5/1.7) H, J = 5.5 Hz}, 3.55 (d, 2H, J = 8.5 Hz), 3.07 (s, 3H), 2.92 
(s, 3H), 1.46/0.73 {q/s, (1.3/0.3) H, J = 7.0 Hz}, 0.78/0.22 {t/s, (2.3/0.5) H, J = 7.0 Hz}; 
13
C 
NMR (CDCl3, 600 MHz) δ 171.56, 166.82, 166.19, 148.50, 146.47, 146.42, 145.91, 135.39, 
134.89, 133.19, 132.31, 130.75, 128.76, 127.97, 127.75, 127.58, 127.20, 126.51, 126.41, 126.13, 
125.19, 124.99, 124.69, 114.94, 112.73, 67.72, 67.04, 66.76, 58.96, 58.74, 58.55, 40.15, 39.18, 
37.64, 35.85, 35.65, 21.64, 10.30; HRMS calculated for C32H35N4O8 603.2455, found 603.2447.  
 
 (2''-Iodoethyl) propyl 4'-nitro-2-phenyl-8-(2-(dimethylamino)-2-
oxoethyl)-6H,12H-5,11-methanodibenzo[b,f]  [1,5]diazocine-3',6'-
dicarboxylate (28d): To a solution of 0.01 g (0.01 mmol) of 28a in 
0.3 mL of dry acetone was added 0.1 g (0.38 mmol) of sodium iodide, which was heated to 
reflux for 16 hours. The solution was cooled to room temperature, the salt removed by filtration, 
and the reaction mixture diluted with 10 mL H2O. The aqueous layer was extracted with CH2Cl2 
(3 x 10 mL). The organic extracts were dried over MgSO4, filtered and volatile components of 
the filtrate were removed under reduced pressure. The crude residue was purified by column 
chromatography (pentane: EtOAc, 1:8) to afford 0.01 g (quantitative yield) of the title 
compound: IR (thin film) υ 2924, 2854, 1823, 1640, 1530, 1494, 1306; 1H NMR (CDCl3, 500 
MHz, 25 °C) δ 8.64 (s, 2H), 7.15 (d, 1H, J = 8.0 Hz), 7.00-7.08 (m, 3H), 6.84 (s, 1H), 6.78 (s, 
1H), 4.70 (d, 1H, J = 16.5 Hz), 4.66 (d, 1H, J = 15.0 Hz), 4.30 (s, 2H), 4.17 (d, 2H, J = 15.5 Hz), 
4.33/3.87 {s/s, (0.6/1.33) H}, 4.02/3.58 {s/d, (1.1/0.4+0.4) H, J = 50.0 Hz}, 3.57 (s, 2H), 3.01 (s, 
3H), 2.92 (s, 3H), signal obscured at ~3.0/2.20 {signal obscured/s, (signal obscured/1.1) H}, 
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1.46/0.75 {s/s, (0.8/0.5) H}, 0.79/0.22 {s/s, (1.7/0.9) H}; 
13
C NMR (CDCl3, 700 MHz) δ 171.06, 
146.76, 146.62, 146.55, 146.49, 131.37, 131.22, 127.80, 127.73, 127.72, 127.67, 127.59, 127.23, 
126.71, 126.65, 126.61, 126.58, 125.47, 125.07, 124.98, 67.97, 66.09, 58.99, 58.76, 38.00, 35.88, 
32.15, 29.92, 29.54, 22.91, 14.35; HRMS calculated for C32H34
127
IN4O7 713.1472, found 
713.1509. 
 
2-Bromo-8-((di-tert-butoxycarbonylamino)methyl-6H,12H-5,11-
methanodibenzo[b,f]  [1,5]diazocine (35): To a stirred solution of 0.50 
g (1.5 mmol) of 21 and 0.6 mL (4.5 mmol) of triethylamine in 3.4 mL of THF at 0 °C was added 
0.99 g (3.8 mmol) of triphenylphosphine and 1.31 g (6.0 mmol) of di-tert-butyl 
iminodicarboxylate in 13.4 mL of THF. Di-tert-butyl azodicarboxylate (0.70 g, 3.0 mmol) was 
added portionwise to the reaction mixture at 0 °C. The solution was heated to 60 °C for 2 hours, 
volatile components were removed under reduced pressure, and the crude material was purified 
by column chromatography (hexanes: EtOAc, 8:1) to afford 0.52 g (65%) of the carbamate: IR 
(KBr) υ 2978, 1744, 1697, 1477, 1367, 1348, 1323; 1H NMR (CDCl3, 300 MHz) δ 7.21 (d, 1H, J 
= 2.1 Hz), 6.96-7.10 (m, 5H), 6.81 (s, 1H), 4.55-4.67 (m, 4H), 4.26 (dd, 2H, J = 12.9 and 18.3 
Hz), 4.07 (dd, 2H, J = 9.3 and 16.8 Hz), 1.38 (s, 18H); 
13
C NMR (CDCl3, 300 MHz) δ 152.78. 
147.28, 146.80, 134.60, 130.59, 130.19, 129.85, 127.44, 127.07, 126.89, 126.29, 125.01, 116.68, 
82.71, 67.06, 59.06, 58.69, 49.17, 28.16; HRMS calculated for C26H32BrNaN3O4 552.1474, 
found 552.1491. 
 
2-(Di-tert-butoxycarbonylamino)methyl-8-4,4,5,5-tetramethyl-
[1,3,2]dioxaborolan-2-yl-6H,12H-5,11-methanodibenzo[b,f]  
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[1,5]diazocine (34): The carbamate (0.82 g, 1.6 mmol), bis(pinacolato)diboron (0.79 g, 3.1 
mmol), dichloro[1,1]-bis(diphenylphosphine)ferrocene] palladium dichloromethane adduct (0.11 
g, 0.2 mmol), and potassium acetate (0.30 g, 3.1 mmol) were combined in a flask, which was 
placed under vacuum for five to ten minutes and then filled with N2. Addition of 9.3 mL of 
anhydrous DMSO to this mixture provided an orange solution which was degassed twice by 
freeze pump thaw cycle and then heated at 80°C for 16 hours. The reaction was cooled to room 
temperature, diluted with 50 mL of CH2Cl2, and the resultant mixture was washed with water (3 
x 50 mL). The combined aqueous layers were extracted with CH2Cl2 (2 x 50 mL). The organic 
extracts were dried over MgSO4, filtered and the volatile components of the filtrate were 
removed under reduced pressure. The residue was purified by column chromatography (pentane: 
Et2O, 6:1) to afford 0.83 g (93%) of the title compound as a white foam: IR (thin film) υ 2977, 
1746, 1598, 1361, 1143, 1113; 
1
H NMR (CDCl3, 300 MHz) δ 7.56 (dd, 1H, J = 1.2 and 8.1 Hz), 
7.35 (s, 1H), 7.00-7.10 (m, 3H), 6.80 (s, 1H), 4.53-4.67 (m, 4H), 4.29 (s, 2H), 4.14 (d, 2H, J = 
16.8 Hz), 1.37 (s, 18H), 1.26 (s, 12H); 
13
C NMR (CDCl3, 300 MHz) δ 152.79, 151.33, 147.10, 
140.39, 134.32, 134.11, 133.9, 127.72, 127.35, 126.98, 126.37, 125.03, 124.48, 83.87, 82.66, 
67.17, 59.12, 58.93, 49.20, 28.19, 25.00; HRMS calculated for C32H44B
23
NaN3O6 600.3221, 
found 600.3274. 
 
2-Bromoisophthalic acid 1-methyl ester (36): Step 1 - Esterification: To a 
stirred solution of 18.58 g (75.8 mmol) of 12 in 330 mL of methanol at 0°C was 
added 80 mL (1441 mmol) of concentrated H2SO4 over an hour. The reaction was slowly 
warmed and then refluxed for two days. The solution was cooled to room temperature and 
methanol was removed under reduced pressure. The residue was diluted with 1000 mL EtOAc 
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and washed with saturated K2CO3 (3 x 500 mL). The organic extract was dried over MgSO4, 
filtered, and volatile components of the filtrate were removed under reduced pressure. The 
residue was purified by column chromatography (hexanes: EtOAc, 20:1) to afford 13.24 g (64%) 
of 2-bromoisophthalic acid dimethyl ester as an amber liquid: IR (liquid) υ 2953, 1736, 1587, 
1433, 1417; 
1
H NMR (CDCl3, 300 MHz) δ 7.68 (d, 2H, J = 7.4 Hz), 7.40 (t, 1H, J = 7.8 Hz), 
3.94 (s, 6H).  Step 2 – Selective Hydrolysis: To a stirred solution of 1.64 g (6.0 mmol) of 2-
bromoisophthalic acid dimethyl ester in 15 mL of methanol:acetone (1:4) was added 0.26 g (6.6 
mmol) of sodium hydroxide. The mixture was stirred for two days at room temperature, after 
which the acetone and methanol were removed under reduced pressure. The residue was treated 
with 50 mL of 1 M HCl and extracted with EtOAc (3 x 75 mL). The organic extracts were 
washed with brine (100 mL), dried over MgSO4, filtered and the volatile components of the 
filtrate were removed under reduced pressure. The residue was purified by column 
chromatography (hexanes: EtOAc, 3:1) to afford 1.34 g (86%) of the 2-bromoisophthalic acid 
monomethyl ester: IR (thin film) υ 2954 (broad), 1731, 1586, 1556, 1421, 1288, 1256, 1207; 1H 
NMR (MeOD, 300 MHz) δ 7.71-7.81 (m, 2H), 7.51-7.57 (m, 1H), 3.96 (s, 3H).23  
 
Benzyl 3-hydroxypropionate (38): To a stirred solution of 0.72 g (8.0 mmol) of 3-
hydroxypropionic acid
159
 in 20.0 mL of dimethylsulfoxide was added 1.20 g (8.0 mmol) of 
sodium iodide, 1.33 g (9.6 mmol) of potassium carbonate at 10 °C. The reaction was stirred for 
five minutes, after which 1.2 mL (9.6 mmol) of benzyl bromide was added. The reaction was 
heated to 55 °C and stirred for 6 hours. The reaction was added to water and EtOAc (50 mL 
each). The layers were separated and the organic layer was washed with water (2 x 50 mL). The 
combined aqueous layers were extracted with EtOAc (5 x 50 mL). The organic extracts were 
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dried over MgSO4, filtered, and volatile components of the filtrate were removed under reduced 
pressure. The residue was purified by column chromatography (hexanes: EtOAc, 5:1) to afford 
0.84 g (58%) of the title compound as an oil: IR (KBr) υ 3436 (broad), 2920, 2850, 1731, 1163, 
1041, 737; 
1
H NMR (CDCl3, 300 MHz) δ 7.32-7.36 (m, 5H), 5.14 (s, 2H), 3.87 (q, 2H, J = 6.0 
Hz), 2.61 (t, 2H, J = 5.7 Hz), 2.42 (t, 1H, J = 6.6 Hz); 
13
C NMR (CDCl3, 300 MHz) δ 172.72, 
135.63, 128.65, 128.41, 128.28, 66.55, 58.27, 36.84; HRMS calculated for C10H12O3 
180.078644, found 180.078368. 
 
2-Bromoisophthalic acid 1-(3'-(benzyloxy)-3'-oxopropyl) ester 3-
methyl ester (37): By the general esterification procedure, 0.09 g (0.5 
mmol) of benzyl 3-hydroxypropionate (38), 0.10 g (0.4 mmol) of DCC and 0.01 g (0.1 mmol) of 
DMAP in 2.0 mL of dry CH2Cl2 treated with 0.10 g (0.4 mmol) of the carboxylic acid 36, 
provided 0.14 g (82%) of the title compound: IR (thin film) υ 3066, 3032, 2953, 1735, 1586, 
1455, 1283, 1254, 1202, 1148; 
1
H NMR (CDCl3, 300 MHz) δ 7.68 (dd, 1H, J = 1.8 and 7.8 Hz), 
7.59 (dd, 1H, J = 1.8 and 7.8 Hz), 7.30-7.37 (m, 5H), 5.15 (s, 2H), 4.62 (t, 2H, J = 6.3 Hz), 3.93 
(s, 3H), 2.83 (t, 2H, J = 6.3 Hz); 
13
C NMR (CDCl3, 300 MHz) δ 170.45, 167.10, 166.31, 135.79, 
135.64, 135.32, 132.59, 132.53, 128.81, 128.59, 128.54, 127.32, 119.34, 66.94, 61.43, 52.95, 
34.04; HRMS calculated for C19H17BrO6 420.020850, found 420.020498. 
 
2-Bromo-5-nitroisophthalic acid 1-methyl ester (39): To a stirred solution of 
1.5 mL of fuming nitric acid and 8.9 mL of concentrated sulfuric acid at 0°C was 
added 1.34 g (5.2 mmol) of 2-bromoisophthalic acid monomethyl ester (36). The reaction was 
slowly warmed to room temperature and stirred for 16 hours. The reaction was added dropwise 
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to a stirring mixture of 100 mL of EtOAc and 100 mL of ice water. The layers were separated 
and the organic layer was washed with water (2 x 100 mL). The combined aqueous layers were 
extracted with EtOAc (2 x 100 mL). The organic extracts were dried over MgSO4, filtered, and 
volatile components of the filtrate were removed under reduced pressure to yield 1.41 g (89%) of 
the title compound as a crude yellow solid: IR (KBr) υ 3093 (broad), 1741, 1713, 1607, 1531, 
1352, 1297, 1201; 
1H NMR (MeOD, 300 MHz) δ 8.58 (dd, 2H, J = 2.7 and 11.4 Hz), 4.02 (s, 
3H); 
13C NMR (MeOD, 300 MHz) δ 167.64, 165.92, 147.19, 138.32, 137.64, 126.64, 126.39, 
126.21, 52.97.
23
  
 
2-Bromo-5-nitroisophthalic acid 1-(3'-(benzyloxy)-3'-oxopropyl) ester 
3-methyl ester (40): By the general esterification procedure, 0.39 g (2.1 
mmol) of benzyl 3-hydroxypropionate (38), 0.68 g (3.3 mmol) of DCC and 0.05 g (0.4 mmol) of 
DMAP in 8.3 mL of dry CH2Cl2 treated with 0.50 g (1.6 mmol) of the carboxylic acid 39, 
provided 0.45 g (59%) of the title compound: IR (thin film) υ 3084, 2954, 2854, 1739, 1535, 
1352, 1239, 1174; 
1
H NMR (CDCl3, 300 MHz) δ 8.52 (d, 1H, J = 2.7 Hz), 8.44 (d, 1H, J = 2.7 
Hz), 7.29-7.31 (m, 5H), 5.16 (s, 2H), 4.68 (t, 2H, J = 6.0 Hz), 3.99 (s, 3H), 2.85 (t, 2H, J = 6.0 
Hz); 
13
C NMR (CDCl3, 300 MHz) δ 170.21, 165.04, 164.40, 146.46, 136.85, 136.80, 135.63, 
128.82, 128.66, 128.63, 126.89, 126.86, 67.11, 62.17, 53.61, 33.89; HRMS calculated for 
C19H17BrNO8 466.013753, found 466.013582. 
 
2-Bromoisophthalic acid 1-isoamyl ester (41): To a stirred solution of 
1.00 g (3.9 mmol) of 2-bromoisophthalic acid (12) in 38.6 mL of dimethylsulfoxide was added 
0.58 g (3.9 mmol) of sodium iodide, 0.64 g (4.6 mmol) of potassium carbonate at 10 °C. The 
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reaction was stirred for five minutes, after which 0.5 mL (3.9 mmol) of 1-bromo-3-methylbutane 
was added. The reaction was heated to 40 °C, stirred overnight, and cooled to room temperature. 
The reaction was treated with aqueous HCl (20 mL, 1M) and was extracted with EtOAc (3 × 50 
mL). The combined organic layers were washed with water and brine (50 mL each), dried over 
MgSO4, and filtered, and volatile components of the filtrate were removed under reduced 
pressure. The residue was purified by column chromatography (hexanes: EtOAc, 8:1) to afford 
0.65 g (54%) of the title compound as a solid: IR (KBr) υ 3500-2800 (broad), 2959, 1732, 1586, 
1289, 1256, 1204, 1150; 
1
H NMR (CDCl3, 700 MHz) δ 7.91 (dd, 1H, J = 2.1 and 7.7 Hz), 7.69 
(dd, 1H, J = 2.1 and 7.7 Hz), 7.44 (t, 1H, J = 7.7 Hz), 4.38 (t, 2H, J = 7.0 Hz), 1.78 (quintet, 1H, J 
= 7.0 Hz), 1.65 (q, 2H, J = 7.0 Hz), 0.95 (d, 6H, J = 6.3 Hz); 
13
C NMR (CDCl3, 700 MHz) δ 
170.64, 167.03, 136.96, 133.37, 133.31, 133.13, 127.44, 119.87, 65.03, 37.38, 25.26, 22.65; 
HRMS calculated for C13H15BrO4 314.015370, found 314.015298. 
  
2-Bromoisophthalic acid 1-(3'-(benzyloxy)-3'-oxopropyl) ester 3-
isopentyl ester (42): By the general esterification procedure, 0.14 g 
(0.8 mmol) of benzyl 3-hydroxypropionate (38), 0.26 g (1.3 mmol) of DCC and 0.02 g (0.2 
mmol) of DMAP in 3.2 mL of dry CH2Cl2 treated with 0.20 g (0.6 mmol) of the carboxylic acid 
41, provided 0.26 g (84%) of the title compound as an oil: IR (thin film) υ 2959, 1737, 1253, 
1197, 1149; 
1
H NMR (CDCl3, 300 MHz) δ 7.64 (dd, 1H, J = 1.8 and 7.8 Hz), 7.57 (dd, 1H, J = 
1.8 and 7.8 Hz), 7.29-7.36 (m, 5H), 5.14 (s, 2H), 4.62 (t, 2H, J = 6.3 Hz), 4.36 (t, 2H, J = 6.6 
Hz), 2.82 (t, 2H, J = 6.3 Hz), 1.76 (sextet, 1H, J = 6.6 Hz), 1.63 (q, 2H, J = 6.9 Hz), 0.94 (d, 6H, 
J = 6.6 Hz); 
13
C NMR (CDCl3, 300 MHz) δ 170.38, 166.73, 166.23, 136.00, 135.69, 135.08, 
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132.33, 132.30, 128.71, 128.49, 128.45, 127.25, 119.06, 66.82, 64.80, 61.33, 37.30, 33.92, 25.17, 
22.56; HRMS calculated for C23H25BrNaO6 499.0732, found 499.0694. 
 
2-Bromo-5-nitroisophthalic acid 1-isoamyl ester (43): To a stirred 
solution of 1.00 g (3.4 mmol) of 2-bromo-5-nitroisophthalic acid (13) in 
34.5 mL of dimethylsulfoxide was added 0.52 g (3.4 mmol) of sodium iodide, 0.72 g (5.2 mmol) 
of potassium carbonate at 10 °C. The reaction was stirred for five minutes, after which 0.4 mL 
(3.4 mmol) of 1-bromo-3-methylbutane was added. The reaction was heated to 40 °C, stirred 
overnight, and cooled to room temperature. The reaction was treated with aqueous HCl (20 mL, 
1M) and was extracted with EtOAc (3 × 50 mL). The combined organic layers were washed with 
water and brine (50 mL each), dried over MgSO4, and filtered, and volatile components of the 
filtrate were removed under reduced pressure. The residue was purified by column 
chromatography (hexanes: EtOAc, 8:1) to afford 0.68 g (55%) of the title compound as a solid: 
IR (KBr) υ 3300-2500 (broad), 3091, 2961, 1741, 1705, 1609, 1534, 1354, 1298, 1252; 1H NMR 
(CDCl3, 700 MHz) δ 8.74 (d, 1H, J = 2.8 Hz), 8.52 (d, 1H, J = 2.8 Hz), 4.44 (t, 2H, J = 3.0 Hz), 
1.78 (quintet, 1H, J = 7.0 Hz), 1.68 (q, 2H, J = 7.0 Hz), 0.96 (d, 6H, J = 6.3 Hz; 
13
C NMR 
(CDCl3, 700 MHz) δ 168.98, 164.99, 146.51, 138.36, 134.64, 127.65, 127.40, 127.39, 65.97, 
37.28, 25.28, 22.62; HRMS calculated for C13H15BrNO6 360.008274, found 360.007537. 
 
2-Bromo-5-nitroisophthalic acid 1-(3'-(benzyloxy)-3'-oxopropyl) 
ester 3-isopentyl ester (44): To a stirred solution of 0.15 g (0.4 
mmol) of 43 and 0.03 mL (0.4 mmol) of DMF in 10.4 mL of CH2Cl2 at 0 °C was added oxalyl 
chloride dropwise (1.2 mL, 2 M in CH2Cl2, 2.3 mmol). The reaction was stirred for one hour at 
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room temperature and volatile components were removed under reduced pressure. The residue 
was diluted with 10.4 mL of CH2Cl2 and added dropwise to a stirred solution of 0.15 g (0.8 
mmol) of benzyl 3-hydroxypropionate (38), and 0.4 mL (2.8 mmol) of triethylamine in 10.4 mL 
of CH2Cl2 at 0 °C. The solution was stirred for two hours at room temperature. The reaction was 
treated with saturated NaHCO3 (50 mL) and was extracted with EtOAc (3 × 50 mL). The 
combined organic layers were washed with brine (50 mL), dried over MgSO4, and filtered, and 
volatile components of the filtrate were removed under reduced pressure. The residue was 
purified by column chromatography (hexanes: EtOAc, 15:1) to afford 0.13 g (60%) of the title 
compound as an oil: IR (KBr) υ 30.86, 2960, 1740, 1536, 1608, 1536, 1352, 1237, 1183; 1H 
NMR (CDCl3, 300 MHz) δ 8.47 (d, 1H, J = 2.7 Hz), 8.43 (d, 1H, J = 2.7 Hz), 7.26-7.33 (m, 5H), 
5.15 (s, 2H), 4.67 (t, 2H, J = 6.0 Hz), 4.42 (t, 2H, J = 6.6 Hz), 2.85 (t, 2H, J = 6.3 Hz), 1.76 
(sextet, 1H, J = 6.3 Hz), 1.67 (q, 2H, J = 6.6 Hz), 0.96 (d, 6H, J = 6.3 Hz); 
13
C NMR (CDCl3, 300 
MHz) δ 170.20, 164.78, 164.36, 146.42, 137.41, 136.57, 135.58, 128.77, 128.61, 128.58, 126.65, 
126.62, 67.05, 65.75, 62.11, 37.26, 33.83, 25.24, 22.59; HRMS calculated for C23H24BrNaNO8 
544.0583, found 544.0562. 
 
General Suzuki coupling procedure: The isophthalate (37, 40, 42, or 44) benzodiazocine 
pinacolatoboronate (34), and 1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium (II) were 
combined in a pressure reaction tube, which was placed under vacuum for five to ten minutes 
and then filled with N2. The solids were dissolved in 1,2-dimethoxyethane (DME), and the 
solution was degassed twice by freeze pump thaw cycle. Saturated sodium bicarbonate was 
added to the pressure tube, and the contents were degassed two more times. The reaction was 
heated to 80°C for approximately 12 hours, cooled to room temperature, diluted with less than 1 
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mL of water. The subsequent mixture was extracted with CH2Cl2 (3 x 5 mL), the organic extracts 
were dried over MgSO4, filtered and volatile components of the filtrate were removed under 
reduced pressure. The residue was purified by column chromatography and then by HPLC. 
 
(3'-(benzyloxy)-3'-oxopropyl) methyl 2-phenyl-8-((di-tert-
butoxycarbonylamino)methyl)-6H,12H-5,11-
methanodibenzo[b,f] [1,5]diazocine-3',6'-dicarboxylate (45a): 
By the general Suzuki coupling procedure, 0.07 g (0.16 mmol) of isophthalate 37, 0.06 g (0.10 
mmol) of the pinacolatoboronate 34, and 6 mg (0.01 mmol) of the palladium catalyst in 0.5 mL 
of DME were treated with 0.05 g (0.62 mmol) of sodium bicarbonate in 0.5 mL of water and 
purified by column chromatography (pentane: Et2O, 1:4) to provide 0.05 g (57%) of the title 
compound: IR (thin film) υ 2978, 1737, 1495, 1367, 1174, 1144, 1115; 1H NMR (CDCl3, 600 
MHz, 25 °C) δ 7.73-7.82 (m, 2H), 7.39 (s, 1H), 7.29 (s, 5H), 6.77-7.07 (m, 6H), 6.61 (s, 1H), 
5.10/5.00 {s/s, (1.0/1.0)H}, 4.54-4.63 (m, 4H), ~4.3/3.67 {signal obscured/d, (~0.7/0.9)H, J = 
112.4 Hz}, 4.26-4.33 (m, 2H), 4.06-4.11 (m, 2H), 3.59/2.77 {s/s, (1.5/1.3) H}, 2.42/1.21 
{d/signal obscured, 0.9/signal obscured, J = 19.2 Hz}, 1.47 (s, 18H); 
13
C NMR (CDCl3, 600 
MHz, 25 °C) δ 170.40, 169.08, 168.39, 167.66, 152.95, 147.33, 147.06, 140.89, 135.85, 135.23, 
134.16, 133.61, 132.79, 132.12, 131.95, 128.75, 128.61, 127.80, 127.39, 127.14, 126.81, 126.13, 
126.06, 124.99, 124.41, 124.20, 82.77, 67.11, 66.73, 66.54, 60.62, 58.80, 49.01, 33.61, 32.27, 
28.44, 28.29, 28.15, 28.00; HRMS calculated for C45H49N3O10 791.341795, found 791.343319. 
 
(3'-(benzyloxy)-3'-oxopropyl) methyl 4'-nitro-2-phenyl-8-
((di-tert-butoxycarbonylamino)methyl)-6H,12H-5,11-
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methanodibenzo[b,f][1,5]diazocine-3',6'-dicarboxylate (45b): By the general Suzuki coupling 
procedure, 0.04 g (0.09 mmol) of isophthalate 40, 0.04 g (0.06 mmol) of the pinacolatoboronate 
34, and 3 mg (0.006 mmol) of the palladium catalyst in 0.3 mL of DME were treated with 0.03 g 
(0.36 mmol) of sodium bicarbonate in 0.3 mL of water and purified by column chromatography 
(pentane: Et2O, 1:4) to provide 0.04 g (72%) of the title compound: IR (thin film) υ 2978, 1738, 
1531, 1495, 1350, 1231, 1171, 1143; 
1
H NMR (CDCl3, 300 MHz, 25 °C) δ 8.57 (s, 2H), 7.29 (s, 
5H), 7.02 (s, 3H), 6.81 (s, 2H), 6.61 (d, 1H, J = 1.8 Hz), 5.02/5.01 {s/s, (1.0/1.0)H}, 4.52-4.65 
(m, 4H), 4.25-4.35 (m, 2H), 4.09 (dd, 2H, J = 4.5 and 16.5 Hz), ~4.29/3.71 {signal obscured/d, 
(~1.2/1.0)H, J = 63.3 Hz}, 3.67/2.85 {s/s, (1.5/1.2)H}, 2.48/~1.25 {s/signal obscured, (0.6/signal 
obscured)H}, 1.43 (s, 18H); 
13
C NMR (CDCl3, 300 MHz, 25 °C) δ 170.08, 166.15, 152.98, 
148.59, 146.93, 146.82, 146.52, 135.74, 135.39, 134.32, 133.92, 132.89, 128.74, 128.66, 127.84, 
128.66, 127.84, 127.66, 127.36, 126.54, 126.41, 126.04, 125.03, 124.70, 82.80, 67.21, 66.76, 
61.32, 59.07, 52.97, 52.15, 49.00, 33.42, 32.36, 28.22; HRMS calculated for C45H48NaN4O12 
859.3166, found 859.3113. 
 
(3'-(benzyloxy)-3'-oxopropyl) isopentyl 2-phenyl-8-((di-tert-
butoxycarbonylamino)methyl)-6H,12H-5,11-
methanodibenzo[b,f][1,5]diazocine-3',6'-dicarboxylate (45c): 
By the general Suzuki coupling procedure, 0.06 g (0.13 mmol) 
of isophthalate 42, 0.05 g (0.09 mmol) of the pinacolatoboronate 34, and 5 mg (0.005 mmol) of 
the palladium catalyst in 0.4 mL of DME were treated with 0.04 g (0.52 mmol) of sodium 
bicarbonate in 0.4 mL of water and purified by column chromatography (pentane: Et2O, 1:2) to 
provide 0.04 g (55%) of the title compound: IR (thin film) υ 2958, 1738, 1495, 1302, 1259, 
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1173, 1144; 
1
H NMR (CDCl3, 300 MHz, 25 °C) δ 7.79 (s, 1H), 7.73 (dd, 1H, J = 1.2 and 7.8 
Hz), 7.39 (t, 1H, J = 8.5 Hz), 7.28 (s, 5H), 6.78-6.99 (m, 5H), 6.62 (s, 1H), 5.09/4.99 {s/s, 
(0.7/1.3)H}, 4.59 (m, 4H), ~4.3/3.69 {signal obscured/d, (0.7/1.2)H, J 51.3 Hz}, 4.27 (s, 2H), 
4.08 (d, 2H, J = 17.4 Hz), 2.37/~1.3 {s/signal obscured, (0.4/signal obscured)H}, 1.43 (s, 18H), 
~1.2/~0.7 {signals obscured}, 0.80/0.60 {s/s, (4.3/1.6)H}; 
13
C NMR (CDCl3, 500 MHz, 25 °C) δ 
170.38, 168.40, 152.95, 147.39, 147.22, 147.05, 140.53, 135.85, 135.39, 134.15, 133.48, 133.41, 
131.85, 128.72, 128.63, 128.59, 127.77, 127.33, 127.11, 126.73, 126.39, 126.09, 125.70, 125.07, 
124.51, 82.72, 67.18, 66.51, 63.97, 60.51, 58.81, 49.04, 37.12, 32.21, 30.48, 28.21, 24.85, 22.55; 
HRMS calculated for C49H57N3O10Na 870.3942, found 870.3964. 
 
(3'-(benzyloxy)-3'-oxopropyl) isopentyl 4'-nitro-2-phenyl-8-
((di-tert-butoxycarbonylamino)methyl)-6H,12H-5,11-
methanodibenzo[b,f][1,5]diazocine-3',6'-dicarboxylate (45d): 
By the general Suzuki coupling procedure, 0.7 g (0.13 mmol) of 
isophthalate 44, 0.5 g (0.09 mmol) of the pinacolatoboronate 34, and 5 mg (0.01 mmol) of the 
palladium catalyst in 0.4 mL of DME were treated with 0.04 g (0.52 mmol) of sodium 
bicarbonate in 0.4 mL of water and purified by column chromatography (pentane: Et2O, 2:1) to 
provide 0.06 g of the title compound: IR (thin film) υ 2959, 1738, 1532, 1495, 1387, 1366, 1350, 
1173, 1145; 
1
H NMR (CDCl3, 700 MHz, 5 °C) δ 8.62/6.56 {s/s, (0.5/0.5)H}, 8.55 (s, 1H), 7.29 
(s, 5H), 7.00-7.09 (m, 2H), 6.93 (d, 1H, J = 7.0 Hz), 6.80 (d, 1H, J = 7.0 Hz), 6.77 (s, 1H), 6.62 
(d, 1H, J = 13.3 Hz), 5.10/4.98 {s/dd, (0.5/1.2)H, J = 11.9 and 20.3 Hz}, 4.52-4.68 (m, 4H), 
4.33/3.72 {d/d, (0.4/1.0)H, J = 35 and 147 Hz}, 4.26 (s, 2H), 4.06/3.60 {d/d, (signal 
obscured/0.2)H, J = 41.0 and 155.4 Hz}, 4.02-4.15 (m, 2H) 2.45/1.29 {d/d, (0.3/signal 
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obscured)H, J = 35 and 210.7 Hz}, 1.42 (s, 18H), 1.27/0.71 {d/d, (1.6/0.6)H, J = 6.3 and 32.9 
Hz}, 1.37/1.18 {s/s, (0.9/0.7)H}, 0.81/0.59 {t/s, (4.4/1.9)H, J = 6.3 Hz}; 
13
C NMR (CDCl3, 500 
MHz, 25 °C) δ 170.06, 166.22, 165.95, 152.97, 148.61, 147.1, 146.87, 146.53, 146.43, 135.76, 
135.69, 135.18, 135.08, 134.32, 133.19, 128.72, 128.67, 127.77, 127.6, 127.31, 126.5, 126.26, 
126.01, 125.68, 125.09, 124.87, 82.76, 67.13, 66.63, 64.81, 61.28, 58.90, 58.66, 49.02, 37.06, 
32.25, 28.21, 24.87, 22.51; HRMS calculated for C49H56N4O12Na 915.3792, found 915.3837. 
 
General deprotection procedure (aminomethyl torsion balances, 47a-d): Step 1 –  To the 
torsion balance (45a-d) in CH2Cl2 was added trifluoroacetic acid dropwise at 0 °C. The solution 
was stirred for 30 minutes at room temperature and added to NH4OH (1 M). The solution was 
extracted with EtOAc three times, which in turn was washed with brine. The organic extracts 
were dried over MgSO4 and filtered, and volatile components of the filtrate were removed under 
reduced pressure. Step 2 – To a two-dram vial was added the crude material in methanol and a 
suspension of 10% palladium/carbon in water. The vial was placed in a Parr shaker bottle and the 
debenzylation was carried out at 40 psi H2 for 48 hours. The solution was filtered through a plug 
of Celite, the volatile components of the filtrate were concentrated under reduced pressure, and 
the residue was then purified by reverse phase HPLC.   
 
2-Carboxyethyl methyl 2-phenyl-8-aminomethyl-6H,12H-5,11-
methanodibenzo[b,f][1,5]diazocine-3',6'-dicarboxylate (47a): By 
the general deprotection procedure, 0.05 g (0.06 mmol) of the torsion balance 45a in 0.4 mL of 
dichloromethane was treated with 0.2 mL (2.73 mmol) of trifluoroacetic acid. Following the 
workup, to the crude material in 6.2 mL of methanol was then added 0.03 g (10%, 0.03 mmol) of 
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palladium/carbon in 0.7 mL of water and purified by reverse phase HPLC (linear gradient of 
80% solvent A to 69% A in solvent B) to provide 24 mg (81% over two steps) of the title 
compound: IR (KBr pellet) υ 3433, 3700-2500 (broad), 1684, 1435, 1262, 1205, 1136; 1H NMR 
(D2O, 700 MHz) δ 7.89 (dd, 1H, J = 7.7 and 18.2 Hz), 7.78 (dd, 1H, J = 7.7 and 34.3 Hz), 7.48 (t, 
1H, J = 7.7 Hz), 7.40 (dd, 2H, J = 8.4 and 13.3 Hz), 7.35 (dd, 1H, J = 8.4 and 20.3 Hz), 7.20 (d, 
1H, J = 14.7 Hz), 7.04 (dd, 1H, J = 8.4 and 13.3 Hz), 6.86/6.797 {s/s, (0.5/0.4)H}, 4.96 (dd, 1H, 
J = 16.8 and 21.7 Hz), 4.83-4.88 (m, 2H), 4.52 (dd, 1H, J = 16.8 and 41.3 Hz), 4.40 (dd, 1H, J = 
16.8 and 25.2 Hz), 4.23-4.26/3.73 {m/dm, (0.8/1.0)H, J = 72.1 Hz}, 3.61/2.90 {s/s, (1.7/1.2)H}, 
2.38/1.38-1.43 {dm/m, (0.7/1.1)H, J = 53.2 Hz}; 
13C NMR (MeOD, 700 MHz, 25 °C) δ 175.99, 
171.30, 171.00, 170.56, 164.26, 164.06, 146.12, 144.41, 140.84, 137.76, 134.00, 133.49, 133.42, 
133.31, 133.05, 131.13, 129.81, 129.37, 129.32, 128.34, 128.20, 128.07, 127.62, 126.43, 125.27, 
118.32, 116.67, 66.75, 62.28, 58.76, 58.48, 54.00, 53.13, 43.65, 33.85, 33.34; HRMS calculated 
for C28H27NaN3O6 524.1798, found 524.1852. 
 
2-Carboxyethyl methyl 4'-amino-2-phenyl-8-aminomethyl-6H, 
12H-5,11-methanodibenzo[b,f][1,5]diazocine-3',6'-dicarboxylate 
(47b): By the general deprotection procedure, 0.05 g (0.06 mmol) 
of the torsion balance 45b in 0.4 mL of dichloromethane was treated with 0.2 mL (2.89 mmol) of 
trifluoroacetic acid. Following the workup, to the crude material in 6.6 mL of methanol was then 
added 0.03 g (10%, 0.03 mmol) of palladium/carbon in 0.7 mL of water and purified by reverse 
phase HPLC (linear gradient of 90% solvent A to 78% A in solvent B) to provide 23 mg (71% 
over two steps) of the title compound: IR (KBr pellet) υ 3373, 3700-2300 (broad), 1678, 1464, 
1263, 1203, 1132; 
1
H NMR (D2O, 700 MHz) δ 7.67 (dd, 1H, J = 2.1 and 11.2 Hz), 7.57 (dd, 1H, 
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J = 2.8 and 34.3 Hz), 7.39 (dd, 2H, J = 8.4 and 23.8 Hz), 7.19 (d, 1H, J = 16.8 Hz), 7.12 (d,1H,  J 
= 8.4 Hz), 6.94/6.88 {s/s, (0.5/0.4)H}, 4.95 (dd, 1H, J = 16.8 and 22.4 Hz), 4.87 (t, 2H, J = 16.8 
Hz), 4.53 (dd, 1H, J = 16.8 and 35.7 Hz), 4.43 (t, 1H, J = 17.5 Hz), 4.23-4.29/3.74 {m/dm, 
(0.8/1.0)H, J = 58.1 Hz}, 4.05 (s, 2H), 3.63/2.94 {s/s, (1.7/1.2)H}, 2.38/1.37 {dm/dm, 
(0.6/1.0)H, J = 58.1 and 11.9 Hz); 
13
C NMR (D2O, 700 MHz, 25 °C) δ 174.51, 169.40, 169.02, 
168.59, 168.27, 163.05, 162.85, 142.33, 139.98, 137.81, 135.22, 134.08, 133.30, 132.46, 131.30, 
129.23, 128.28, 127.37, 125.55, 125.43, 126.56, 126.36, 125.16, 124.66, 124.60, 124.33, 120.14, 
118.48, 116.83, 67.52, 62.51, 58.35, 58.12, 54.36, 53.50, 43.63, 33.95, 33.29; HRMS calculated 
for C28H28NaN4O6 539.1907, found 539.1902. 
 
2-Carboxyethyl isopentyl 2-phenyl-8-aminomethyl-6H,12H-5, 
11-methanodibenzo[b,f][1,5]diazocine-3',6'-dicarboxylate (47c): 
By the general deprotection procedure, 0.04 g (0.05 mmol) of the 
torsion balance 45c in 0.3 mL of dichloromethane was treated with 
0.2 mL (2.10 mmol) of trifluoroacetic acid. Following the workup, to the crude material in 4.9 
mL of methanol was then added 0.03 g (10%, 0.02 mmol) of palladium/carbon in 0.5 mL of 
water and purified by reverse phase HPLC (linear gradient of 70% solvent A to 58% A in solvent 
B) to provide 13 mg (51% over two steps) of the title compound: IR (KBr pellet) υ 3431, 2959, 
3500-2500 (broad), 1717, 1499, 1307, 1280, 1203, 1139; 
1
H NMR (D2O, 700 MHz) δ 7.80 (dd, 
1H, J = 7.7 and 48.3 Hz), 7.73 (dd, 1H, J = 9.1 and 28.0 Hz), 7.44-7.46 (m, 1H), 7.31 (d, 2H, J = 
9.8 Hz), 7.25 (dd, 1H, J = 8.4 and 28.0 Hz), 7.14 (d, 1H, J = 21.7 Hz), 7.00 (dd, 1H, J = 7.7 and 
23.1 Hz), 6.79 (d, 1H, J = 13.3 Hz), 4.68-4.87 (m, 1H), 4.61 (dd, 1H, J = 11.9 and 39.2 Hz), 4.52 
(dd, 1H, J = 12.6 and 39.2 Hz), 4.38 (d, 1H, J = 16.8 Hz), 4.29 (t, 1H, J = 15.4 Hz), 4.18-
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4.24/3.66 {m/dm, (0.9/1.2)H, J = 86.0 Hz}, 4.02 (s, 2H), 3.96-4.00/3.48 {m/dm, (1.4/0.8)H, J = 
77.7 Hz}, 2.33/1.32 {dm/t, (0.6/1.1)H, J = 70.0 Hz and 6.3 Hz}, 1.10/0.50 {s/dd, (1.3/0.9)H, J = 
6.3 and 12.6 Hz}, 1.1/0.96-0.99 {signal obscured/m, (0.5/0.3)H}, 0.66-0.69/0.42 {m/dd, 
(3.9/2.7)H, J = 6.3 and 14.0 Hz}; 
13
C NMR (MeOD, 700 MHz, 25 °C) δ 175.65, 171.49, 170.82, 
170.61, 164.18, 163.98, 145.76, 145.52, 144.40, 140.25, 138.20, 137.97, 134.05, 133.76, 133.44, 
133.18, 132.94, 131.35, 130.12, 129.88, 129.40, 128.40, 128.25, 128.14, 127.41, 126.40, 125.44, 
125.21, 118.32, 116.67, 67.00, 66.20, 65.83, 62.39, 62.16, 58.58, 58.43, 43.64, 37.41, 36.73, 
33.21, 25.29, 25.11, 22.73, 22.59, 22.26; HRMS calculated for C32H35NaN3O6 580.2424, found 
580.2431. 
 
2-Carboxyethyl isopentyl 4'-amino-2-phenyl-8-aminomethyl-
6H,12H-5,11-methanodibenzo[b,f][1,5]diazocine-3',6'-
dicarboxylate (47d): By the general deprotection procedure, 0.05 g 
(0.06 mmol) of the torsion balance 45d in 0.4 mL of 
dichloromethane was treated with 0.2 mL (2.10 mmol) of trifluoroacetic acid. Following the 
workup, to the crude material in 3.7 mL of methanol was then added 0.02 g (10%, 0.02 mmol) of 
palladium/carbon in 0.4 mL of water and purified by reverse phase HPLC (linear gradient of 
80% solvent A to 50% A in solvent B)  to provide 10 mg (29% over two steps) of the title 
compound: IR (KBr pellet) υ 3449.58, 3700-2700 (broad), 1686, 1463, 1204, 1128; 1H NMR 
(MeOD, 700 MHz) δ 7.48 (d, 1H, J = 39.9 Hz), 7.41 (dd, 1H, J = 2.1 and 27.3 Hz), 7.34 (d, 2H, J 
= 23.1 Hz), 7.29 (dd, 1H, J = 8.4 and 27.3 Hz), 7.17 (d, 1H, J = 23.8 Hz), 7.06 (dd, 1H, J = 7.7 
and 22.4 Hz), 6.86 (s, 1H), 4.74-4.90 (m, 1H), 4.66 (dd, 1H, J = 12.6 and 42.7 Hz), 4.58 (dd, 1H, 
J = 13.3 and 34.3 Hz), 4.43 (d, 1H, J = 16.8 Hz), 4.35 (t, 1H, J = 16.1 Hz), 4.22-4.25/3.69 
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{m/dm, (0.6/0.5)H, J = 81.9 Hz}, 4.03 (s, 2H), 4.01-4.03/3.51 {m/dm, (signal obscured/0.2)H, J 
= 87.5 Hz}, 2.35/1.34 {dm/dd, (0.4/1.0)H, J = 77.0/6.3 and 13.3 Hz}, 1.13-1.16/0.52-0.54 {m/m, 
(1.4/0.9)H}, 1.11-1.12/0.99-1.01 {m/m, (signal obscured/0.2)H}, 0.71/0.44 {t/dd, (4.0/3.0)H, J = 
7.0/7.0 and 13.3 Hz}; 
13C NMR (MeOD, 700 MHz, 25 °C) δ 174.47, 174.18, 170.36, 170.31, 
170.04, 163.06, 148.89, 148.00, 146.03, 138.40, 135.64, 135.36, 130.90, 130.20, 130.06, 129.32, 
128.87, 128.75, 127.98, 127.05, 126.89, 118.88, 68.00, 67.65, 59.44, 59.31, 44.06, 38.20, 26.12, 
26.00, 22.97, 22.90; HRMS calculated for C32H36NaN4O6 595.2533, found 595.2559. 
 
General guanylation and deprotection procedure (guanidinomethyl torsion balances, 48a-
d): Step 1 –  To torsion balance 45a-d in CH2Cl2 was added trifluoroacetic acid dropwise at 0 
°C. The solution was stirred for 30 minutes at room temperature and added to NH4OH (1 M). 
The solution was extracted with EtOAc, which in turn was washed with brine. The organic 
extracts were dried over MgSO4 and filtered, and volatile components of the filtrate were 
removed under reduced pressure. Step 2 – To the crude material in DMF was added Hünig‘s 
base (DIPEA) and pyrazole-1-carboxamidine hydrochloride. The reaction was stirred at room 
temperature for 8 hours. The reaction was diluted with water and extracted with EtOAc. The 
organic extracts were dried over MgSO4 and filtered, and volatile components of the filtrate were 
removed under reduced pressure. Step 3 – To a two-dram vial was added the crude guanylated 
torsion balances in methanol and 10% palladium/carbon suspended in water. The vial was placed 
in a Parr shaker bottle and the debenzylation was carried out at 40 psi H2 for 48 hours. The 
solution was filtered through a plug of Celite, the volatile components of the filtrate were 
concentrated under reduced pressure, and the residue was then purified by reverse phase HPLC.   
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2-Carboxyethyl methyl 2-phenyl-8-guanidinomethyl-6H,12H- 
5,11-methanodibenzo[b,f][1,5]diazocine-3',6'-dicarboxylate 
(48a): By the general guanylation and deproection procedure, 
0.03 g (0.04 mmol) of the torsion balance 45a in 0.3 mL of dichloromethane was treated with 0.1 
mL (1.93 mmol) of trifluoroacetic acid. The crude material was dissolved in 0.04 mL of 
anhydrous DMF and reacted with 0.02 mL of DIPEA and 0.01 g of pyrazole-1-carboxamidine 
hydrochloride. Following the workup, to the crude material in 4.4 mL of methanol was then 
added 0.02 g (10%, 0.02 mmol) of palladium/carbon in 0.5 mL of water and purified by reverse 
phase HPLC (linear gradient of 90% solvent A to 78% A in solvent B) to provide 15 mg (66% 
over three steps) of the title compound: IR (KBr pellet) υ 3433, 3600-2700 (broad), 1685, 1205; 
1H NMR (MeOD, 700 MHz, 25 °C) δ 8.00 (t, 1H, J = 8.4 Hz), 7.89 (dd, 1H, J = 7 and 32.9 Hz), 
7.614 (s, 1H), 7.41-7.46 (m, 2H), 7.37 (s, 1H), 7.17 (s, 2H), 6.94 (d, 1H, J = 42.7 Hz), 4.88-5.01 
(m, 4H), 4.52 (dd, 1H, J = 16.8 and 80.5 Hz), 4.51 (d, 1H, J = 16.1 Hz), 4.38 (s, 2H), 4.31/3.78 
{s/dm, (0.8/0.9)H, J = 78.4 Hz}, 3.68/2.92 {s/s, (1.6/1.1)H}, 2.46/1.42 {dm/dm, (0.5/0.9)H,  J = 
64.4 and 20.3 Hz}; 
13C NMR (MeOD, 700 MHz, 25 °C) δ 175.61, 175.27, 171.27, 170.78, 
170.44, 170.04, 163.99, 163.79, 158.00, 141.50, 141.34, 140.62, 139.45, 137.04, 133.81, 133.69, 
133.60, 133.20, 133.06, 130.04, 129.60, 128.73, 128.42, 128.31, 127.27, 126.83, 126.83, 126.83, 
125.05, 118.39, 116.73, 67.80, 67.60, 62.34, 62.05, 58.49, 58.20, 53.87, 52.86, 44.81, 33.87, 
33.14; HRMS calculated for C29H29NaN5O6 566.2016, found 566.2009. 
 
2-Carboxyethyl methyl 4'-amino-2-phenyl-8-guanidinomethyl-
6H,12H-5,11-methanodibenzo[b,f][1,5]diazocine-3',6'-
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dicarboxylate (48b): By the general guanylation and deproection procedure, 0.04 g (0.04 mmol) 
of the torsion balance 45b in 0.3 mL of dichloromethane was treated with 0.1 mL (1.91 mmol) of 
trifluoroacetic acid. The crude material was dissolved in 0.04 mL of anhydrous DMF and reacted 
with 0.02 mL of DIPEA and 0.01 g of pyrazole-1-carboxamidine hydrochloride. Following the 
workup, to the crude material in 4.4 mL of methanol was then added 0.02 g (10%, 0.02 mmol) of 
palladium/carbon in 0.5 mL of water and purified by reverse phase HPLC (linear gradient of 
90% solvent A to 78% A in solvent B) to provide 12 mg (51% over three steps) of the title 
compound: IR (KBr pellet) υ 3449, 3700-2700 (broad), 1686, 1464, 1351, 1264, 1205; 1H NMR 
(D2O, 700 MHz, 5 °C) δ 7.37/7.27 {d/d, (0.3/0.5)H, J = 2.1/2.8 Hz}, 7.35/7.21 {d/d, (0.8/0.3)H, J 
= 1.4/2.1 Hz}, 7.14 (t, 1H, J = 8.4 Hz), 7.10-7.12 (m, 1H), 7.07 (d, 1H, J = 7.7 Hz), 6.90 (s, 1H), 
6.87 (d, 1H, J = 16.1 Hz), 6.71/6.63 {s/s, (0.5/0.3)H}, 4.67 (dd, 1H, J = 16.1 and 24.5 Hz), 4.58-
4.65 (m, 1H), 4.56 (s, 1H), 4.27 (dd, 1H, J = 16.8 and 48.3 Hz), 4.20 (d, 1H, J = 17.5 Hz), 4.11 
(d, 2H, J = 9.1 Hz), 4.01-4.08/3.51 {m/dm, (0.5/1.0)H, J = 76.3}, 3.44/2.67 {s/s, (1.8/0.9)H}, 
2.16/0.98 {dm/dm (0.4/0.9)H, J = 87.5/93.1 Hz}; 
13
C NMR (MeOD, 700 MHz, 25 °C) δ 174.22, 
170.21, 158.74, 148.89, 148.41, 146.90, 137.73, 135.25, 133.88, 129.91, 129.84, 129.57, 128.80, 
128.19, 127.77, 127.32, 126.70, 125.20, 118.35, 118.27, 67.95, 67.40, 64.85, 64.05, 61.81, 59.74, 
45.60; HRMS calculated for C29H31N6O6 559.2305, found 559.2290. 
 
2-Carboxyethyl isopentyl 2-phenyl-8-guanidinomethyl-6H, 
12H-5,11-methanodibenzo[b,f][1,5]diazocine-3',6'-
dicarboxylate (48c): By the general guanylation and deproection 
procedure, 0.05 g (0.05 mmol) of the torsion balance 45c in 0.4 
mL of dichloromethane was treated with 0.2 mL (2.44 mmol) of trifluoroacetic acid. The crude 
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material was dissolved in 0.05 mL of anhydrous DMF and reacted with 0.02 mL of DIPEA and 
0.02 g of pyrazole-1-carboxamidine hydrochloride. Following the workup, to the crude material 
in 2.8 mL of methanol was then added 0.01 g (10%, 0.01 mmol) of palladium/carbon in 0.3 mL 
of water and purified by reverse phase HPLC (linear gradient of 70% solvent A to 58% A in 
solvent B) to provide 21.6 mg (68% over three steps) of the title compound: IR (KBr pellet) υ 
2411, 2959, 3700-2700 (broad), 1686, 1309, 1204, 1137; 
1H NMR (MeOD, 600 MHz, 25 °C) δ 
7.81 (d, 2H, J = 14.4 Hz), 7.52 (t, 1H, J = 7.8 Hz), 7.19 (dd, 3H, J = 8.4 and 22.8 Hz), 6.98 (d, 
2H, J = 7.8 Hz), 6.77 (d, 1H, J = 1.8 Hz), 4.72 (dd, 2H, J = 16.8 and 31.2 Hz), 4.39 (s, 2H), 4.30 
(s, 4H), 4.22/3.75 {s/d, (0.9/1.4)H, J = 108.6 Hz}, 4.04/3.68 {s/d, (1.2/0.8)H, J = 81.6 Hz}, 
2.33/1.61 {d/s, (0.3/1.0)H, J = 49.8 Hz}, 1.39/~1.3 {s/signal obscured, (0.6/signal obscured)H}, 
1.26/~0.9 {s/signal obscured, (1.3/signal obscured)H}, 0.85/0.69 {s/s, (4.2/2.2)H}; 
13
C NMR 
(MeOD, 600 MHz, 25 °C) δ 174.73, 170.56, 170.23, 163.79, 163.57, 159.29, 149.22, 148.84, 
141.94, 137.46, 135.66, 135.39, 134.29, 133.26, 130.22, 129.80, 129.30, 129.12, 128.86, 127.96, 
127.88, 127.35, 126.23, 68.60, 65.62, 62.38, 60.21, 60.13, 46.25, 38.91, 34.30, 26.59, 23.47; 
HRMS calculated for C31H37NaN5O6 622.2642, found 622.2620. 
 
2-Carboxyethyl isopentyl 4'-amino-2-phenyl-8-guanidino-
methyl-6H,12H-5,11-methanodibenzo[b,f][1,5]diazocine-
3',6'-dicarboxylate (48d): By the general guanylation and 
deproection procedure, 0.09 g (0.10 mmol) of the torsion 
balance 45d in 0.7 mL of dichloromethane was treated with 0.3 mL (4.48 mmol) of 
trifluoroacetic acid. The crude material was dissolved in 0.10 mL of anhydrous DMF and reacted 
with 0.03 mL of DIPEA and 0.03 g of pyrazole-1-carboxamidine hydrochloride. Following the 
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workup, to the crude material in 2.6 mL of methanol was then added 0.01 g (10%, 0.01 mmol) of 
palladium/carbon in 0.3 mL of water and purified by reverse phase HPLC (linear gradient of 
80% solvent A to 66% A in solvent B) to provide 25.2 mg (42% over three steps) of the title 
compound: IR (KBr pellet) υ 3368, 2961, 3800-2800 (broad), 1675, 1465, 1349, 1260, 1199, 
1134; 
1H NMR (MeOD, 700 MHz, 5 °C) δ 7.34 (d, 1H, J = 8.4 Hz), 7.28 (dd, 2H, J = 11.9 and 
21.0 Hz), 7.21 (d, 2H, J = 25.2 Hz), 7.03-7.11 (m, 2H), 6.83 (s, 1H), 4.90 (td, 2H, J = 16.1 and 
46.6 Hz), 4.70 (s, 2H), 4.45 (dd, 2H, J = 17.5 and 44.1 Hz), 4.40 (s, 2H), 4.19/3.75 {s/d, 
(1.0/1.4)H, J = 125.3 Hz}, 4.03/3.69 {d/d, (1.4/0.8)H, J = 5.6 and 74.9 Hz}, 2.34/1.62 {d/d, 
(0.9/1.4)H, J = 69.3 and 5.6 Hz}, 1.44/1.33 {s/s, (0.8/0.6)H}, 1.30/0.92 {s/s, (1.8/1.1)H}, 
0.87/0.70 {d/s, (3.8/2.2)H, J = 5.6 Hz}; 
13C NMR (MeOD, 700 MHz, 25 °C) δ 174.11, 170.06, 
169.82, 162.58, 162.36, 158.81, 147.67, 146.15, 144.65, 139.09, 135.55, 135.32, 130.37, 128.95, 
128.42, 128.32, 127.48, 126.64, 125.15, 119.14, 118.78, 117.13, 68.13, 64.87, 64.81, 61.80, 
59.08, 45.52, 38.34, 33.77, 26.06, 22.90; HRMS calculated for C33H39N6O6 615.2931, found 
615.2948.  
 
2-Bromoisophthalic acid 1-isopentyl ester 3-methyl ester (49): By the 
general esterification procedure, 0.05 mL (0.5 mmol) of isoamyl alcohol, 
0.16 g (0.8 mmol) of DCC and 0.01 g (0.1 mmol) of DMAP in 2.0 mL of dry CH2Cl2 treated 
with 0.10 g (0.4 mmol) of the carboxylic acid 36, provided 0.10 g (81%) of the title compound as 
an oil: IR (thin film) υ 2957, 1734, 1307, 1283, 1254, 1202, 1150; 1H NMR (CDCl3, 300 MHz) δ 
7.66 (dd, 1H, J = 1.8 and 5.1 Hz), 7.63 (dd, 1H, J = 1.8 and 5.4 Hz), 7.36 (t, 1H, J = 7.5 Hz), 1.73 
(sextet, 1H, J = 6.6 Hz), 1.61 (q, 2H, J = 6.9 Hz), 0.91 (d, 6H, J = 6.6 Hz); 
13
C NMR (CDCl3, 300 
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MHz) δ 167.04, 166.76, 135.98, 135.36, 132.24, 132.22, 127.25, 119.02, 64.78, 52.88, 37.27, 
25.13, 22.54; HRMS calculated for C14H17BrNaO4 351.0208, found 351.0199. 
 
Isopentyl methyl 2-phenyl-8-((di-tert-butoxycarbonylamino)-
methyl)-6H,12H-5,11-methanodibenzo[b,f][1,5]diazocine-3',6'-
dicarboxylate (50): By the general Suzuki coupling procedure, 0.04 
g (0.13 mmol) of isophthalate 49, 0.05 g (0.08 mmol) of the pinacolatoboronate 34, and 5 mg 
(0.008 mmol) of the palladium catalyst in 0.4 mL of DME were treated with 0.04 g (0.50 mmol) 
of sodium bicarbonate in 0.4 mL of water and purified by column chromatography (pentane: 
Et2O, 2:1) to provide 0.03 g (44%) of the title compound: IR (thin film) υ 2956, 1721, 1367, 
1304, 1144; 
1
H NMR (CDCl3, 300 MHz, 25 °C) δ 7.76 (d, 2H, J = 17.1 Hz), 7.39 (t, 1H, J = 7.8 
Hz), 7.06 (dd, 3H, J = 8.4 and 12.4 Hz), 6.97 (d, 1H, J = 8.7 Hz), 6.85 (s, 1H), 6.70 (s, 1H), 4.66 
(d, 2H, J = 16.5 Hz), 4.59 (s, 2H), 4.33 (s, 2H), 4.12 (dd, 2H, J = 8.1 and 16.8 Hz), 4.04/3.41 
{s/s, (0.9/0.4)H}, 3.58/2.75 {s/s, (0.9/1.5), 1.42 (s, 18H), 1.23 (broad m, 3H), 0.80/0.65 {s/s, 
(4.6/1.5)H}; 
13
C NMR (CDCl3, 300 MHz, 25 °C) δ 169.16, 168.50, 152.89, 147.44, 147.13, 
140.51, 135.17, 134.25, 133.11, 133.00, 131.81, 131.62, 127.94, 127.78, 127.33, 127.28, 126.97, 
126.19, 124.97, 124.35, 82.73, 77.44, 67.49, 63.97, 59.27, 51.49, 49.04, 37.14, 29.89, 28.23, 
24.84, 22.55; HRMS calculated for C40H49NaN3O8 722.3417, found 722.3401. 
 
Isopentyl methyl 2-phenyl-8-aminomethyl-6H,12H-5,11-methano-
dibenzo[b,f][1,5]diazocine-3',6'-dicarboxylate (51): By the general 
deprotection procedure, 0.05 g (0.05 mmol) of the torsion balance 50 in 
0.4 mL of dichloromethane was treated with 0.2 mL (2.10 mmol) of trifluoroacetic acid to 
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provide the title compound in quantitative yield: IR (thin film) υ 2955, 2925, 1718, 1496, 1307, 
1280, 1203, 1136; 
1
H NMR (CDCl3, 300 MHz, 25 °C) δ 7.76 (d, 2H, J = 15.3 Hz), 7.40 (t, 1H, J 
= 8.1 Hz), 7.04 (s, 3H), 6.95 (d, 1H, J = 7.5 Hz), 6.84 (s, 1H), 6.65 (s, 1H), 4.59 (t, 2H, J = 17.1 
Hz), 4.26 (s, 2H), 4.05 (d, 2H, J = 16.2 Hz), ~4.1/3.59 {signal obscured/s, (~1.0/1.2)H}, 
3.64/2.93 {s/s, (1.8/1.4)H}, 1.2-1.3 (m, 3H), 0.80/0.64 {s/s, (4.4/1.5)H}; 
13
C NMR (CDCl3, 300 
MHz, 25 °C) δ 169.15, 168.47, 162.09, 148.38, 147.40, 140.50, 134.96, 133.60, 13348, 131.91, 
131.69, 128.57, 128.04, 127.71, 127.41, 127.36, 127.02, 125.53, 124.50, 124.37, 67.21, 64.05, 
58.85, 51.72, 44.15, 38.11, 29.92, 24.91, 22.55; HRMS calculated for C30H33NaN3O4 522.2369, 
found 522.2390.  
6.2 PREPARATION OF BUFFER SOLUTIONS  
Preparation of Stock Solutions 
Deuterium chloride (35% wt in D2O) was purchased from Aldrich. To a 5 mL volumetric 
flask was added 0.043 mL of the DCl solution, which was diluted to 5 mL with D2O. This stock 
solution was 0.10 M in DCl and was used to adjust the pD of the buffer solutions.  
 Sodium deuteroxide (40% wt in D2O) was purchased from Cambridge Isotopes. To a 5 
mL volumetric flask was added 0.035 mL of the concentrated NaOD solution, which was diluted 
to 5 mL with D2O. This stock solution was 0.10 M in NaOD and used to adjust the pD of the 
buffer solutions.  
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Preparation of the 0.050 M Potassium Deuterium Phthalate Buffers 
A solution of 2.0 g of potassium hydrogen phthalate (KHP) in 20 mL of D2O was dried 
by lyophilization. The solid was redissolved in another 20 mL portion of D2O, and the solvent 
was again removed by lyophilization.  
A solution of 0.1026 g of the deuterated potassium salt and 2.2 mL of the 0.10 M DCl 
stock solution was diluted to 10 mL with D2O in a 10 mL volumetric flask. The solution was 
0.050 M in phthalate and was used as an NMR solvent for the torsion balances. The pD of the 
solution was calculated as 3.1, which was determined by adding 0.4 to a reading taken from a 
glass electrode pH meter.
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A solution of 0.1026 g of the deuterated potassium salt and 2.2 mL of the 0.10 M NaOD 
stock solution was diluted to 10 mL with D2O in a 10 mL volumetric flask. The solution was 
0.050 M in phthalate and was used as an NMR solvent for the torsion balances. The pD of the 
solution was calculated as 5.5.   
Preparation of the 0.050 M Deuterated Phosphate Buffer 
A solution of 1.4196 g (0.0100 mol) of Na2HPO4 and 1.3609 g (0.0100 mol) of KH2PO4 
in 10 mL of D2O was dried by lyophilization. The solid mixture was redissolved in another 
portion of D2O, and the solvent again was removed by lyophilization. The deuterated solid was 
transferred to a 100 mL volumetric flask and diluted to 100 mL with D2O. This stock solution 
was 0.200 M in phosphate and diluted to 0.050 M by standard methods. The 0.050 M solution 
was used as an NMR solvent for the torsion balances. The pD of the solution was calculated as 
7.2.  
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Preparation of the 0.050 M Deuterated Borate Buffer 
A solution of 0.0478 g of sodium tetraborate and 0.4 mL of the 0.10 M DCl stock 
solution was diluted to 10 mL with D2O in a 10 mL volumetric flask. The solution was 0.050 M 
in borate and was used as an NMR solvent for the torsion balances. The pD of the solution was 
calculated as 10.0. 
6.3 ERROR ANALYSIS 
For torsion balances 26a-c, 27a-c, 28a-d, and 29a-b, NMR simulations were conducted 
on three sets of protons: the inner methylene, and outer methyl of the propyl group, and the 
bromoethyl group.  NMR simulations were conducted on the methyl ester or the methyl of the 
isoamyl group for torsion balances 47a-d and 48a-d.  In Figure 23, a simulation of a bromoethyl 
group (blue) was overlaid with the experimental spectrum of 26a (red).  The simulated spectrum 
was similar to the experimental one and was sensitive to changes in the folding ratio.  Changes as 
little as 1.5% to the overall folding percent led to distinct discrepancies between observed and 
calculated spectra.  The error in the percent of the folded conformer was minimized in Figure 23, 
whereas a 1.5% decrease and increase in the folding ratios were featured in Figures 24 and 25 
respectively.  Therefore, a ±1.5% error was estimated for the folding ratios for the torsion 
balances.  
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Figure 23. A simulation of the bromoethyl protons (blue) overlaid with the experimental 
spectrum (red) of 26a at -5 °C. 
 
Figure 24. A simulation of the bromoethyl group with a 1.5% reduction in the folding ratio. 
 
The error for the folding energies can be determined by multiplying the derivative of the 
energy equation by the error in the folding percentages (±1.5%).  The Gibbs free energy equation 
(Equation 2) was redefined in terms of the folding energy.  The equilibrium constant was written 
in terms of folding percentage, x (Equation 3), which was plugged into Equation 2.  
ln eqG RT K
       (Equation 2) 
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Figure 25. A simulation of the bromoethyl group with a 1.5% increase in the folding ratio. 
 
The derivative of Equation 4 is  
 
( ) 100
(100 )
d G
RT
dx x x

 

 (Equation 5) 
in which x is the folding percentage.  The error for the folding energies is the product of 
Equation 5 multiplied by Δx (1.5%, Equation 6) and the relative error is given by Equation 7.  
  
( ) 100
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(100 )
d G RT
G x x
dx x x

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At 55% folding with a temperature of 268 K, the folding energy is -0.107 kcal/mol with 
an absolute error of ±0.03 kcal/mol and a relative error of ±30%. At 65% folding, the folding 
energy is -0.329 kcal/mol with an absolute error of ±0.035 kcal/mol. The relative error is ±11%. 
At 75% folding, the folding energy is -0.585 kcal/mol, the absolute error is 0.43, and the relative 
error is 7%.  A graph that depicts the relative error in the folding energies with relation to the 
folding ratios, assuming a ±1.5% error in the folding ratios, is shown in Figure 26.  Therefore, 
we estimated the relative error in the range of 55% to 75% folding to be ±15% in folding energy.  
 
Figure 26. Relative error in folding energies versus folding ratios for a ±1.5% error in 
folding ratios. 
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